DeepScience

In the Shadow of Similarity

The Art of Differentiation in Diagnostic Pathology

DeepScience

Birupaksha Biswas

In the Shadow of Similarity: The Art of Differentiation in Diagnostic Pathology

Birupaksha Biswas

Department of Pathology, Burdwan Medical College & Hospital, Burdwan, India



DeepScience

Published, marketed, and distributed by:

Deep Science Publishing, 2025
USA | UK | India | Turkey
Reg. No. MH-33-0523625
www.deepscienceresearch.com
editor@deepscienceresearch.com
WhatsApp: +91 7977171947

ISBN: 978-93-7185-703-1

E-ISBN: 978-93-7185-400-9

https://doi.org/10.70593/978-93-7185-400-9

Citation: Biswas, B. (2025). *In the Shadow of Similarity: The Art of Differentiation in Diagnostic Pathology*. Deep Science Publishing. https://doi.org/10.70593/978-93-7185-400-9

Preface

It must start as a on act of wonder, every book. This one was not born of certainty but of curiosity as to why some fabrics fool the brain, why certain pathways shout verity and others scream falsehood. In the Shadow of Similarity is born of insomnia at the interface of known and unknown, where the slide under the microscope becomes a lesson and a reflection.

Many times, as a pathologist, I have discovered that the false security of recognition provides more of a hindrance to understanding rather than the lack of knowledge itself. The familiarity of something often breeds confidence. And if confidence goes unchecked it turns into an illusion. This is why I wanted to explore the narrow boundary between morphological identification (the study of form) and meaning and the process of observation becoming a thoughtful exercise in discernment.

Each and every page that follows is a result of my history of learning far more from the numerous experiences of pseudo-failure that I've had than I would have learned from any single experience of success. Because in those times of pause (where we look at a slide with absolutely no clue what it's telling us), is where real empathy begins to occur. After all pathology is not just a science of diseases but also a science of the way we perceive things, our humility and the quiet morality of simply being able to see.

If this reflection inspires a reader to take a moment before jumping to conclusions, question their assumptions regarding what they are familiar with and view tissues as stories and not structures, then this book will have accomplished its purpose.

Birupaksha Biswas

Preface

The book looks at those undetectable spaces in which the body is located, and in which the spirit finds a way to be saved from itself. It is written in an interpretative style, with a focus on making science relatable through reflection; it tries to bridge the space that exists between what we see in our minds when looking at something, and how the images appear when seen under a microscope.

Instead of providing a step-by-step guide to diagnosing, this book focuses on the influence of bias, cognition, and emotion upon the process of diagnosing. Each chapter has a dialogue about the relationship between tissue and thought; shadow and substance; ultimately, to provide the reader with the understanding that diagnosis is both an intellectual and a moral undertaking.

This book does not attempt to create a list of lesions or other diagnostic entities. Instead, it is a philosophical exploration of the terrain of similarity and difference in pathology. This work also provides recognition of the pure specificity of mindfulness, and the fragile nature of the practice of perception, where a great deal more than just accuracy is being learned, specifically the study of humility in search of truth through imperfect and fallible human observation.

About the Author

Dr Birupaksha Biswas, MBBS, MD (Pathology), says the journey of his life may not be a tale of achieving the best but a gradual deposition of murmurs of resilience, learning and retention His intellectual trellis is marked by a veritable bibliographic constellation: The Comic Book of Neuropathology: When Neurons Throw Tantrums, a witty yet earnest interrogation of neurological pathology; Blood on the Edge: Critical Care Hematology Unplugged, an adroit untangling of hematologic crises; Pediatric Hematopathology: Bone Marrow Disorders, Leukemias, Lymphomas, and Molecular Diagnostics, a hearing of children and childhood through the lens of pathology and molecular insight; Pathology at the Edge of Certainty: Flesh, Code, and the Semiotics of Diagnosis, a meditation on the very language; Integrative Diagnostic Pathology: Cytomorphology, Genomics, and Translational Perspectives in Systemic and Organ-

Specific Diseases, an attempt to harmonize the molecular and the morphological; and The Art of Being a Pathologist The Alchemy of Lesions: What Disease Tells Us and How to Make it Better:Using Pathology as an Art of Translation and Repair These books may carry his name but are presented as conversations with friends, colleagues, patients and the unending field of pathology itself. The monographs, along with two others under way on Endocrine Disorders and contraindications to Organ Biopsies (and a total of nearly fifty-one journal articles published in both national and international peer-reviewed journals), reflect a long history of publishing scholarly papers on various topics, such as review papers, case studies, systematic synthesis papers, and translational papers, among others, including one manuscript. The form of this body of research is more of a collection of scholarly investigations than a showy display, and if we view this body of research as an archive of inquiry, it can also be seen as a document of the investigation of questions and their pursuit through discipline rather than self-expression.

If one were to look at the "grammar" of his scholarly career, it would become clear that his writing was not written to celebrate triumphs but as a careful observation. As a result, the complexity of the syntactic structure of his writing reflects the complexity of the pathological phenomenon he has chosen to study. For him, the academic degree represents the start of the journey, but the true calling is represented by the continued refinement of manuscripts, development of diagnostic algorithms, and attempts to make difficult ideas understandable and reproducible. His scholarship is a tapestry and not a patchwork; it is based upon Hematology, yet it knows no boundaries between personality and psyche and has benefited from Oncology and Infectious Disease, and continues to be tied to the principles of transparency and receptivity. His work is organized within a unified framework, in order to allow cellular morphology, genomics, and therapeutic translation to inform each other, and not compete with each other. However, underneath this framework of academic study, lies a more delicate and personal foundation: painful memory, in which individualized loss became a public voice, wounds turned into words. It is from this emotional crucible that his literary style was developed, as contemplative rather than declarative, and humble, rather than triumphant.

As he himself elaborates, he never wrote to be acknowledged, but to be remembered. He found that language could produce consolation as well as clarity in the wake of loss. Through this infusion of grief with purpose and scientific pursuit he was not a memorable personality or person of start, but a witness; someone who writes in order to transform pain into durable knowledge

Acknowledgement

In the weaving of this book and every word I have ever written, I remain profoundly indebted to all those who entrusted their most fragile, intimate hours to my care, for their stories are the very inspiration to these pages, and I extend a boundless, silent gratitude to colleagues whose vigilance, intellect, and endurance transformed despair into possibility, ***yet above all I must honor the SPECIAL ONE***, ***whose presence, whether seen or felt in quiet moments, rendered the act of writing inseparable from the act of love and healing, and to family especially my father Shri.Biswa Ranjan Biswas (Ex-Bureaucrat) , my mentors,my teachers and well-wishers , Dr.Avik De the elder,*** *whose constancy carried me when the weight of grief and responsibility threatened to silence my voice, for medicine, like literature, is never a solitary pursuit but a chorus of shared vigilance, and wi****th every beat of my heart I dedicate all royalties from all my books, past, present, and future, entirely to the cathedrals that cradle memory and solace, those sacred spaces where grief was met with grace, names whispered into the silence, and candles flickered like fragile, persistent hopes, and where these offerings will ripple outward to feed the poor, tend to the sick, and uplift the needy, granting not merely sustenance but dignity****,* yet still I speak from the depths of humility, for I am nobody to quantify or label suffering, for it wears innumerable faces, and need is often invisible, and this act of giving is born not from pride but from sorrow and a fervent wish that no soul ever feels forgotten, for the hardest truth is not in saying goodbye, but in realizing that sometimes, we never truly do, and in that enduring ache, we find both sorrow and love entwined, guiding every word, every gesture, and every offering that this life of witness has allowed me to make.

Table of Contents

Deep Science Publishing, 2025
https://doi.org/10.70593/978-93-7185-400-9

DeepScience
Open Access Books

Chapter 1: The Mirage of Morphology: When the Familiar Deceives

The Mirage of Morphology: When the Familiar Deceives

In the silent world beneath the microscope, every pathologist seeks comfort in patterns. The nucleus, the cytoplasm, the arrangement of cells : each detail becomes a familiar friend. Over time, our eyes learn to recognize harmony and disharmony in tissue architecture much like a musician identifies a wrong note. We rely on familiarity, because familiarity is what guides our judgment.

Yet, within that comfort lies the greatest danger. The same familiarity that gives us confidence can also betray us. What looks like a classical “papillary pattern” may hide a metastatic lesion. What seems like “chronic inflammation” may conceal an early lymphoma. Morphology, for all its elegance and precision, can sometimes become a mirage , an illusion formed by the brain’s need to simplify, categorize, and decide.

This chapter explores that fragile balance between perception and reality, between morphology and meaning. It is about the deceptive nature of the familiar , and how the art of pathology demands both trust and suspicion toward what our eyes see.

A. The Illusion of Pattern Recognition

Human vision thrives on recognition. From childhood, the mind learns to group shapes and colors, to form patterns out of chaos. In pathology, this instinct becomes both our greatest tool and our quietest trap.

When we examine slides, our brains do not process each cell individually. Instead, we see patterns : glandular, papillary, solid, diffuse, storiform, alveolar, or fascicular. With experience, these patterns begin to speak a language of their own. “This looks like adenocarcinoma.” “That resembles a granuloma.” The decision feels natural, almost intuitive.

But pattern recognition is not foolproof. The brain's tendency to fill in gaps :to make incomplete information appear complete , is what allows illusions to exist. A few misplaced cells, an unusual staining artifact, or an incomplete section can make one disease look like another. In these moments, the mind quietly replaces the uncertain with the familiar.

Consider a case of reactive atypia in the cervix. The cells may appear enlarged, with prominent nucleoli and irregular contours. To the inexperienced observer, the slide screams "dysplasia." Yet, the context tells another story — inflammation, repair, regeneration. Here, morphology teases the pathologist with resemblance. The difference lies not in what the eyes see, but in how the mind interprets what it sees.

B. The Seduction of Familiarity

Every single pathologist will attest to having felt the comforting familiarity of recognizing something on a slide. That rush of feeling satisfied with oneself when you see an identifiable pattern is the very definition of "heuristic thinking" as coined by psychologists: quick judgments based upon past experiences that are generally correct but sometimes incorrect.

For instance, a spindle-shaped cell running through several layers of interlacing fascicles immediately leads one to suspect leiomyoma. Nevertheless, fibrosarcoma, schwannoma or reactive fibrosis may all have a fascicular appearance which could be identical to leiomyoma. It is this knowledge that allows the veteran pathologist to recognize that while the histological findings have led to a particular diagnosis being given consideration, the stroma, cellular atypia and mitotic count reveal nothing. The ability to listen to both is the essence of pathology.

C. The Mirage in Reactive and Neoplastic Pathology

And perhaps the most controversial of all are Reactive vs. Neoplastic Processes. Both types of lesions will display signs of proliferation (such as increased cellularity), atypia (abnormality of cellular appearance) and architectural distortion (alteration of the architecture of the tissue). The main differences between these two types of lesions lie within their 'motivations' or reasons for developing. One type of process is a response to some form of insult; the other represents an invasion by abnormal cells.

For example; Nodular Fasciitis presents initially as a very malignant-appearing lesion. It has high cellular density and is highly mitotically active and invasive. However, once

placed into proper clinical context, and evaluated using immunohistochemical techniques, this "malignant" appearance vanishes. It can seem like sarcoma but really is a self-limiting myofibroblast storm. Similarly, regenerative nodules in the liver can mimic well-differentiated hepatocellular carcinoma, their trabecular thickening creating a deceptive pattern of neoplasia.

Such examples remind us that morphology exists on a continuum. Nature does not draw sharp lines between reactive and malignant; it paints gradients. The pathologist's role is to interpret these gradients with humility and curiosity, resisting the urge to categorize prematurely.

D. Cognitive Bias : The Invisible Stain

Even the most experienced pathologist carries invisible stains on perception , cognitive biases that shape, and sometimes distort, interpretation. Among these, anchoring bias is the most common: the tendency to stick to an initial impression despite new evidence. The first glance at a slide often anchors the mind, and subsequent observations merely reinforce that initial image.

Confirmation bias follows closely , the selective search for features that support one's hypothesis while overlooking contradicting details. For example, once convinced that a slide shows squamous carcinoma, the observer may unconsciously ignore glandular differentiation.

Awareness of these biases is essential. Every pathologist should cultivate an inner voice that challenges certainty : a small but persistent whisper asking, "What else could this be?"

E. Histologic Context — The Frame Around the Picture

Cells or structures are rarely isolated from their environment as they are part of an architectural picture. The importance of the architecture, or the overall arrangement of components in pathology is to be emphasized as the architecturally relevant components are generally more important than individual structural elements. For example, a cluster of atypical glandular cells in a rectal biopsy may have features that suggest malignancy -- however, if there is surrounding inflammation, ulcers in the mucosa, and evidence of regeneration then those atypical glandular cells could represent reactive changes. Similarly, an aggregate of histiocytes found in a lymph node may indicate either sinus histiocytosis or a histiocytic neoplasia based on where the histiocytes are located, their immunophenotypic characteristics, and their distribution.

The morphology is a form of language, and it is only by understanding how cells (words) relate to each other (sentences), and ultimately to tissue (paragraphs), that we can begin to understand what an individual cytologic characteristic represents. Without understanding the architecture of the cellular elements in relation to one another, even the most clear cytologic feature becomes ambiguous..

F. When Morphology Meets Technology

Pathology has moved from a time when morphology was all there is. Pathologists today use morphology in conjunction with immunohistochemistry (IHC), molecular diagnostics, and digital analysis. But they must apply the same principles of skepticism to the new technologies as they do to morphology.

Morphology can mislead just like IHC markers. Overexpression may be secondary to cross-reactivity or under-expression may be a result of a technical issue. That is what makes the artistry of pathology; how one interprets morphologic findings in light of molecular information.

Although we are now in the "molecular" era, the first word for the pathologist remains morphology. Morphology will always be the initial step in the process in which other disciplines take their place. Therefore, pathologists need to be aware of both over-confidence in the appearance and too much faith in the technology.

G. Case Reflections — Lessons from the Deceptive Familiar

Chronic Inflammation Hides A Malignant Cell:

A cancerous cell can present like chronic colitis in a middle-aged man. Biopsy from endoscopy revealed inflammatory cells and distorted crypts, which was believed to be the signs of inflammatory bowel disease (IBD). However, upon deeper examination of the biopsy slide, it was discovered that there were dysplastic glands, indicative of an early stage carcinoma, camouflaged by chronic inflammation for at least 4 months. It demonstrated how persistence in reviewing previously examined slides may provide a clear solution when a diagnosis is masked by the effects of chronic inflammation.

The Familiar Can Be Misleading:

Adenocarcinoma-like appearance of a solitary much ting lung nodule, but due to the patient's history of rheumatoid arthritis and the use of methotrexate, organizing pneumonia seemed to be the most likely explanation. Upon review, tumor glands

appeared to be fibroblasts as opposed to tumor glands. Familiarity with adenocarcinoma could have led to error here, as the common (organizing pneumonia) disguised itself as the rare (adenocarcinoma).

H. The Ethics of Uncertainty

Diagnostic reports are consequential. The wrong words may change the course of a patient's life. But uncertainty is not failure, it is honesty in its purest form. Being aware of the limitations of morphology is an ethical action. The inability to assign a category to a lesion does not represent a lack of courage by writing "indeterminate" or "requires correlation." Rather, this represents courage and a recognition of the illusion that is certainty. Pathology is not merely to name all things. Pathology is to understand what can be named by morphology alone and what cannot. This acceptance of uncertainty creates a transition between pathology as science and as philosophy.

I. Seeing Beyond the Slide

While an expert in morphology may have many patterns to learn by memory, the true morphological expert sees beyond the patterns, the connections, history and biological behavior that exist underneath what can be seen under a microscope. A microscope provides only a view of the specimen; the mind that views the specimen will determine the truth. It is this type of pathologist who has cultivated both sharp vision and a reflective mind. These pathologists respect each slide they examine and are cautious because the most familiar images contain the deepest secrets.

The morphology, which is both gift and deception. It provides us beauty, order, and hints — and it seduces us into thinking that seeing is knowing. The shedding of the slides into visuality & Visual Drag: Truth is they are not the truth of the slides nor are we really — Pathology is the art of Diagnostic pathology — Pathology is Pathology Path Check & Balance — Trust your eyes but question them, Search the familiar but seek the hidden, let the image speak but don is Drag.

So to see one must unrecognize some of it and be okay with that and then the illusion can dissolve into the simple comforting warmth of the flesh replaced with the instant recognition and this is the same amount of light as the shadow — nothing fancier than a face not of a tissue.

Deep Science Publishing, 2025
https://doi.org/10.70593/978-93-7185-400-9

DeepScience
Open Access Books

Chapter 2: Between Shadows and Substance: The Symbolism of Tissue Diagnosis

In the quiet cosmos below the microscope, the tissue talks in metaphors. Every stain, every cellular constellation, every architectural whisper has a scientific or symbolic story to tell. In many ways, the pathologist becomes an interpreter of meaning from the structure. This distance between the blackness of hematoxylin, and the pink of eosin tells a tale of living, of hurt, of healing and of hope. Tissue diagnosis has never simply been about determining if there is disease in a specimen. It has always involved an interaction between form and function, between what is destroyed and what is restored, between how things appear versus their true nature. What is on the slide (the glass and pigment) is much more than simply the physical elements of which it is comprised. Each slide represents a single moment in time, when the body was struggling to regain control over forces of nature and entropy. In a histological section, the shadows are either not present (and therefore, the area is blank), or they represent artifacts of the staining process. However, most importantly, the shadows represent that even though something may not be visible, it does exist, and its absence is significant. Therefore, while the "empty" space within the histological plot can represent necrosis, regression, or repair; each has its own significance to the trained eye.

Each type of tissue has a unique and secret way of functioning. The nuclear behavior of the cells in a particular tissue type will mirror the oscillations between order and chaos that occur in our daily lives. The cytoplasm reflects the metabolic activity occurring at that site, the stroma provides the background of support for all cellular processes, and the inflammatory cell infiltrates indicate the ongoing battle with external pathogens. To reduce this to only a histologic perspective would be equivalent to attempting to silence the music of Beethoven. Histology is not merely about seeing into the tissues. It is also about hearing the internal rhythms of the tissues, and those that listen to them become the interpreters of the messages embedded within.

A. The Metaphor of Staining: Life in Two Colors

Diagnostic vision is made up of two colors created by hematoxylin and eosin staining. The first color binds to the nucleus, where the cell's 'brain' is located, while the second stains the cytoplasm, where the cell's "work" occurs[4]. The blue and red hues, placed side-by-side in this way create a contrast of viewpoints between the "commander" (the nucleus), which is stained with a cooler, distant hue and the "worker" (cytoplasm) which is stained with a warmer, brighter hue. This juxtaposition of opposing forces mirrors the eternal dialectical relationship of the mind and matter, the master and servant, or light and dark.

The staining process is essentially a type of reveal: When slides are prepared for examination, they serve as invitations. The unseen materializes; the concealed becomes a reality. It is in that moment that the pathologist sees not biology, but metamorphosis : the passage from mist to sign[5],[6]. The color itself becomes symbolic. The nucleus: The darker, the more life there is. A vague guide might be: the paler the cytoplasm, the more tired the cell. In this game, dim and tone, we decipher life and demise, dysfunction and reminiscence.

The artifact — that unwanted blemish — also speaks in symbols. First of all, there is what initially may seem an incidental phenomenon: a fold in the section, a tear, or a pale zone (which serves as the ground in the work of Demichati). But they seem to teach us about the vulnerability of tissues, and thus of life itself[7]. Nothing ever in pathos is meaningless, for error too becomes metaphor when the eye is sufficiently awake to notice their existence.

B. Form as a Symbol of Function

The student of pathology learns one of his earliest lessons: structure is function. But as you grow older in this vocation, that simple quote becomes deep philosophical wisdom. Function, form, adaptation, suffering, and resilience. The spheroid hepatocyte signifies metabolic work, the elongated myocyte contraction, and the branched neuron communication[8].

Then when disease intervenes, these forms skew and deformity becomes a message in itself. An irate cell speaks of trauma, a shattered nucleus of mortality, a sclerotic scar of survival[9]. Each alteration is an indicator, an apparent manifestation of an internal physiological story. A slide of glass are a means of diagnosing as well as a vehicle of philosophical introspection to the reflective pathologist. A tumor's structure may be an indicator of the hubris that occurs when growth is unchecked; the arrangement of necrosis may be indicative of defeat. Commentary about the human experience as it exists between the preserved and the broken[10].

C. The Dance of Order and Chaos

At all levels of biology, from the molecular to the macroscopic, the struggle for order versus chaos exists. The normal tissue has symmetry, an ordered epithelial layer, and an organized stroma with balanced nuclei. However, when disease enters into a tissue space, abnormalcy invades what was once a healthy balance. Cancer cells lose their sense of place and become heterogenous to their previous microenvironment[11]. Yet, even in the midst of chaotic behavior, a form of beauty appears to exist in the eye of the beholder. The pathologist views mitotic figures as more than just indicators of proliferation. They are seen as symbols of defiant cells that refuse to be controlled. The inflammation process also represents a battle of order vs. chaos. In many ways the inflamed tissue, which includes both polymorphous infiltration and vascular congestion, represents a conflict of identity. The use of temporal labelling allows one to see the neutrophils as soldiers who respond to urgent situations, while the lymphocytes represent tacticians of memory[12]. These two types of cells have never intentionally irritated tissue, they define a situation of urgency, establish a plan, and execute it.

From the resulting chaos emerges a new form of order, the fibrosis. Once cellular chaos dissipates, collagen begins to organize in response to injury and becomes a silent acceptance of damage. The resulting scar is the last punctuation mark in the story of healing. To the pathologist, the scar represents both victory and loss. The life is saved, but perfection is lost[13].

D. The Symbolism of Boundaries

Boundaries hold great significance in the world of tissue. The Basement Membrane, that very thin dividing line between epithelial and stromal tissues, carries both structural and ethical weight. When cells obey this boundary, they demonstrate restraint; however, when they disregard this boundary they demonstrate an invasion into neighboring areas[14]. In many ways, the Basement Membrane, and all boundaries in general, serve as a representation of "integrity," if breached; will signal the beginning of malignancy.

Each of the tumor's capsule, the margin of resection, the periphery of necrosis are symbolic representations of transition or thresholds. These are the crossroads between health and disease, containment and diffusion. The pathologist will typically focus on these borders to uncover the truth[15]. There is beauty in these margins. The central area of necrosis within a tumor appears lifeless, however, it provides evidence of the paradox of excess; i.e., a tumor so ravenous for nutrients that it ultimately starves itself. The viable periphery of the same tumor represents persistence and adaptability. Between the necrotic center and the viable periphery is the story of the disease's ambitions and eventual downfall.[16].

E. The Ethics of Seeing

In every single action of observing there are ethics at work. In addition to magnifying cells, the microscope magnifies one's sense of conscience. The ability to name the nature of the disease is essentially the ability to name the nature of one's future. A diagnosis for cancer versus benign can radically shift the path of treatment, emotions, and even survival[20]. Thus, every observation has to be tempered with a consciousness of the consequences. To observe ethically is to observe in a non-hasty manner, free of pride and free of bias. There is certainly a strong temptation to insist on certainty where there is ambiguity. However, true scholarship exists in recognizing the limits of what we know. "Cannot be ruled out" is not a sign of weakness, it is a sign of integrity[21]. This integrity is symbolic of the connection between science and humanity. The tissue provides us with some clues, however it will never provide us with all of the clues. The interpretation of those clues needs to be done with humility, an understanding that the eye can be deceived, the stain can mislead and the pattern can be misleading. This understanding changes pathology from a purely mechanical function to a form of moral art.[22].

F. The Symbolism of Diagnostic Doubt

Doubt in pathology has a sacred role. It protects truth from the arrogance of assumption. The uncertain slide, the ambiguous pattern, the equivocal staining — all these moments of hesitation are deeply symbolic. They remind us that life itself is filled with gray zones. The world inside tissue, like the world outside, rarely conforms to perfect definitions[23].

When a pathologist pauses before making a decision, that pause is not ignorance but reverence. It is an acknowledgment that between shadow and substance lies a spectrum of possibilities. Just as the light of the microscope refracts through varying densities, so too does understanding refract through the complexities of biology[24].

Each time we write “suggestive but not diagnostic,” we confess that truth is layered. The very act of writing such a phrase is a moral gesture which is a commitment to honesty rather than illusion. In this sense, diagnostic doubt becomes a symbol of wisdom. The greatest pathologists are not those who know everything, but those who know when to question what they see[25].

G. The Pathologist as Interpreter of Silence

Every disease has a voice, but not every voice is loud. Some lesions whisper. Some remain mute until years later when the body’s balance collapses. The pathologist’s role is to listen not only to what is said but also to what is left unsaid.

The necrotic zone in a tumor, for instance, may say nothing directly, yet it speaks of hypoxia, of failed vascularization, of a desperate attempt at survival[26]. The fibrotic scar that replaces inflammation tells of the body's reluctant acceptance of loss. Even the normal tissue adjacent to a lesion holds secrets , adaptation, compensation, resilience.

Silence in tissue is never emptiness; it is potential meaning. The same holds true for human life. Many times what is not said speaks louder than that which is declared. Tissue diagnosis is, therefore, a science of presence but also, even more so, of absence[27].

H. Emotional Geometry of the Slide

No matter how experienced a pathologist, they will admit that every slide elicits emotion. A glance brings curiosity, a second brings doubt and a third brings an aspect of intimacy. There is a geometry to this emotion, the circular field of vision is but a reflection of the circularity of reflection itself. Within that bounded space, the mind oscillates between objectivity and empathy.

Certain patterns evoke immediate feelings. The orderly alignment of normal mucosa brings calm. The chaotic invasion of carcinoma stirs unease. The inflammatory exudate evokes sympathy for the body's struggle. The pathologist may not express it aloud, but the emotion exists nonetheless[28].

These emotions do not corrupt judgment; they refine it. They remind the observer that medicine, even at its most microscopic, is a human story. The beauty of a well-stained section or the tragedy of a necrotic field is not purely aesthetic; it is a mirror of the life that tissue once sustained[29].

I. Symbolism in Cellular Identity

In the world of cells, each cell has a specific character or role (like an actor in a play) and is expected to fulfill its obligations and respect those around it. Disease creates a disruption to those relationships. The cell then begins to lose sight of its ancestry and loses all restraint as it wanders off into unauthorized areas of the body, which can be seen as a representation of individualism that has gone wrong[30].

The metastatic cell, which has broken free from its original location and is now floating through space, represents the idea of exile. This cell travels to foreign lands to take over other organs, much like a person who is traveling with no destination or allegiance. On the other hand, the inflammatory cell represents the concept of defending the body (and sacrificing oneself) at risk for the benefit of the entire body[31]. The apoptotic cell, which slowly disintegrates itself, represents dignity in death.

Each cellular action conveys a level of symbolism that transcends biological significance. Through cellular actions, the tissue reflects the moral and existential aspects of being alive. Organ structure that is harmonious with one another is symbolic of cooperation while the chaotic nature of cancer is a direct representation of disobedience. Thus, pathology is able to serve as a symbolic reflection of both the ethical and emotional order of existence.[32].

J. The Mirror of the Observer

In reading the tissues, the tissues are able to read us back. The microscope is both a lens and a mirror reflecting the sample before us as well as our own awareness at the time of viewing. Our interpretation of what appears ambiguous will ultimately reflect how we respond to ambiguity based on our nature. For example, a rapid movement toward certain interpretations will likely be indicative of an impatient individual whereas an ability to remain open and uncertain will be indicative of a deeper person[33].

Even the same field viewed through the microscope will appear differently to each viewer as their differing "selves" come into play with their perception of the cellular structure of the sample. Therefore, the microscope serves as a meeting place for biological and psychological components and provides a diagnostic outcome that is relational (i.e., formed from training, memory, intuition, and empathetic understanding) as opposed to merely mechanical[34]. Because this relational aspect of the process cannot be replaced with technology such as automation or artificial intelligence, machines can measure but do not meditate, machines can categorize but machines cannot consider. The symbolic value of the slide (its aesthetic appeal, its sadness, and its message) is outside of the capability of computers to calculate and determine through algorithms[35].

K. When Diagnosis Becomes Story

Each report coming out of the pathology lab is fundamentally a story. This story starts at the point of suspicion, flows through investigation, and ends when there is a full revelation of what has been found. The terms "consistent with," "likely represents," and "in keeping with" can be seen as the narrative bridges that join the observation of the pathologist to his/her understanding. These bridge terms have the same rhythm and meter as the sentences of literature.

A well-constructed pathology report is essentially an act of translation. This translation is taking the language of cells (the "language of biology") and converting it into the language of care. Beneath each technical term lies emotion, caution, and hope. The

pathologist has taken on the role of being the storyteller of truth, and as such, the pathologist has the responsibility to translate the unseen to the person reading the report.

The dimension of storytelling within pathology reports is not an embellishment; it is a necessity. The process of translating science into the realm of human experience, restoring the emotional aspect of the patient's illness to the scientific analysis, is vital to creating a complete medical picture. The doctor/surgeon who reads the report will not simply read data; he/she will read a story that provides both emotional and practical guidance for their decision-making process.

While a tissue diagnosis is a visual interpretation, it is so much more than that. Tissue diagnoses represent the silence of a myriad of biologies. A nucleus is not just a structure; it is a lengthy paragraph of cellular history. The cytoplasm is the outer boundary of cellular existence. There are footnotes upon footnotes of biological survival occurring within this space. Every single mark on the tissue is a conversation between life and death. The pathologist is the translator of this secret dialogue.

When we state that "tissue never lies," we actually want to mean that tissue never speaks too quickly. While the pathologist waits for the proper interpreter, the only difference between an accurate and inaccurate diagnosis is the degree of precision lost by not having the correct "purchaser" for every tissue section: patience and humility. More frequently than not, the difference between an accurate diagnosis and an incorrect diagnosis is not the quality of the vision, but rather the clarity of the mind's eye.

L. The Symbol of Space and Silence

The spaces between objects (empty) in the microscopic world serve as metaphors for space and time themselves. The "space" or "voids" do not merely represent the absence of things; these voids provide temporal intervals to the symphony of space. Vacuoles, which can appear as voids, can be an indicator of either degenerative processes, transformations, or adaptations. The blank spaces within tissues indicate the place where life once paused before continuing forward. Blank spaces can also help remind us that biology, just like art, has its own poetry of silence.

The microscopic world's cellular structure and the grammatical structure of cell-to-cell relations can be seen by careful observation of sections cut and viewed with a calm eye. Crowding represents desperation. Separation represents loneliness or apoptosis. The nucleic material is interwoven like the chaotic mass of uncontrolled growth, and the clear boundaries represent limitations and respect for boundaries. Therefore, every part of a histological picture can be interpreted as a representation of behavior.

M. The Color of Meaning

Pathology is not an ornamental use of color but is actually an anthropophagic use of it; hematoxylin, which stains the nucleus of cells a blue color, tells you where thought and command are located within the cell; eosin, which stains the cytoplasm of cells a red (or pink) color, tells you where energy and submissiveness coexist in the cell. In combination with each other, these two colors create a dialogue between mind and body, power and submissiveness.

With the addition of routine stains, and the more specialized and mystical world of immunohistochemistry and molecular markers, the use of color in pathology takes on even greater allegorical value. At this level of analysis, color represents identity. A positive reaction to a stain is a declaration, a confirmation that a cell belongs to a particular lineage, clan, or molecular coat of arms. A negative reaction to a stain does not represent a counterpoint, but instead represents a cell that has failed to maintain its conformity to the location it was intended to be[7,8].

N. Tissue as Metaphor of the Human Condition

Prolonged examination of tissue reveals the structure of the human body. Tissue in its normal state symbolizes stability, proportion, and performance. The process of inflammation demonstrates conflict and reaction. The development of neoplastic tissue manifests an uncontrolled desire to grow. The manifestation of necrotic tissue illustrates a final exhaustion with the will to live.

Each diagnostic category in pathology is a representation of existentialism. Hyperplastic cells are cells that have a desire to grow simply for the purpose of growing. Atrophic cells illustrate the quiet acceptance of limitations. Dysplasia is confusion on the end of instability Metaplasia survival by means of conversion. These are not just biological occurrences, are shaped by forces that are also responsible for human decisions[11,12].

When we stand at the edge of malignancy, we are not simply eyeing chaos. And we see a sad drama of lack of governance where growth forgets governance and, on the other, that individuality destroys calls for community. Perhaps cancer, in addition to being the failure of regulation, is thus the metaphor of isolation. Its a cell whose is part of the collective and not known as of itself, and so it tries for immortality, but this time through the detriment of wholeness[13,14].

O. Between the Knife and the Eye

Diagnosis is always held in the balance between the knife-cutting and the eye-seeing. The blade of the pathologist, short and lethal, has performed the most elementary of metaphysical arts: it has taken the Whole and divided it into analysable parts.. It creates knowledge through separation. But this separation is not destruction. It is a ritual of understanding[15].

When the microtome slices through tissue, it is as though we are slicing through memory. Each section is a fraction of truth, not the whole truth. To believe that one section alone tells the entire story is to mistake a single word for an entire book. That is why the art of diagnosis requires imagination: the ability to reconstruct wholeness from fragments[16],[17].

P. Light as Revelation

Light, the quiet partner of the pathologist, is the final interpreter. It is through light that tissue reveals its inner architecture. In a way, the microscope is an altar, and light is its sacred flame. The play of illumination on stained sections transforms mere material into meaning. The pathologist, peering through the eyepiece bends down to perform an act of discovery that is very similar to what pathologists have done for nearly one hundred years.

However, there are also shadows of light. The quality of lighting is important because poor lighting can affect how we interpret what we see, just as bias can affect our judgment. We must develop the ability to observe, not just what we see using the microscope, but what lies beyond the lens of the microscope to be able to see clearly with a sense of understanding and not simply with a sense of comfort and familiarity[19],[20].

Q. The Ethic of Observation

Observation in pathology is not neutral. Every gaze carries moral weight. The diagnosis that follows may change a life, dictate a therapy, or alter a family's destiny. Therefore, observation must be pure, unhurried, and free from the pollution of presumption[21],[22].

The symbolic act of "looking" in pathology is thus not mere visual function but ethical engagement. The tissue that lies before us is not an object; it is a testimony. It once formed part of a living being who trusted that we would interpret it with dignity. Each slide, therefore, is both scientific evidence and sacred relic. To observe it without reverence is to betray its truth[23].

R. The Hidden Music of Form

All morphology has rhythm. The arrangement of cells, the sequence of ducts, the recurrence of patterns as they all form an unspoken music. When that music falters, disease emerges. The pathologist, like a musician, must learn to hear dissonance. An infiltrative carcinoma disturbs the rhythm of the parenchyma; a fibrotic scar dulls the resonance of vitality. Recognition of disease is, therefore, the recognition of broken music[24],[25].

To restore that rhythm in understanding is the aim of diagnosis. It is not merely to label disease but to appreciate its composition. Pathology, in this sense, is the musicology of the body which is the study of its harmonies and discords.

S. Between Shadows and Substance

And so we return to the title of this reflection - Between Shadows and Substance. Pathology lives precisely in that interval. The shadow is the morphology: the visible, the tangible, the patterned. The substance is the truth beneath it: the biological intent, the molecular logic, the unseen motive. The great danger of mechanistic medicine is confusing shadow for substance[26].

And the experienced pathologist knows how to tread this tightrope. The shadow, he must perceive, but the reality is what Seeks. He has to see patterns without following them. Each diagnosis is however both a recognition and an act of imagination.

This balance is what makes the moral value of the field so beautiful. We all become scientists as poets of evidence. Our microscope, beyond being a tool to show the details of life, is actually a mirror that shows how we view life itself.

In essence, Tissue Diagnosis is the art of taking the invisible and transforming it into an understanding of it. It serves as a reminder to physicians and patients alike that sometimes the truth is right in front of you and can only be revealed by having the right perspective or "eyes" to see it.

Slide, Stain, Cell, etc. represent the bigger picture of life and the universe. Each time a pathologist signs off a report, they confirm both the accuracy of their findings, and the continuation of the relationship of trust between Medicine and Humanity. In the vast area of form (morphology) and substance (meaning), lies the quiet wonder of diagnosis. This is an art that needs both Science and Faith, Logic and Intuition, and most importantly Humility.

Though the tissue on the glass may be silent, it tells the story of life, of struggle, of memories. The Pathologist listens. In that act of listening, Medicine finds its greatest

Metaphor; that even though broken down into parts, the Spirit still tells the story of the Body.

References:

[1] Kumar V, Abbas AK, Aster JC. Robbins and Cotran Pathologic Basis of Disease. 11th ed. Philadelphia: Elsevier; 2024.

[2] Rosai J. Rosai and Ackerman's Surgical Pathology. 11th ed. Elsevier; 2018.

[3] Weinreb I. The art and science of histopathologic interpretation: a narrative reflection. Mod Pathol. 2020;33(3):451–459.

[4] Damasio A. The Feeling of What Happens: Body and Emotion in the Making of Consciousness. New York: Harcourt; 1999.

[5] Kassan DG. Histopathology and the metaphor of space: reflections on emptiness and form. Hum Pathol. 2017;64:24–30.

[6] Bancroft JD, Gamble M. Theory and Practice of Histological Techniques. 8th ed. Elsevier; 2019.

[7] Shi SR, Taylor CR. Antigen retrieval and epitope exposure in immunohistochemistry: history and theory. J Histochem Cytochem. 2017;65(1):5–23.

[8] Ramos-Vara JA. Technical aspects of immunohistochemistry. Vet Pathol. 2011;48(1):42–87.

[9] Cotran RS. Morphology as metaphor: reflections on disease as disorder. Am J Pathol. 1998;153(5):1313–1320.

[10] Chugh S, et al. Necrosis, regeneration and the symbolic language of tissue: a modern reinterpretation. Histopathology. 2021;78(2):215–225.

[11] Wright JR. The evolving role of the pathologist as philosopher of disease. Histopathology. 2022;80(6):831–841.

[12] Laín Entralgo P. The Healing Relationship: Doctor, Patient and Society. New York: Elsevier; 1969.

[13] Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell. 2011;144(5):646–674.

[14] Couzin-Frankel J. Cancer's complexity: the many faces of a single disease. Science. 2013;342(6161):1320–1322.

[15] Srigley JR. The histologic section as narrative: the knife, the slide, and the search for meaning. Am J Surg Pathol. 2019;43(12):1639–1647.

[16] Burton JL. A bite of the apple: on the limits of histologic sampling. Histopathology. 2015;66(5):635–642.

[17] Balis JU. The microtome and the metaphor: slicing the truth of tissue. Arch Pathol Lab Med. 2018;142(2):127–134.

[18] Underwood JCE. General and Systematic Pathology. 6th ed. Elsevier; 2019.

[19] Barisoni L, Kriz W. The power and peril of visual diagnosis in renal pathology. Kidney Int. 2016;90(6):1209–1217.

[20] Lester SC. Manual of Surgical Pathology. 5th ed. Elsevier; 2021.

[21] Lundberg GD. Ethical dimensions of diagnostic pathology. Arch Pathol Lab Med. 2014;138(6):745–748.
[22] Sappol M. A Traffic of Dead Bodies: Anatomy and Embodied Social Identity in Nineteenth-Century America. Princeton University Press; 2002.
[23] Foucault M. The Birth of the Clinic. New York: Vintage; 1975.
[24] Pinar A. The rhythm of form: aesthetic perception in histopathology. Diagn Pathol. 2019;14(1):63–70.
[25] Bussolati G, Comoglio PM. Pattern and rhythm in tissue architecture: lessons from morphology. Virchows Arch. 2021;479(5):905–915.
[26] Lakhani SR. Morphology and molecular pathology: bridging shadow and substance. J Clin Pathol. 2020;73(10):582–589.
[27] Gatter KC, Brown DC. The art of seeing: pathology as epistemology. Histopathology. 2018;72(1):1–9.
[28] Kumar RK. The humanity of the microscope: reflections on pathology as narrative. Pathology. 2022;54(3):325–331.
[29] Evans AJ. Digital pathology and the transformation of diagnostic vision. Mod Pathol. 2020;33(3):373–380.
[30] Tavassoli FA. The moral beauty of tissue diagnosis: a personal reflection. Hum Pathol. 2016;55:1–7.

Deep Science Publishing, 2025
https://doi.org/10.70593/978-93-7185-400-9

DeepScience
Open Access Books

Chapter 3: Cognitive Bias in Microscopic Vision: The Human Factor in Diagnostic Confusion

In the stillness of the laboratory, the pathologist's eyes meet a slide that is both instantly familiar yet also mysterious. Every cell, every nucleus, every aspect of the architecture has a story to tell. However, the human mind is neither completely objective nor always accurate. It sees and interprets, filters out and can even distort what it observes. Cognitive biases act as an unseen lens on perception and influence how we view every glance and draw conclusions about what we see. The errors or distortions that occur due to cognitive biases are not failures of intellectual reasoning, they are simply inherent characteristics of the human observer that subtly affect the medical decisions made based on observations and the quality of patient care.

The observation of pathology is a dialogue between the observer (the eye) and the interpreter (the mind). The slide provides the factual basis of the physical structure of the tissue; however, the mind interprets those facts based upon its accumulated knowledge, past experiences, expectations and possibly fatigue. A variety of cognitive distortions including anchoring, confirmation bias and others do not result from a lack of attention to detail, rather they represent the normal ways in which the brain functions to be efficient. The mind looks for patterns, tends to seek coherence, and is drawn to things that look like what it knows best. In this process, it may fail to identify slight deviations and in the failure to recognize these deviations, there exists the possibility of an error in diagnosis.

A. The Architecture of Bias

The effects of cognitive bias occur when a person makes decisions based on expectations rather than objective fact. Cognitive bias has an effect on how a pathologist interprets microscopic images because they are looking at the microscopic image with a preconceived idea of what they expect to see (their subjective frame of reference) rather than being purely objective. Confirmation bias is a cognitive bias that leads a person to

focus their attention on characteristics of a microscopic image that confirm their hypothesis, and to disregard characteristics that contradict that hypothesis. Anchoring bias is a cognitive bias in which the first impression that a person forms of a microscopic image becomes the anchor for all subsequent impressions that person will form.

Pathology is an example of an area of study in which perception is highly influenced by prior experience and mental state. A single nuclear change can determine whether a tumor is benign or malignant; therefore, in pathology, small deviations from the expected result may be significantly weighted due to the way in which humans perceive and interpret information. Perception, cognition, and the observer's prior experiences, mental states, and contexts cannot be separated..

B. Anchoring Bias: The Seduction of First Impressions

Microscopic diagnostic anchoring bias, is arguably one of the most insidious of all the cognitive traps. Once an initial impression of a microscopic lesion (benign vs malignant) has been made, it creates a cognitive anchor. This anchor will influence the observer's subsequent interpretations; i.e., if a biopsy is labeled "likely reactive," the observer will likely interpret atypical nuclei as benign, even when objective criteria indicate otherwise. On the other hand, exposure to an exceptionally malignant case in the morning, may lead the observer to be overly critical of ambiguous changes during the rest of the day.

Anchoring bias is further enhanced by training and experience. Pathologists develop mental models for common entities, allowing for rapid identification and increased efficiency of the workflow. However, these mental models can also act as a "blind spot." When atypical presentations deviate from the mental model, the mind may unconsciously force the observation into pre-existing expectations. Anchoring bias must be recognized through conscious reflection and deliberate questioning: Is the diagnosis derived from the current microscopic examination of the slide, or from prior impressions?

C. Confirmation Bias: The Comfort of Agreement

Confirmation bias can also reinforce anchoring by drawing an observers' attention towards any evidence supporting a prior hypothesis while excluding conflicting evidence. In microscopic examination confirmation bias may occur when the observer's attention is selectively drawn to well-known nuclear characteristics while ignoring abnormal cell morphology or architectural disruption.

A lymph node biopsy may contain early lymphoma if it was initially believed to be reactive, and if the pathologist is biased towards small, mature lymphocytes and ignores

small clusters of large atypical cells the diagnosis will likely be missed. On the other hand, once the clinician has a strong suspicion for malignancy the clinician may begin to see too much significance in minor abnormalities which are typically benign. As such, confirmation bias increases the amount of expectation while decreasing the weight of negative evidence.

D. Visual Cognition and Pattern Recognition

A microscopic examination represents an interplay of the way that we visually recognize patterns and how they are remembered by our brains. Humans are capable of recognizing many patterns because this ability is evolutionary advantageous; however, it also predisposes us to make errors. Experienced pathologists use mental "libraries" of morphology to rapidly identify and classify common objects. This efficiency in the identification process may inadvertently perpetuate and enhance the effect of anchoring and confirmation biases.

The cognitive load associated with fatigue, stress, and distraction increases the reliance on heuristics for decision-making, thereby increasing the likelihood of errors. Even minor lapses in judgment in a field that is defined by the presence or absence of subtle morphological differences, have significant clinical implications. Therefore, observers need to strike a balance between speed of examination and thoroughness; pattern recognition and critical thinking; and efficiency and deliberate reflection.

E. The Ethical Dimension of Cognitive Bias

A Pathologist does not simply view cells, he/she has a responsibility to patients' lives. The potential for mis-interpretation in pathology has the potential to change the course of treatment, patient's overall prognosis, and patient's trust in their physician. A pathologist practicing in a manner that is ethical must be vigilant for cognitive shortcuts, and recognize that the brain's tendency to make mental short cuts will affect what happens with each case. Thinking about how you think (metacognition), is one of the most important tools that a pathologist can have to help him/her from being influenced by cognitive biases, specifically, "Anchoring" and "Confirmation".

Peer Review, Second Opinions, and Systematic Slide Review are all ways that pathologists use to create a check against individual bias through the redistribution of cognitive load.

F. Reflections on Human Perception

The ability to rapidly recognize or interpret is due to the same cognitive processes that lead to errors. As such, expertise is inherently biased by the same mechanisms that allow for those rapid interpretations. Anchoring and confirmation biases serve as a reminder that observation is subjective and that humans are prone to cognitive biases. These biases are a natural part of being human, and this is why it's so important for pathologists to develop a sense of self-awareness, reflective thinking, and a commitment to lifelong learning. Knowing you have a bias is a major transformation in how you utilize your bias. Once you know you have a bias, you can use that knowledge to intentionally counteract it, which will result in what could otherwise be error becoming an intentional choice, and therefore, an intentional act of reflective thought. The microscope isn't just used for measurement, but also as a vehicle for philosophical inquiry. With each case, there is a negotiation between what we expect to see (bias) and what we actually see (evidence).

Cognitive biases work subtly and the best way to understand them is through case studies. A cervical biopsy was read as low-grade dysplasia initially. That initial read created an anchor for the observer, and for a very short time, anything that didn't fit the initial impression was ignored. Upon additional sectioning, early carcinoma became apparent. This illustrates how powerful and subtle the anchoring bias can be. Skilled observers can be misdirected by their own initial impressions of a case. A similar example is found in a liver biopsy from a patient who has had chronic hepatitis. Initially the observer identified regenerative changes and ignored scattered atypical hepatocytes. Confirmation bias supported the original diagnosis and the observer looked for characteristics that would support the benign interpretation while ignoring any characteristics that wouldn't.

These examples illustrate that the bias isn't about negligence on the part of the observer, but rather, it is an inherent aspect of human cognition. However, developing a high level of self awareness, developing a habit of reflective thinking and making a commitment to watching for your biases are necessary to recognizing and managing them.

G. The Human Factor in Diagnostic Confusion

The cognitive bias in pathology is really a narrative of the human eye. All such factors impact microscopic interpretation including the observer's own knowledge, expectations, fatigue and even mood [10],[11]. She puts a microscope on not just the tissue but the thoughts that lead to the tissue. Because pathologists need to create templates for identifying patterns, these mental shortcuts can both benefit and hinder a pathologist trained to spot neutral and/or familiar patterns. They enable quick identification of

common entities whilst priming for misdiagnosis when presentations stray from the familiar[12],[13].

Then there's also the emotional part of the equation. Previous experience with a dramatic malignancy can create a heightened state of awareness that lends itself to overinterpretation. On the other hand, long exposure to benign cases can make us complacent with subtle atypia[14],[15]. Microscopic perception, then, becomes wedded to the observer's affective experience of the world, and bias occurs at the intersection between cognition, emotion and expectation[16],[17].

H. Strategies to Recognize and Mitigate Bias

Awareness of cognitive bias is the first step in mitigation. Pathologists should be mindful that what they see is conditioned by previous experiences and expectation[18],[19]. Metacognition, or structured reflection, gives observers a chance to stop and consider whether what they are observing is a reflection of truth or history written through mental shortcuts. Double-reading is an institutional mechanism that can help remove bias on a personal basis. Double-reading means that another pathologist will review your findings. Peer-review is also a way to have other pathologists evaluate your findings. It's useful to share your slides with your colleagues so you can get their perspective; this allows them to find something that you may have missed. Having a systematic approach to reviewing slides (i.e., all areas are reviewed) will reduce the possibility of selectively focusing on one area of concern and skewing your judgment.

Using technology such as digital pathology and computerized image analysis can provide a numerical assessment of microscopic images which may bring out details that would otherwise be missed by humans alone. However, use of technology does not eliminate the need for a human interpreter to assess those images. The best ways to avoid cognitive biases are through awareness of how we think, self-reflection and collaboration.

I. The Role of Training and Experience

Experience will not eliminate biases; however experience will help shape how a skilled pathologist manifests a bias. The development of a schema for a pathologist in order to recognize patterns improves efficiency by providing a framework for making diagnoses in a timely manner; however this same framework creates an opportunity for the pathologist to fall victim to ananchoring or confirmatory bias. Therefore, education that is focused on teaching variability, atypical presentations and the limitations of relying on patterns will assist in mitigating the impact of a bias. Educational strategies include

the use of the retrospective case review process, exposure to rare entities and the use of a structured reflection process to foster cognitive flexibility. This allows the pathologist to look at each case individually and avoid categorizing the case based upon previously learned experiences, and encourages the pathologist to use their intuition to make a diagnosis while using deliberate and evidence based decision-making processes.

J. Bias as an Ethical Concern

Cognitive bias affects patient care and treatment as well as patient results. Each slide has the potential for serious implications in terms of the quality of care patients receive. Bias may lead to delayed diagnoses, misinterpreted treatment options or diminish public trust in physicians. Pathology involves a moral obligation to actively resist the tendency to use cognitive short cuts. Pathologists have a professional duty to be vigilant about using observational skills in a thoughtful and purposeful way.

Understanding that all observations involve some level of cognitive bias turns what was once a purely scientific process into an ethically based activity. It is an acknowledgment that interpreting tissue is not only a scientifically based process, but is also a morally responsible one. Each sample sent for analysis represents the life and experiences of a person.

K. Emotional and Philosophical Dimensions

The influence of cognitive biases is so deeply rooted within the nature of humanity that the mind has a strong desire to create both a coherent narrative and to understand the seemingly random variability present in biological tissues. The influences of anchoring and confirmation bias illustrate how humans have an innate tendency to identify and impose structure and expectations upon the world. Both of these biases exemplify how the process of observing is not simply a passive activity; rather it is an active collaboration between the observer's perception, cognition, and the creation of meaning.

Incorporating philosophy regarding the presence of cognitive bias allows pathology to become an activity of self-reflection. The observer now recognizes that the tissue before them does tell a story; however, the observer's own mental construct can alter that story by means of their preconceptions and prior knowledge. Therefore, the observer's cognitive and emotional awareness of their potential biases allows the observer to elevate the process of microscopic observation from a purely mechanical task, to one of profound engagement with ambiguity, evidence, and accountability.

Therefore, cognitive bias is a natural part of all human perception, especially when human observers need to identify specific patterns in their field of work (i.e., pathology).

Anchoring and confirmation bias do not represent intellectual failures, but rather represent natural inclinations of the human brain. These biases operate covertly, frequently without conscious acknowledgment and they affect the observer's focus, interpretation and decision-making processes.

Examples of cases illustrate that the presence of cognitive bias can lead to delayed diagnosis, obscure subtle characteristics and result in the over-reading of tissue samples. Tools that assist in reducing the negative effects of cognitive bias include awareness, structured self-reflection, peer-review and technology. Education that incorporates variability, uncharacteristic presentations, and an intentional skepticism of the material being examined promote cognitive flexibility among observers.

Ultimately, the study of cognitive bias in pathology represents a study of the nature of human perception itself. The microscope allows the observer to visualize the tissue; however, the microscope also illustrates the observer themselves. Through a greater understanding of cognitive bias and the ability to think about and analyze cognitive bias, the practicing pathologist will practice with increased clarity, precision and ethical responsibility. In this interaction between the observer and the tissue, the limitations of human cognition and the possibility of making a conscious, thoughtful and perceptive observation are created.

While there is growing awareness regarding cognitive bias and its impact on human observation, the challenge of eliminating its effects remains significant. The mind's tendency to rely upon established patterns and to create a sense of coherence is a fundamental aspect of human cognition and will not be able to be completely removed. However, recognizing and acknowledging the presence of cognitive bias transforms these influences into observable events which can be recognized and negotiated consciously. Recognizing these aspects of human cognition encourages the observer to engage in a conscious dialogue between what the slide presents and what the observer expects to see. This involves a willingness to accept limitations, to maintain a state of awareness, to make conscious choices regarding the objects of observation and to be mindful of the ethics involved in the observational process.

Pathologists who incorporate self-reflection as an essential component of their daily practice develop the ability to stop, assess and ask questions. These observers recognize that the initial assessment is not necessarily the definitive assessment and that each cell, each acinar unit, each slight deviation of the cytoplasmic membranes presents a unique story that may vary significantly from the observer's original expectation. This attitude creates a conscious approach to microscopic observation and converts the process from a mechanical action to a philosophical exchange. Each slide becomes a dialogue between the tissue and the observer where the tissue provides subtle details of its characteristics and the observer listens with humility and a critical eye.

L. Integrating Technology with Human Cognition

Tools such as digital pathology, AI, and computerized image analysis allow pathologists to identify or emphasize characteristics of tissue samples which may go unnoticed using human vision. The use of quantitative metrics, pattern recognition algorithms, and digital overlays enables a pathologist to identify abnormalities in images which may have been overlooked by even the most experienced eye. While technology provides additional assistance for pathologists to aid in their visual assessment of samples, it cannot eliminate the need for pathologists to rely on their own judgment when making diagnoses. Technology enhances the capabilities of pathologists; however, it also necessitates increased awareness of the potential interpretative biases of the mind.

In order to effectively integrate technology into their practice, pathologists will be required to develop a new form of cognitive discipline. They will need to understand how the suggestions of algorithms are interpreted, and resist the tendency to take them at face value. Rather than attempting to suppress bias associated with interpreting images, pathologists can utilize the advantages of human insight along with the accuracy of technology to synthesize interpretations of images.

M. Advanced Strategies for Minimizing Bias

Cognitive bias has many practical applications. For example, using a blind review system in which an individual's clinical history or past impression is temporarily hidden from their view helps eliminate preconceived notions about what they will see during the observation process. Additionally, utilizing systematic slide review (i.e., evaluating all regions of the slide independently of first impressions) can help reduce selective attention, one common source of cognitive bias. Similarly, deliberately thinking through alternative diagnosis possibilities, a technique referred to by some as "differential forcing," can assist individuals in making more objective decisions regarding diagnostic alternatives when there is conflicting evidence.

In addition to the above, structured reflection, self-awareness, and conscious attempts at slowing down thought processes will be important tools. Intentionally stepping away, re-viewing the tissue in your mind, and questioning your own interpretation can increase cognitive flexibility. Furthermore, peer-review systems, consulting with other professionals, and multidisciplinary case conferences can provide social mechanisms that help reduce the cognitive burden of an individual and provide them with an opportunity to receive input from others who may have had different perspectives. The combination of these various methods will create a comprehensive approach to help reduce the impact of bias on a clinician's decision-making process while maintaining an efficient workflow.

N. Bias, Error, and the Human Condition

Cognitive bias has a number of philosophical and symbolic implications as well. Cognitive error is not just the result of poor thinking; rather, cognitive error demonstrates the human quality of the observer. The brain functions as an organ of interpretation, which is shaped by one's experiences, expectations, and emotions. As such, in pathology, where the outcome is often determined by minor or subtle variations, the human aspect of the observer can be seen at the microscopic level.

Confirmation and anchoring bias serve to illustrate how perception is not always objective, but is influenced by the mind's need for order and coherence versus the inherent complexity of the tissues being examined. The fact that there exists this duality does not indicate a deficiency in the way we observe, but rather indicates the natural characteristics of how humans observe. Being aware of these biases will lead to a more reflective approach to observing, acknowledging uncertainty, exercising caution, and emphasizing ethics.

O. The Poetics of Error

Philosophically speaking, there are valuable lessons in an error, or misinterpretation. In particular, an error demonstrates how far our perceptions can fall short of reality, and the degree to which we rely on recognizing patterns. An error in this context also reminds us that the slide before us is merely a static image, but one that presents an opportunity for us to engage with uncertainty, and the complexities of biological systems.

Through reflection on errors, Pathologists will develop a sense of humility; they will realize that no matter what their experience level, they will always take mental shortcuts, and therefore, that they must always remain vigilant. Ultimately, the "poetics" of error, turns pathology into both a scientific and an artistic discipline, and an ethical, emotional, and philosophical one as well.

P. Human Factors and Systemic Support

Cognitive bias is not the only factor that impacts performance. It is influenced by various environmental, organizational and system-related factors. Workload, time constraints, fatigue and interruptions can affect how likely a cognitive bias will occur; however, acknowledging their impact on the manifestation of cognitive bias creates opportunities for structural intervention. Structural interventions include scheduled breaks, appropriate workload and peer support systems that together help mitigate errors. When organizations recognize the existence of cognitive bias, they create a culture of reflective practice. Organizations that recognize the presence of cognitive bias encourage

continuous learning and critical discussions about cognitive bias. In an environment where there is no stigma or blame attached to cognitive bias, individuals recognize that cognitive bias exists in every interaction with tissue, and therefor it is incumbent upon them to be aware of and actively manage their cognitive bias.

As a final thought, cognitive bias is deeply entwined into the human perceptual process. Anchoring, confirmational and other types of cognitive bias are present in every encounter with tissue. They are not always apparent, often unconscious, and are extremely difficult to avoid; however, they demonstrate the incredible ability of the human brain to quickly and effectively interpret complex information.

The skill of the pathologist lies in understanding and working around these cognitive processes. Methods to promote awareness and moderate cognitive bias include peer review and discussion, the use of systematic review, and technological integration that promotes accurate interpretation. The pathologists' eye is capable of seeing, but the mind needs training to think critically and challenge its own assumptions. Therefore, when observing tissue, the pathologist must navigate a dialogue between the tissue and themselves to achieve clarity that is derived from a combination of their conscious and critical thinking rather than suppressing their human nature. Thus, the practice of pathology is both a science, ethics, and philosophy that represents a balance of expectations and evidence, instinct and logic, and individual fallibility and accountability.

As the pathologist navigates the fine line between what is real (substance) and what is perceived (shadow), and between patterns observed in tissue and the perceptions of the observer, cognitive bias serves as a reminder of the limitations of our minds and the potential for increased awareness, accuracy and ethical behavior when we are engaged with live tissue.

References

[1] Kahneman D. Thinking, Fast and Slow. New York: Farrar, Straus and Giroux; 2011.

[2] Croskerry P. Cognitive forcing strategies in clinical decision making. Ann Emerg Med. 2003;41(1):110–120.

[3] Redelmeier DA. The cognitive psychology of missed diagnoses. Ann Intern Med. 2005;142(2):115–120.

[4] Trowbridge RL, et al. Cognitive bias and clinical decision making. Acad Med. 2013;88(7):1029–1035.

[5] Norman GR, Eva KW. Diagnostic error and clinical reasoning. Med Educ. 2010;44(1):94–100.

[6] Graber ML. The incidence of diagnostic error in medicine. BMJ Qual Saf. 2013;22(Suppl 2):ii21–ii27.

[7] Croskerry P. From mindless to mindful practice — cognitive bias and clinical decision making. N Engl J Med. 2013;368:2445–2448.
[8] Saposnik G, et al. Cognitive biases in medical decision making. BMC Med Inform Decis Mak. 2016;16:70.
[9] Norman GR, Young M, Brooks LR. Non-analytical models of clinical reasoning. Med Educ. 2007;41(12):1140–1145.
[10] Mamede S, Schmidt HG. Cognitive perspectives on diagnostic error in medicine. J Eval Clin Pract. 2004;10(1):59–66.
[11] Schiff GD, et al. Diagnostic error in medicine: analysis of 583 physician-reported errors. Arch Intern Med. 2009;169(20):1881–1887.
[12] Redelmeier DA. Improving diagnosis in medicine. BMJ. 2005;330:839–841.
[13] Elstein AS. Heuristics and biases: selected errors in clinical reasoning. Acad Med. 1999;74(7):791–794.
[14] Tversky A, Kahneman D. Judgment under uncertainty: heuristics and biases. Science. 1974;185:1124–1131.
[15] Croskerry P. Cognitive error in diagnosis: implications for patient safety. J Crit Care. 2003;18(4): 245–251.
[16] Eva KW. What every teacher needs to know about clinical reasoning. Med Educ. 2005;39(1):98–106.
[17] Norman G. Dual processing and diagnostic errors. Adv Health Sci Educ Theory Pract. 2009;14(Suppl 1):37–49.
[18] Graber ML, Franklin N, Gordon R. Diagnostic error in internal medicine. Arch Intern Med. 2005;165(13):1493–1499.
[19] Croskerry P, Singhal G, Mamede S. Cognitive debiasing 1: origins of bias and theory of debiasing. BMJ Qual Saf. 2013;22(Suppl 2):ii58–ii64.
[20] Norman GR, Young M, Brooks LR. Non-analytical models of clinical reasoning. Med Educ. 2007;41(12):1140–1145.
[21] Eva KW, Regehr G. Self-assessment in the health professions: a reformulation and research agenda. Acad Med. 2005;80(Suppl 10):S46–S54.
[22] Kassirer JP. Teaching clinical reasoning: case-based and coached. Acad Med. 2010;85(7):1118–1124.
[23] Croskerry P. Achieving quality in clinical decision making: cognitive strategies and detection of bias. Acad Emerg Med. 2002;9(11):1184–1204.
[24] Shapiro M, et al. The influence of bias on diagnostic judgment in pathology. Arch Pathol Lab Med. 2012;136:1444–1450.
[25] Schmidt HG, Mamede S. How to improve the teaching of clinical reasoning: a narrative review and a proposal. Med Educ. 2015;49(10):961–973.
[26] Eva KW, Norman GR. Heuristics and biases – a biased perspective on clinical reasoning. Med Educ. 2005;39(7):870–872.
[27] Graber ML, et al. Cognitive interventions to reduce diagnostic error. BMJ Qual Saf. 2012;21:535–540.
[28] Croskerry P. A universal model of diagnostic reasoning. Acad Med. 2009;84(8):1022–1028.
[29] Saposnik G, et al. Cognitive biases associated with medical decisions: a systematic review. BMC Med Inform Decis Mak. 2016;16:109.

[30] Schiff GD. Minimizing diagnostic error: the importance of cognitive psychology. Acad Med. 2012;87(8):1101–1107.
[31] Trowbridge RL. Teaching clinical reasoning. Acad Med. 2007;82(6):606–611.
[32] Eva KW, Regehr G. Exploring the divergence between self-assessment and feedback. Med Educ. 2007;41(12):1223–1229.
[33] Croskerry P. Cognitive forcing strategies in diagnosis. Ann Emerg Med. 2003;41(1):110–120.
[34] Norman GR. Dual processing in reasoning: the case for intuition and analysis. Adv Health Sci Educ Theory Pract. 2009;14(Suppl 1):37–49.
[35] Mamede S, Schmidt HG, Rikers RM. Diagnostic errors and reflective practice. Med Educ. 2007;41(6):539–546.
[36] Graber ML. Diagnostic errors in medicine: a case study approach. Am Fam Physician. 2007;76(1):38–44.
[37] Norman G, Eva KW. Diagnostic error in internal medicine. BMJ. 2010;340:c2574.
[38] Croskerry P. From mindless to mindful practice. N Engl J Med. 2013;368:2445–2448.
[39] Saposnik G, et al. Cognitive biases in medical decision making. BMC Med Inform Decis Mak. 2016;16:70.
[40] Elstein AS, Schwarz A. Clinical problem solving and diagnostic decision making. In: Clinical Problem Solving in Medicine. 2nd ed. London: Butterworth-Heinemann; 2002. p. 1–30.
[41] Schiff GD. Minimizing diagnostic error. Acad Med. 2012;87(8):1101–1107.
[42] Graber ML, et al. Cognitive interventions to reduce diagnostic error. BMJ Qual Saf. 2012;21:535–540.
[43] Croskerry P, Singhal G, Mamede S. Cognitive debiasing 2: impediments to and strategies for change. BMJ Qual Saf. 2013;22(Suppl 2):ii65–ii72.
[44] Norman GR, Eva KW. Diagnostic error and clinical reasoning. Med Educ. 2010;44(1):94–100.
[45] Kassirer JP. Teaching clinical reasoning: case-based and coached. Acad Med. 2010;85(7):1118–1124.
[46] Shapiro M, et al. Cognitive bias in pathology diagnosis. Arch Pathol Lab Med. 2012;136:1444–1450.
[47] Schmidt HG, Mamede S. How to improve the teaching of clinical reasoning. Med Educ. 2015;49(10):961–973.
[48] Eva KW, Norman GR. Heuristics and biases – a biased perspective. Med Educ. 2005;39(7):870–872.
[49] Croskerry P. Achieving quality in clinical decision making. Acad Emerg Med. 2002;9(11):1184–1204.
[50] Graber ML, Franklin N, Gordon R. Diagnostic error in internal medicine. Arch Intern Med. 2005;165(13):1493–1499.
[51] Tversky A, Kahneman D. Judgment under uncertainty: heuristics and biases. Science. 1974;185:1124–1131.
[52] Norman GR, Young M, Brooks LR. Non-analytical models of clinical reasoning. Med Educ. 2007;41(12):1140–1145.

Deep Science Publishing, 2025
https://doi.org/10.70593/978-93-7185-400-9

DeepScience
Open Access Books

Chapter 4: Inflammation Versus Neoplasia: The Borderlands of Reactive Pathology

The transition from benign to malignant in those contexts is a continuum. It's not a ladder that you climb up, it's a gradient; an intentional transformation from repair to destruction.

It's worth considering the ductular reaction, since it can be considered a tipping point between regeneration and neoplasia. Histologically, these ductules are formed from periportal areas of the liver and form long strings or small ducts encircled by fibrotic tissue and inflammation. Bile plugs are found in the lumens of some of these ductules, the cytoplasm of others appears blue/black and the nuclei although uniform appear misaligned. While the morphology of ductular reactions does differ from cholangiocarcinomas, the transitions are generally not instantaneous. A number of lesions have been identified as being intermediate in nature and were designated as "biliary intraepithelial neoplasia" (BilIN). These lesions represent a morphologic bridge between the ductular reaction and carcinoma and can be seen as abnormal, flat or micro-papillary epithelium lining the pre-existing ducts of the liver, representing potential precursor fields to carcinomas. The recognition of BilIN has changed our understanding of the process of cholangiocarcinogenesis from a single step jump from normalcy to a continuum of molecular dysregulation.

This mimicry also has its own radiology-based terminology. Small duct type intrahepatic cholangiocarcinomas may present as masses in the setting of cirrhosis of the liver, whereas ductular proliferations may present as regenerative foci with peripheral enhancement. Even advanced imaging techniques, such as diffusion weighted MRI and contrast enhanced ultrasound, have difficulty distinguishing mimics from true malignancies.

A. Granulomas: Organized Chaos

Granulomas provide an example of the contradictory aspects of reactive pathology. Granulomas can be thought of as organized reactions that have the appearance of neoplasms in terms of density and architectural organization; however, the source of the granuloma is inflammatory. The epithelioid histiocyte, multinucleated giant cell, and lymphocytic cuff can form nodular lesions that may have the appearance of carcinoma or lymphoma when viewed macroscopically. The formation of granulomas is indicative of the immune systems ability to coordinate a complex, localized reaction to the presence of antigens persisting within tissues.

When caseating granulomas are formed by mycobacterial infections, they may appear as firm nodules that may mimic a malignant process. In addition, sarcoidosis can be confused with a lymphoproliferative process because the non-caseating granulomas that penetrate into the tissue planes can give the impression of a neoplastic process. Distinguishing between reactive granulomatous lesions and neoplastic processes will require the pathologist to use all available resources including morphology, clinical correlation, special stains, and in some instances molecular analysis to arrive at a diagnosis.

The essence of granulomas lies in their dualism. They are both orderly and chaotic, responsive and organized. They are both protective mechanisms and destructive forces in the "borderlands" between inflammation and the recapitulative nature of neoplasia.

B. Pseudotumors: The Masquerad

Performance of Pseudotumors , The Pseudotumor Actors Are the Stars of the Reactive Pathology Stage.

While fibroinflammatory reactions, immune-mediated inflammatory responses, and local proliferative processes do not represent neoplastic growth, they can mimic neoplastic growth with great fidelity. For instance, while orbital pseudotumors may present clinically as increasing masses which could simulate lymphoma, IgG4-related sclerosing disease can also produce tumefactive (enlarged) lesions in many areas of the body potentially simulating malignancy.

One of the biggest challenges for the pathologist is recognizing that size, density and cellular proliferation are not exclusive characteristics of neoplasms. While a reactive proliferation may be very active, it will still display architectural and cytologic characteristics, and molecular markers that clearly indicate its benign immune mediated nature. Therefore, understanding pseudotumors involves a greater appreciation of biological process than morphological process alone. An understanding of pattern

without assuming purpose or intent is required, and this is a conceptual discipline which requires a balance between skepticism and curiosity.

C. Immune-Mediated Mimics: The Subtle Deception

A particular challenge exists when immune-mediated processes are examined. The chronic inflammation, autoimmune reactions and cytokine-mediated cellular proliferation can mimic neoplastic architectural patterns (e.g., follicular hyperplasia in lymphoid tissues simulating lymphoma; autoimmune hepatitis simulating liver neoplasm; inflammatory pseudotumor of the lung simulating pulmonary adenocarcinoma).

Pathologists must use both microscopic observation and mental interpretation to determine whether observed morphological patterns represent an immune-mediated process or a neoplastic process. Clinical correlation of the morphologic pattern along with immunohistochemical studies and molecular diagnostic testing may provide supportive evidence to aid the pathologist's determination. Ultimately, the decision relies on the pathologist's conceptual ability to interpret the tissue as a "story" and discern intent, sequence and consequences.

The study of immune-mediated mimics teaches the observer that morphology is a language. Not only do cells express themselves morphologically, they interact, organize and respond to their microenvironment. Misreading this language leads to misinterpreting the cell's intent and mistakenly identifying a reactive process as a transformed process.

D. Histopathologic Principles in the Borderlands

Guiding principles for understanding the relationship between inflammation and cancer include contextualizing atypical cell appearance; recognizing the importance of the architectural organization of cells; considering the distribution of cells within tissues; assessing the temporal progression of lesions; and obtaining supportive data through specialized staining techniques, flow cytometry, and molecular studies. Ultimately, each of these approaches must be used with an appreciation for the complexities of the inflammatory/neoplastic continuum.

E. Clinical Correlation: A Humanized Approach

Histopathological reactive lesions force observers to synthesize their histological analysis with the clinical history of the patient. Therefore, when analyzing

granulomatous inflammation in the lung, the observer will need to correlate this finding with any radiographic abnormalities as well as the patient's medical history. Similarly, lymphocytic hyperplasia within a lymph node necessitates knowledge of any recent infections or vaccinations that may have occurred. Orbital pseudotumor often requires consultation with ophthalmology and IgG4 related orbital masses require correlation with both serum IgG4 levels and systemic involvement.

In addition, the pathologist becomes a chronicler of the 'history' of tissues and therefore morphology is not just an independent entity, it is one chapter in the broader history of how the host has responded to its environment and the manner in which the host has been orchestrated by the immune system. Through application of this more "human" approach to morphologic analysis, the observer can reduce error and gain a greater understanding of the tissue they are examining.

F. Philosophical Reflections

The "borderlands" of reactive pathology represent, as much as they do scientifically, philosophically. Inflammation masquerading as neoplasia illustrates that appearance is conditional, that structure can mislead, and that biological systems are dynamic rather than static. As such, the pathologists' role is to serve as an interpreter; to provide an ethical framework for the evaluation of cellular behavior, to judge the weight of evidence versus expectation, and to be cognizant of the limitations of observation.

Reactive lesions (granulomas, pseudotumors, etc.) demonstrate that disease is a process, a transaction, and a narrative. This recognition of disease changes pathology from classification of diseases to an interaction with living systems; pathology is no longer simply a matter of classifying or naming diseases, but instead a relationship of understanding as opposed to absolute knowledge.

Therefore, the line drawn between inflammation and neoplasia represents an intersection of technical skill, imaginative creativity, and intellectual curiosity. Reactive lesions are neither an aberration waiting to be dismissed, nor a singular fact waiting to be trampled upon, but rather a clinical entity that highlights the sophisticated response of tissue to stimulus. Similarly, granulomas, pseudotumors, and immune-mediated mimics are illustrative of the complexity of cell-to-cell communication, including the intent of cells, context of cells, and consequences of cells, which challenge simplistic categorizations.

In these "borderlands," the observer must continually balance skepticism with openness, systemic thinking with critical evaluation, morphological judgment with clinical assessment. While form is determined by microscopic examination, meaning is determined by the observer's intellect. From this basis of conceptual awareness, and the personalization of his/her relationship to the patient, the pathologist will then be able to

differentiate reactive processes from neoplastic disease, recognizing both the biologic processes occurring within the tissue, and the lived experiences of the patient.

Thus, detectible responses to stimuli represent properties that exist not as a limit, but as a transitive medium through which the observer appreciates the multivalency, uncertainty, and elegance of physiological reaction. It is here that science and philosophy converge, and observation evolves into a story of both viscera and virtue.

Crossing the Borderlands of Inflammation and Neoplasia: A Framework for Pathologists to Engage in Reflective Practice, Ethical Assessment and Conceptual Development Each granuloma, each pseudotumor, each immunemediated mimic: a teacher, guiding the pathologist through the functions of reaction and transformation, form and function, shadow and substance.

References

[1] Kahneman D. *Thinking, Fast and Slow.* New York: Farrar, Straus and Giroux; 2011.

[2] Croskerry P. Cognitive forcing strategies in clinical decision making. *Ann Emerg Med.* 2003;41(1):110–120.

[3] Redelmeier DA. The cognitive psychology of missed diagnoses. *Ann Intern Med.* 2005;142(2):115–120.

[4] Trowbridge RL, et al. Cognitive bias and clinical decision making. *Acad Med.* 2013;88(7):1029–1035.

[5] Norman GR, Eva KW. Diagnostic error and clinical reasoning. *Med Educ.* 2010;44(1):94–100.

[6] Graber ML. The incidence of diagnostic error in medicine. *BMJ Qual Saf.* 2013;22(Suppl 2):ii21–ii27.

[7] Croskerry P. From mindless to mindful practice — cognitive bias and clinical decision making. *N Engl J Med.* 2013;368:2445–2448.

[8] Saposnik G, et al. Cognitive biases in medical decision making. *BMC Med Inform Decis Mak.* 2016;16:70.

[9] Norman GR, Young M, Brooks LR. Non-analytical models of clinical reasoning. *Med Educ.* 2007;41(12):1140–1145.

[10] Mamede S, Schmidt HG. Cognitive perspectives on diagnostic error in medicine. *J Eval Clin Pract.* 2004;10(1):59–66.

[11] Schiff GD, et al. Diagnostic error in medicine: analysis of 583 physician-reported errors. *Arch Intern Med.* 2009;169(20):1881–1887.

[12] Redelmeier DA. Improving diagnosis in medicine. *BMJ.* 2005;330:839–841.

[13] Elstein AS. Heuristics and biases: selected errors in clinical reasoning. *Acad Med.* 1999;74(7):791–794.

[14] Tversky A, Kahneman D. Judgment under uncertainty: heuristics and biases. *Science.* 1974;185:1124–1131.

[15] Croskerry P. Cognitive error in diagnosis: implications for patient safety. *J Crit Care.* 2003;18(4):245–251.
[16] Eva KW. What every teacher needs to know about clinical reasoning. *Med Educ.* 2005;39(1):98–106.
[17] Norman G. Dual processing and diagnostic errors. *Adv Health Sci Educ Theory Pract.* 2009;14(Suppl 1):37–49.
[18] Graber ML, Franklin N, Gordon R. Diagnostic error in internal medicine. *Arch Intern Med.* 2005;165(13):1493–1499.
[19] Croskerry P, Singhal G, Mamede S. Cognitive debiasing 1: origins of bias and theory of debiasing. *BMJ Qual Saf.* 2013;22(Suppl 2):ii58–ii64.
[20] Norman GR, Young M, Brooks LR. Non-analytical models of clinical reasoning. *Med Educ.* 2007;41(12):1140–1145.
[21] Eva KW, Regehr G. Self-assessment in the health professions: a reformulation and research agenda. *Acad Med.* 2005;80(Suppl 10):S46–S54.
[22] Kassirer JP. Teaching clinical reasoning: case-based and coached. *Acad Med.* 2010;85(7):1118–1124.
[23] Croskerry P. Achieving quality in clinical decision making: cognitive strategies and detection of bias. *Acad Emerg Med.* 2002;9(11):1184–1204.
[24] Shapiro M, et al. The influence of bias on diagnostic judgment in pathology. *Arch Pathol Lab Med.* 2012;136:1444–1450.
[25] Schmidt HG, Mamede S. How to improve the teaching of clinical reasoning: a narrative review and a proposal. *Med Educ.* 2015;49(10):961–973.
[26] Eva KW, Norman GR. Heuristics and biases – a biased perspective on clinical reasoning. *Med Educ.* 2005;39(7):870–872.
[27] Graber ML, et al. Cognitive interventions to reduce diagnostic error. *BMJ Qual Saf.* 2012;21:535–540.
[28] Croskerry P. A universal model of diagnostic reasoning. *Acad Med.* 2009;84(8):1022–1028.
[29] Saposnik G, et al. Cognitive biases associated with medical decisions: a systematic review. *BMC Med Inform Decis Mak.* 2016;16:109.
[30] Schiff GD. Minimizing diagnostic error: the importance of cognitive psychology. *Acad Med.* 2012;87(8):1101–1107.
[31] Trowbridge RL. Teaching clinical reasoning. *Acad Med.* 2007;82(6):606–611.
[32] Eva KW, Regehr G. Exploring the divergence between self-assessment and feedback. *Med Educ.* 2007;41(12):1223–1229.
[33] Croskerry P. Cognitive forcing strategies in diagnosis. *Ann Emerg Med.* 2003;41(1):110–120.
[34] Norman GR. Dual processing in reasoning: the case for intuition and analysis. *Adv Health Sci Educ Theory Pract.* 2009;14(Suppl 1):37–49.
[35] Mamede S, Schmidt HG, Rikers RM. Diagnostic errors and reflective practice. *Med Educ.* 2007;41(6):539–546.
[36] Graber ML. Diagnostic errors in medicine: a case study approach. *Am Fam Physician.* 2007;76(1):38–44.
[37] Norman G, Eva KW. Diagnostic error in internal medicine. *BMJ.* 2010;340:c2574.
[38] Croskerry P. From mindless to mindful practice. *N Engl J Med.* 2013;368:2445–2448.
[39] Saposnik G, et al. Cognitive biases in medical decision making. *BMC Med Inform Decis Mak.* 2016;16:70.

[40] Elstein AS, Schwarz A. Clinical problem solving and diagnostic decision making. In: *Clinical Problem Solving in Medicine.* 2nd ed. London: Butterworth-Heinemann; 2002. p. 1–30.
[41] Schiff GD. Minimizing diagnostic error. *Acad Med.* 2012;87(8):1101–1107.
[42] Graber ML, et al. Cognitive interventions to reduce diagnostic error. *BMJ Qual Saf.* 2012;21:535–540.
[43] Croskerry P, Singhal G, Mamede S. Cognitive debiasing 2: impediments to and strategies for change. *BMJ Qual Saf.* 2013;22(Suppl 2):ii65–ii72.
[44] Norman GR, Eva KW. Diagnostic error and clinical reasoning. *Med Educ.* 2010;44(1):94–100.
[45] Kassirer JP. Teaching clinical reasoning: case-based and coached. *Acad Med.* 2010;85(7):1118–1124.
[46] Shapiro M, et al. Cognitive bias in pathology diagnosis. *Arch Pathol Lab Med.* 2012;136:1444–1450.
[47] Schmidt HG, Mamede S. How to improve the teaching of clinical reasoning. *Med Educ.* 2015;49(10):961–973.
[48] Eva KW, Norman GR. Heuristics and biases – a biased perspective. *Med Educ.* 2005;39(7):870–872.
[49] Croskerry P. Achieving quality in clinical decision making. *Acad Emerg Med.* 2002;9(11):1184–1204.
[50] Graber ML, Franklin N, Gordon R. Diagnostic error in internal medicine. *Arch Intern Med.* 2005;165(13):1493–1499.
[51] Tversky A, Kahneman D. Judgment under uncertainty: heuristics and biases. *Science.* 1974;185:1124–1131.
[52] Norman GR, Young M, Brooks LR. Non-analytical models of clinical reasoning. *Med Educ.* 2007;41(12):1140–1145
[53] Rosai J. *Rosai and Ackerman's Surgical Pathology.* 11th ed. Philadelphia: Elsevier; 2018.
[54] Kumar V, Abbas AK, Aster JC. *Robbins and Cotran Pathologic Basis of Disease.* 10th ed. Philadelphia: Elsevier; 2021.
[55] McPherson RA, Pincus MR. *Henry's Clinical Diagnosis and Management by Laboratory Methods.* 24th ed. Philadelphia: Elsevier; 2021.
[56] Travis WD, Brambilla E, Burke AP, Marx A, Nicholson AG. *WHO Classification of Tumours of the Lung, Pleura, Thymus and Heart.* 4th ed. Lyon: IARC; 2015.
[57] Jaffe ES, Harris NL, Stein H, Vardiman JW. *Pathology and Genetics of Tumours of Haematopoietic and Lymphoid Tissues.* Lyon: IARC; 2001.
[58] Katzenstein AL, Askin FB, Mazur MT. *Surgical Pathology of Non-Neoplastic Lung.* 5th ed. Philadelphia: Saunders; 2015.
[59] Rosenthal NS, Rosai J. Pseudotumors and reactive proliferations. *Hum Pathol.* 1983;14:379–390.
[60] Patterson JW. *Weedon's Skin Pathology.* 5th ed. Edinburgh: Elsevier; 2020.
[61] McCluggage WG, et al. Granulomatous inflammation: mimics of neoplasia. *Histopathology.* 2019;75:175–191.
[62] Ridolfi RL, et al. Diagnostic challenges in inflammatory pseudotumors. *Am J Surg Pathol.* 2007;31:725–735.
[63] Chiu BC, Chan JK. Reactive lymphoid proliferations mimicking lymphoma. *Histopathology.* 2010;56:661–673.

Deep Science Publishing, 2025
https://doi.org/10.70593/978-93-7185-400-9

DeepScience
Open Access Books

Chapter 5: Benign Mimicking Malignant, The Spectrum of Deceptive Histology: From adenosis to atypical hyperplasia and beyond

Looking through a microscope, the ways in which the body's tissues tell us their stories are hardly ever straightforward or easy to read. The way tissues are formed, designed, and vibrate at the atomic level; how they respond to each other; how they talk through the stroma and how cells communicate - all these things create complex conversations. Sometimes a tissue can appear to be an innocent (benign) lesion and still present itself as a malignant lesion. This is my attempt to walk you (delicately but persistently) through the topography of dangerous histology, why it is important, how we differentiate it from what is not dangerous, and where the boundaries become blurred..

A. Why this spectrum matters: the stakes of misinterpretation

Now pretend for a moment that you are a pathologist — or a clinician awaiting a pathology report. Words like irregularity, distortion, atypia or complex proliferation Does that mean cancer?

Misclassification of a benign lesion as malignant can cause overtreatment, unwarranted malignant tumor surgery, radiotherapy, and psychological pressure. However, mislabelling a malignant lesion as benign can lead to underdiagnosis, delay and harm. The interface is treacherous

Furthermore, in a number of organs (breast, prostate, endometrium, lung, etc.), benign proliferations can progress or co-occur with malignancy. Other examples include mimics of carcinoma (e.g., benign lesions such as sclerosing adenosis, tubular adenosis or radial scars in breast pathology and various atrophic or hyperplastic glands that may masquerade as adenocarcinoma in prostate). [1], In brief, the benign mimickers are all around us, and we have an obligation to read them well.

There is therefore utility in conceptualizing a spectrum: purely benign agents (often relatively benign) → borderline lesions or atypical proliferative lesions → early in situ or minimal invasive disease → frank malignancy. Now, along the way, they may become — and in many cases — adopt malignant properties that become part of their entry in the database, but they may not be malignant per se. Triangulating meaning from pattern, context and detail is our job.

B. The earliest nodes: adenosis, florid proliferations, and "benign expansion"

The leftmost end of the spectrum are lesions that superficially look like benign enlargements of normal constituents. For example, in breast pathology adenosis is defined as an increase in the number of acini per terminal duct lobular unit (TDLU). The architecture may be somewhat filled in and distorted, but importantly the basic pattern of ducts and lobules persists.

Yet even adenosis has variants. In fact, in florid adenosis, clumping, mild distortions, or even focal compression of luminal spaces may appear. Such aberrancies if seen on imaging or on core biopsy may set the alarm bells ringing. But on histology the cytology is bland: normal nuclear morphology, preserved myoepithelial layers, no mitotic over-activity.

This can then be followed by sclerosing adenosis characterized by a fibrous stroma that compresses and distorts acini inducing angular profiles, compressed lumina, and tangential cross-sections. That architectural distortion may be similar to invasive carcinoma. [2] The pathologist must remember in these scenarios though: stroma sclerosis exists; acini are still anchor; the myoepithelial layer is still though compressed.

Similarly in the prostate, adenosis (or adenosis-type change) may yield crowded glands with minimal irregularity that may closely mimic low-grade carcinoma. But again there I think basal cells and lobular grouping and a lack of desmoplastic stromal response helps to differentiate. [3]

Looking even fairly benign at this stage, it's a deceptive incrementalism. Expansion wird zu blumig: This is where we need to be cautious and skeptical.

C. The gray zone: hyperplasia and atypical proliferations

Going from benign DoF multiplication to DoF over-proliferation is when things become murky. A few regions exist with atypical hyperplasia in many organs.

The breast is one organ we have already discussed. ADH is a form of proliferative ductal epithelial cell changes that are mildly atypical cytologically and architecturally complex, but not to the extent of DCIS. The distinction between ADH and low-grade DCIS can be difficult to make since the margins of both are subjective and do not represent distinct boundaries. Since ADH has a greater potential than other forms of proliferative lesions for developing into carcinomas, identifying it has clinical implications.

Another example of this type of paradoxical situation exists with apocrine adenosis; this is a lesion with apocrine cytological characteristics (eosinophilic cytoplasm and large nucleolus), but in a good architectural background. This creates a significant clinical dilemma: where does benign apocrine change end, and apocrine carcinoma begin?Only in the context of cytologic subtlety, architectural distribution and topography can you adjudicate.

Simple and complex hyperplasia with atypia may also be challenging to distinguish from what is widely regarded as early endometrioid carcinoma of the endometrium. In some proliferations, glands are crowded, irregular, branching and filled with cells that have enlarged nuclei—but they don't invade. A trained eye should find signs of loss of polarity, stromal desmoplasia, and invasion to shift the balance.

These lesions inhabit a kind of twilight zone. The pathologist needs to ask for not just the slide, but the clinical context: imaging, size, symptoms and molecular adjuncts where available. The words "atypical" or "borderline" are signs to be careful.

D. Benign tumors that masquerade as malignancy

While proliferative changes are one source of mimicry, true benign tumors may also don malignant garb. In breast pathology, many benign tumors (hamartoma, pseudoangiomatous stromal hyperplasia, tubular adenoma, fibromatosis, granular cell tumor) may present with suspicious imaging features and even histologic traps.[26]

Pseudoangiomatous stromal hyperplasia (PASH) is a striking example. It is a benign stromal proliferation forming slit-like spaces lined by spindle cells, often hormonally responsive. Because the spaces can resemble vascular channels, PASH may raise the suspicion for low-grade angiosarcoma or phyllodes tumor. But the lining cells in PASH lack cytologic atypia, and the "vessels" lack true endothelial lining.[2] It may coexist with both benign and malignant lesions.[2]

Hamartoma ("breast within a breast") may sometimes grow large or enhance heterogeneously, simulating phyllodes tumor or even sarcoma on imaging. Histologically, the mix of fibrous, glandular, and fatty elements may look chaotic—but a pathologist knows to trace normal lobular units and see no overt cytologic atypia.[2]

Fibromatosis (desmoid tumors) in the breast are benign but locally aggressive. On imaging, they often present as irregular, spiculated masses indistinguishable from carcinoma. Histologically, the spindle cell proliferation can be infiltrative; but it lacks epithelial tumor cells.[2] The key is noticing that the lesion is purely stromal and negative for epithelial markers.

Granular cell tumor (neural origin) is another benign lesion that can mimic breast carcinoma, even causing nipple retraction and skin dimpling. Radiologically, it may appear spiculated. Histologically, its granular cells must be recognized by their mitochondrial-rich cytoplasm and S100 positivity.[2]

Tubular adenoma is a benign epithelial tumor composed of tightly packed normal but bland tubular structures. Occasionally, microcalcifications or irregular imaging features prompt suspicion. But under the microscope, it is the low mitotic rate, regular epithelial lining and lack of cytologic atypia that reassure us.[2]

These benign tumors remind us that unlike others, architecture and clinical correlation are as important as cytologic detail.

E. Distinguishing features: principles to navigate the masquerade

So how do we, in actual fact, discriminate between benign mimickers and real malignancies or atypical lesions? Let me take you through the lens of thinking that I apply — and welcome your extension to whatever is your practice domain..

I. The three-tier check: architecture, cytology, and context

Architecture

I. Does the lesion preserve recognizably normal relationships (lobules, ducts, gland clusters)?

II. Are the margins circumscribed or infiltrative?

III. Is there desmoplasia, stromal reaction or invasion?

IV. Is the real deformation or cross section side cut, rather than infiltration?

Cytology

I. Are the nuclei uniform or pleomorphic?

II. Are nucleoli modest or prominent?

III. Is the mitotic rate high?

IV. Are there abnormal mitoses?

Even if architecture is suspicious, benign lesions often retain bland cytology.

Context & ancillary clues

I. Imaging correlation: does radiology suggest benign features (fat, well-defined margins) or malignant suspicion?

II. Clinical presentation: age, risk factors, symptoms.

III. Immunohistochemistry or special stains: e.g. myoepithelial markers (p63, smooth muscle actin), Ki-67, hormonal markers.

IV. Molecular tests, if available (for example, FISH or mutation panels).

V. Adequacy of sampling: small cores may mislead.

This is not a rigid checklist but a conversation:architecture talks, cytology whispers, and context frames the meaning.

F. Recognizing concordance and discordance

When we look at a biopsy result, we ask ourselves: does the pathology path "make sense" with what was imaged or suspected by the surgeon? Is it concordant if, say, the imaging suggests a spiculated mass and the biopsy report is limited to sclerosing adenosis? Sometimes yes — but only if the pathologist is certain that sampling was sufficient, and that no higher lesion is hiding. If doubt lingers, a re-biopsy or excision may be prudent.

G. Watch for upgrade potential

Some benign diagnoses have nonzero risk of underlying or future malignancy. For example, stromal fibrosis on breast core biopsy has been reported to "upgrade" to cancer in up to ~7% of cases.[23] Also, classic proliferative breast disease with atypia increases future carcinoma risk significantly.[5] Thus, some "benign" diagnoses demand surveillance or even excision.

H. Using adjuncts wisely, not overzealously

Immunohistochemistry (IHC) and molecular tests are precious tools—but they must be used to clarify, not to rescue a weak interpretation. A marker that is nonspecific or misapplied can mislead. Use IHC to confirm basal cell presence, lineage markers,

proliferation differences, or clonality—but always with an eye on morphology as the backbone.

I. Illustrative vignettes: walking with cases

I believe stories teach better than bullet lists. Here are three brief vignettes to anchor the concepts.

Case A: Sclerosing adenosis masquerading as carcinoma

A 48-year-old woman undergoes mammography; an area of architectural distortion is noted. On core biopsy, the tissue shows compressed, distorted acini in a densely fibrotic stroma. Some acini appear angular; others are tangentially cut. However, the epithelial cells are bland, the myoepithelial cells are intact (p63 positive), and mitoses are rare. Radiologic–pathologic correlation is deemed acceptable, and follow-up, not excision, is recommended. Over the next two years, no lesion grows or evolves. This is classic deception by sclerosing adenosis.

Case B: Atypical ductal hyperplasia on core, upgraded at excision

A 55-year-old woman has a small cluster of microcalcifications on mammography; biopsy shows ADH. Because ADH is a risk lesion and border zone with DCIS, surgical excision is advised. At excision, small foci of low-grade DCIS are found adjacent. This serves to remind us that at the boundary land of atypia, the biopsy can sometimes be sampling a ghost of more sinister progress. The prospect risks need to be controlled.

Case C: Pseudoangiomatous stromal hyperplasia vs low grade angiosarcoma

A 42 year old woman is noted to have a breast lump. On imaging, it is an oval, somewhat circumscribed mass but has heterogeneous enhancement. On core biopsy are seen slit-like spaces within a spindled stromal proliferation. The architectonic impression is vascular -- but cytology is monotonous. IHC with CD31 (vascular) is-ve; CD34 is+ve patchyish; Ki-67 is very low PWMH. A diagnosis of PASH is made. The patient elects for excision, and the mass is benign on histologic examination. But the path to that certainty was filled with gentle scrutiny.

These cases illustrate that deceitful tissue is a process and our work is to cross-examine it.

J. When masquerade becomes overt: progression to malignancy

Perhaps the seemingly innocuous lesion sometimes merely is, or becomes, malignant. Adenosis may contain or result in carcinoma in situ; ADH may approximate DCIS or a benign tumor have regionally undergone malignant change. Accordingly, the lines are not impenetrable.

The atypical hyperplasia →DCIS → invasive Ca sequence has been more an accepted model in breast pathology. [4] But these are not uniform steps. Parallel evolution, field change or multifocal occurrence may occur. "The problem, however, is that one has to be vigilant regarding 'upgrades' at excision or follow-up.

Molecular research is starting to lend a hand. Clonal genetic abnormalities or mutations are shared in some tumor foci, suggesting an actual relationship between the benign and malignant foci. In the future, we could improve prediction of which "benign mimickers" are most likely to transform.

K. A conceptual map: states of tissue identity

Let me offer a mental map (a "phase diagram," if you will) of lesion identity:

I. Benign stable: no cytologic atypia, architecture preserved, low mitotic activity.

II. Proliferative benign: increased proliferation (hyperplasia), architectural complexity, but cytology still bland and no invasion.

III. Atypical / borderline: cytologic irregularity, architectural irregularity, but still contained, no invasion.

IV. In situ: full spectrum of atypia confined to epithelial compartments, no stromal invasion.

V. Invasive / malignant: breach of basement membrane, stromal reaction, capacity for metastasis.

On this spectrum, most benign mimickers live in the early 3 stages but have "echoes" of the later ones—distorted pattern, compressed stroma and/or mild cytologic atypia. Our job is to determine if the echoes are just echoes, or warning signals of hidden malignancy..

L. Broadening horizons: mimicry in other organs

Though much in the foregoing paragraphs has been about the breast, many of the same principles also apply elsewhere. In the prostate, atypical small acinar proliferation (ASAP) is an ambiguous finding in a benign lesion, and absence of basal cells or architectural suggestive patterns may suggest carcinoma. Similarly, benign mimics of prostate adenocarcinoma include atrophic glands, partial atrophy, PIN (prostatic intraepithelial neoplasia), and post-atrophic hyperplasia.[7]

In endometrium, adenomyoma or atypical polypoid adenomyoma may mimic carcinoma; in the lung, atypical adenomatous hyperplasia may border on adenocarcinoma in situ. The general principle remains: know the context, examine carefully, use adjuncts, and be humble before the tissue. &

If I were to reduce this chapter to advice:

I. Approach gray or suspicious lesions with a mixture of curiosity and caution.

II. Always ground your interpretation in architecture first, cytology second, and context third.

III. Embrace radiologic–pathologic correlation as a dialog, not a one-way decree.

IV. Flag lesions with upgrade potential for closer follow-up or excision.

V. Let ancillary techniques (IHC, molecular) be clarifiers not crutches.

VI. Just keep learning from your follow-up and excisions: every mistake is a teacher

From adenosis to atypical hyperplasia and into malignant areas, there is no such thing as "all good" or "all bad", until proven. Deceit can occur with small nuance differences, by altering our expectations and through the dance of stroma and epithelial cells. The strength lies in the patience and the methodical nature of how you read a slide. Hopefully your next glass slide will be an ally, not an enemy. Hopefully your next microscopic slide will be an ally and not an opponent.

References

[1] Trpkov K, Bartczak-McKay J, Yilmaz A. Benign mimics of prostatic adenocarcinoma: diagnostic pitfalls in needle biopsy interpretation. Modern Pathology. 2008;21(S2):S42–S55.

[2] Guirguis MS, Zakhary MM, Tohme W, Shaaban AM. Mimickers of breast malignancy: imaging findings, pathologic concordance, and clinical management. Insights into Imaging. 2020;11(1):107.

[3] Neal L, Sandhu NP, Hieken TJ, Glazebrook KN. Clinician's guide to imaging and pathologic findings in breast biopsy techniques. Mayo Clinic Proceedings. 2018;93(2):265–279.

[4] Bomeisl P, Reynolds C, Glazebrook KN, Visscher DW. Spectrum of atypical ductal hyperplasia and its diagnostic challenges: a practical perspective. Histopathology. 2015;67(2):213–229.
[5] Asirvatham JR, Reddy VB, Gattuso P. Atypical apocrine adenosis: a potential diagnostic pitfall in breast pathology. Annals of Diagnostic Pathology. 2013;17(5):459–463.
[6] Hartmann LC, Sellers TA, Frost MH, Lingle WL, Degnim AC, Ghosh K, et al. Benign breast disease and the risk of breast cancer. New England Journal of Medicine. 2005;353(3):229–237.
[7] Epstein JI, Netto GJ. Prostate biopsy interpretation: pitfalls and challenges including benign mimickers of cancer. Archives of Pathology & Laboratory Medicine. 2016;140(8):804–81

Deep Science Publishing, 2025
https://doi.org/10.70593/978-93-7185-400-9

DeepScience
Open Access Books

Chapter 6: Malignant Masquerades, When Cancer Disguises Its Origin: Metastasis, dedifferentiation, and the enigma of primary site identification

Every Pathologist learns almost immediately that malignancy is not a singular occurrence, but a development; a continuing story. As the orderly array of cells become progressively disordered, purpose in the disorder is still apparent. Many cancers are easily identified based upon their cell of origin and location by utilizing Light Microscopy, and/or Advanced Molecular Techniques. Some cancers however have developed methods to hide their origins, and therefore, remain a mystery or "malignant masquerade". In order to identify those cancers, you will need to first acknowledge that Cancer is Bi-Faceted; the two sides being dependent on one another: The Side of Transformation (the cells lose their normalcy and gain autonomy) and The Side of Deception (The Malignant Cells disguise their lineage; defy identification and travel under a false flag). The latter side; the "Art of Disguise" represents the reason that Metastatic and Dedifferentiated Cancers are so difficult to diagnose.

When the Pathologist examines the tissue sample through the microscope and finds the tissue sample filled with an assortment of abnormal cells; large, pleomorphic and disordered, the first question asked is no longer "What Is It?", but "Where Does It Originate From?". The Tissue of Origin is the Essence of Diagnosis. The Tissue of Origin forms the foundation for Therapy, Prognosis and the Patient's Hope for Recovery. The Tissue of Origin, however, may be lost when the Tissue of Origin is masked by layers of Morphological Deception.

The three major mechanisms that create these deceptions are metastasis, dedifferentiation and phenotypic convergence. All three mechanisms transform the appearance of the tumor, eliminating the evidence that would lead to the determination of its homeland. Within these pages, you will follow us through a world of blurred identity, where malignant cells appear to have forgotten their past.

A. When cells wander: the enigma of metastasis

Metastasis is more than a physical movement of cells; it represents a biological adaptation to environmental constraints. Cancer cells from a primary tumor leave the site of origin, enter the vascular system, remain viable through circulation, and find a new site of growth. The ability to successfully complete each of these steps depends on the ability to survive, adapt, and camouflage themselves in their new environment.. The result is a colony that may no longer resemble its parent.[1],[2]

Histologically, metastases may appear deceptively foreign. A metastatic adenocarcinoma in the liver may mimic hepatocellular carcinoma; a renal cell carcinoma metastasizing to the thyroid may look like a follicular neoplasm; lung carcinomas can populate the brain and mimic glial tumors.[3]

To the naked eye of the clinician, metastasis announces itself through symptoms unrelated to the primary site : a bone pain that turns out to be secondary from a breast or prostate carcinoma, a lung nodule that hides an intestinal adenocarcinoma. The masquerade begins at the clinical level, long before the microscope confirms the deceit.

The most haunting of these cases are those labeled “Carcinoma of Unknown Primary” (CUP),where metastasis presents first, and exhaustive searches fail to reveal where it began.[4] CUP accounts for nearly 3–5% of all cancer diagnoses. It remains enigmatic despite nuclear medicine, immunostudies, and molecular panels. “These are cancers that have traveled far and become so different from the original that they've erased their own paths."

But metastasis is travel not just in space: it is travel through time. The cells that survive the metastatic cascade are those that learn to mimic the tissue microenvironment they invade. Liver colon carcinoma expresses hepatic growth receptors whereas bone breast carcinoma, send out bone matrix proteins. This molecular masquerade lets strange cells feel “at home” in alien soil. [5]

So metastasis is migration and masquerade both. The duty of the pathologist is to see through the disguise of the invader.

B. Dedifferentiation: when memory fades

If metastasis is the seesaw of malignancy, then dedifferentiation is its amnesia. It is a transformation in which tumor cells lose much of the structural and molecular character that characterized them as originating from their tissue site of origin. Lost of differentiation obscures the distinctions between one cancer form and another, making for histologies that appear similar despite separate origins. [6]

Think of a carcinoma of the lung pts. The normal cells in pleomorphic carcinomada are large, but show little in the way of gland formation--a set of features that might just as well easily describe a poorly-differentiated gastric, pancreatic, or ovarian carcinoma. In the presence of these circumstances, it is morphology which turns to the enemy. The visual identity of the cancer has broken down.

Dedifferentiation is not an accidentAnaplasia is the result of the uncontrolled expansion of a malignant cell population. This uncontrolled expansion is the consequence of loss of genetic stability. The process of losing this stability can result in a variety of changes including; mutations, chromosomal breaks, epigenetic reprogramming and loss of lineage specific gene expression. Loss of lineage specific gene expression results in a cancerous cell's ability to lose the production of cytokeratin (a marker of epithelial cells) from the lineage of the cell's origin and begin to produce markers of mesenchymal transition. The "invasive" nature of a large sized tumor further complicates the difficulty in making a proper diagnosis.

The term "anaplastic," describes a cell that does not follow a lineage or differentiate itself. However, anaplasia is not just about disorganization; it is the destruction of a cell's lineage memory that creates the challenge of diagnosing anaplastic tumors. Without evidence of divergent differentiation, a tumor may be categorized as either a "round-cell" neoplasm, a "spindle-cell" sarcoma or a "giant-cell" tumor depending upon the predominance of its morphological characteristics.

In cases like that, the microscope murmurs ambiguity. Only through immunohistochemistry or molecular profiling can we reclaim pieces of the lost identity. Yet these tools can be no good either: dedifferentiation appears to silence the very genes we use for identification.

C. The enigma of primary site identification

“Where did this cancer start? may sound simple yet is among the most complicated questions in oncology. Patients who present with metastases and no discernible primary are frequently diagnosed as having Carcinoma of Unknown Primary (CUP). [4]

CUP is not a single disease but a clinical syndrome arising out of several biological events: 1) early spread (2) dormancy, (3) molecular reprogramming and (4) escaping the immune system. What they share is the capacity to divorce identity from place of birth.[8]

Contemporary diagnostic pathway for CUP starts with morphology and immunohistochemistry. The pathologist reviews architecture (glandular, squamous, neuroendocrine, sarcomatoid), cytological characteristics and stroma. From there, a

rational panel of markers including CK7, CK20, TTF-1, PAX8, CDX2 GATA3 PSA help direct lineage. [9]

However, notwithstanding this arsenal of tools, 20–30% of patients are not fully characterized. Molecular profiling using next-generation sequencing and methylation signatures, with better accuracy determining at what site the cancer originated by comparing genetic expression patterns to large reference databases. [10] But constraints remain: dedifferentiated tumors may not have a clearly identifiable signature, and some lethal metastases might contain hybrid phenotypes as a consequence of clonal evolution.

Clinically, the uncertainty complicates therapy. If the origin of CUP is unknown, then the treatment methods will be based on best-guesses rather than evidence-based site-specific treatments. Prior to molecular subtyping, the standard of care was empirical and non-targeted; patients received broad, systemic chemotherapeutic agents. Although molecular subtyping has allowed for the targeting of therapies to be more tailored to the specific biology of the cancer, the prognosis for CUP remains very poor.

The median survival time for all cases of CUP remains approximately 9-12 months. This is reflective of the biologic aggressiveness of this poorly understood category of cancers.

Using the above as a philosophical framework, when one does not know the origins of a particular curse, the curse's loss of its own identity and inability to recall those origins is an exemplar of the existential experience of losing one's self. Every pathologist who diagnoses a case of CUP may become something greater than "Indiana Jones" (using another example) in the sense they can be considered a type of detective searching for clues to biological memory.

D. Mechanisms of disguise: how malignancy alters its face

To reveal how cancer’s in this game of hide-and-seek, we must understand the cellular sleight-of-hand.

I. Epithelial–mesenchymal transition (EMT)

One key aspect driving both metastasis and dedifferentiation is EMT,a developmental program in which cells undergo a switch in cell polarity and adhesion, as well as morphological changes to give a mesenchymal phenotype with increased motility/invasiveness. 11 Expression of E-cadherin, cytokeratins and epithelial junction proteins decrease during EMT, while expression of vimentin, fibronectin and N-cadherin increase. The cell, once tethered to its neighborhood tissue even as it roamed its spaces, is set free.

Morphologically EMT results in tumors that are less well differentiated, relatively spindle-shaped and occasionally sarcomatous.. This shift confuses both the pathologist and the immune system. What was once clearly a carcinoma may now look like a sarcoma or a mixed neoplasm.

II. Clonal evolution and intratumoral heterogeneity

Malignant cells do not evolve uniformly. Within a single tumor, multiple subclones compete for dominance, each with distinct mutations and phenotypes.[12] Some clones retain features of the primary site; others diverge so radically that their resemblance is lost. When a dedifferentiated clone metastasizes, the resulting lesion bears little morphological resemblance to the original.

This intratumoral heterogeneity explains why metastases can display different histologic grades than the primary, and why biopsies from different sites may yield apparently discordant diagnoses. Evolution within the tumor ensures that identity is a moving target.

III. Microenvironmental adaptation

As soon as metastatic cells have settled into an organ they begin to alter their protein expression to fit the surrounding micro-environment of their new home. As such breast cancer in bone will express osteonectin and bone sialoprotein whereas colorectal carcinoma in the liver mimics hepatocellular structure. All of these are forms of biochemical mimicry that allow cancer cells to "fit-in" or "hide" from host tissue. The ultimate end result of this biochemical mimicry is histological disguise where the structure and markers of the metastasis (cancer) are indistinguishable from host tissue and thus misleading..

IV. Epigenetic reprogramming

Beyond mutations, cancer cells can rewrite their identity epigenetically—by modifying DNA methylation, histone acetylation, and microRNA expression.[13] This reprogramming silences lineage-specific genes while activating stemness pathways. As soon as metastatic cells have settled into an organ they begin to alter their protein expression to fit the surrounding micro-environment of their new home. As such breast cancer in bone will express osteonectin and bone sialoprotein whereas colorectal carcinoma in the liver mimics hepatocellular structure.

All of these are forms of biochemical mimicry that allow cancer cells to "fit-in" or "hide" from host tissue. The ultimate end result of this biochemical mimicry is histological disguise where the structure and markers of the metastasis (cancer) are indistinguishable from host tissue and thus misleading.

V. Molecular Clues and Evolutionary Insights

When morphology is unable to accomplish this; the language of molecules begins to communicate the genetic fingerprint left behind by cancer. The disease of deception leaves a trail of evidence about its origins. We are now entering into the Molecular Pathology Era and for the first time, we have a clear view of who these individuals really are. The genomic map of two visually identical tumor types can look vastly different. On the other hand, two tumor types that would seem to have little or nothing in common may share the exact same "genetic signature".

This paradox is the double edged sword of molecular diagnostics. As an example, gene expression profiling uses the RNA profile from a metastasis and compares it to a library of RNA profiles from well established primary sites. Thousands of RNA profiles have used algorithms to correctly identify the tissue of origin of tumors at rates of 70-90%.

However, while this represents a significant technical achievement, we need to use this technology carefully as mutations in cancer cells can lead to silencing, amplification, and reorganization of the genes in such a complex manner that the reference libraries will not be able to keep up.

In addition, epigenetic maps can also give us information. For example, DNA methylation patterns, histone modifications and microRNA expression panel may be a more reliable method of identifying a stable genetic signature in some cases.. Each of the tools in the molecular toolbox is a supplement to morphologic analysis, not a replacement. With experience, a pathologist can interpret the nuances of cell cohesion, nuclear molding and stromal reaction that algorithms have yet to understand.

VI. Tumor Plasticity and the Spectrum of Transformation

Plasticity is a single-word definition for what cancer is. The ability of malignant cells to morphologically and/or phenotypically adapt to changing environments, is the defining feature of both its successful and deceptive aspects.

The extent of this plasticity is not limited to morphological adaptations alone; malignant cells are capable of adapting at a genetic level (gene expression) as well as at a behavioral/cellular level. For example, carcinomas have the potential to undergo epithelial, mesenchymal transition (EMT), thus developing mesenchymal characteristics and acquiring the ability to migrate and invade; whereas sarcomas have the capability to express epithelial markers, creating ambiguity in distinguishing these two previously distinct lineages.

For example, some forms of breast carcinoma may develop into metaplastic forms that display squamous or spindle cell differentiation making identification by even experienced observers challenging. Anaplastic carcinoma of the thyroid represents a

pinnacle of plasticity, resulting from a molecular catastrophe which has resulted in the convergence of various pathways leading to a state of undifferentiated chaos. Neuroendocrine transformation in the prostate after hormone therapy is a paradigm for how adaptive dedifferentiation occurs in response to selective pressures.

As a result of its plastic nature, tumor plasticity creates many of the challenges associated with accurately diagnosing metastatic tumors. For example, a carcinoma may manifest in the pleura as a sarcomatoid lesion, and in the brain as a glioma-like tumor; without the proper context to understand the significance of these variations, they may be misclassified.

Therefore, while tumor plasticity is a fascinating biological phenomenon, it serves as a major impediment to achieving diagnostic certainty; it also illustrates the dynamic nature of cancer - that cancer is an "organism" that continually adapts to the environmental stresses it experiences and to the assaults that it encounters from the therapies used against it.

VII. The Microenvironment: The Stage of Deception

The cancerous ruse is not an independent play. The TME (tumor microenvironment) functions as both the spectator and accessory to the malignant charade. The TME consists of fibroblasts, macrophages, endothelial cells and components of the ECM (extracellular matrix), thus providing the histological framework for the malignant act to be performed.

When metastatic cells reach distant organs, they will modify these sites to support the best possible conditions for cell division. The metastatic cells will induce the recruitment of the stroma within the site, generate angiogenic vessels and induce a shift in the concentration of various cytokines to establish an environment conducive to continuous growth. In many cases this process will result in histologic mimicry. For example, when metastatic cells establish a metastasis in bone, the metastatic cells can induce the development of osteoid tissue with similar characteristics to those of osteosarcoma. In addition, when metastatic cells develop a metastasis in liver tissue, the cells can induce the formation of fibrous tissue within the sinusoids that masks the normal architectural structure of the glands.

Tumor-associated macrophages may engulf necrotic debris, giving a granulomatous appearance; lymphocytic infiltrates may obscure malignant nests; desmoplastic reactions may simulate benign fibrosing processes.

A great deal of the pathologists' ability to understand the role of the microenvironment is the ability to identify the malignant entity and its location as well as determine whether an observed abnormality represents actual neoplasm vs reactive hyperplasia.

E. Clinicopathological Correlation — The Bridge Between Image and Tissue

All diagnoses are an exchange between pathology and clinical medicine. A pathologist has no matter how experienced or intuitive interprets based on the information that they receive. An adenocarcinoma in the lung that has metastasized could be one of several different cancers that arose in other locations (e.g., colon, pancreas, breast, ovary). Without additional clinical information all of the pathologist's interpretations are speculative.

Radiologic studies provide the topographic map for the disease. PET-CT, MRI, and CT scans give information about patterns of spread and possible primary sites. However, radiologic images do not make sense without histologic correlation. For example, a PET avid liver lesion could either represent a metastasis from another cancer site or represent a primary hepatocellular carcinoma and it is only through microscopic examination that the distinction can be made.

Similarly, serum markers will often suggest a particular type of cancer (e.g., elevated CA-125 is suggestive of ovarian carcinoma) but will rarely confirm that diagnosis. Many types of cancer (e.g., ovarian carcinoma, pancreatic carcinoma, pulmonary carcinoma) can elevate levels of certain serum markers (e.g., CA-125).

In cases where the primary site of a cancer cannot be identified, the process of identifying the cancer requires the integration of multiple disciplines and the synthesis of the findings by each discipline in order to recreate the biologic story of the cancer. The physician, radiologist, and pathologist must come together and share their knowledge to develop a unified understanding of the cancer.

For example, a woman comes into the hospital with a supraclavicular lymph node metastasis that shows a CK7+/CK20−, GATA3+, and ER+ profile. Based upon the immunohistochemistry results the most likely source of the lymph node metastasis was a breast carcinoma. Radiologically, a small retroareolar mass was found. Histopathology confirmed the presence of a small invasive ductal carcinoma in the breast thereby completing the circle of evidence for the presence of the cancer.

The convergence of the evidence that develops when a physician, radiologist, and pathologist work together to solve a case is what is at the core of all forms of diagnostic medicine, i.e., the development of certainty from a multitude of disparate pieces of data..

F. The Diagnostic Philosophy — Knowing When Not to Conclude

Modern pathologists are working in an environment that has never been more precise than today, however they are still practicing an interpretive science. The decision to determine the diagnosis or not to make a diagnosis is both a professional and personal obligation to act as a moral and intellectual agent.

It is all too easy when confronted with a diagnosis of an undifferentiated malignancy to want to place a name on the disease, so you can close the case; however, each and every one of those names carry significant implications for how a physician will treat a patient, what the physician believes the prognosis will be, and how he will counsel his patients. Therefore, misclassifying a tumor can result in misguided treatment and ultimately affect the fate of the patient. For this reason alone, the practice of restraint represents a form of wisdom.

The designation "metastatic poorly differentiated carcinoma, primary undetermined" might appear incomplete, but it is truthful; it is honest about the fact that there is no certainty regarding the source of the metastasis, rather than pretending that there is by using overly simplistic nomenclature. This type of honesty is indicative of scientific integrity.

In the field of pathology, knowledge expands based on the discipline of not expanding beyond the limits of known knowledge; therefore, each time a primary site cannot be identified, that does not represent a failure on behalf of the pathologist, but rather an opportunity to continue observing the tumor and possibly learning something new from the experience.

G. Therapeutic Implications and the Molecular Future

The determination of the primary site for cancer (CUP) is no longer simply an academic exercise, it will impact treatment of the patient. The increasing use of molecularly-targeted therapies in modern oncology now drives the selection of treatments based upon specific molecular mutations associated with a tumor rather than its anatomical location.

Some patients diagnosed with CUP may receive improved outcomes when treated based upon their specific molecular mutation, e.g., EGFR, ALK or NTRK gene rearrangement(s), versus receiving empirically selected chemotherapy. This trend is indicative of a major shift in the way we classify tumors: from morphology-based classification to pathology-based classification through molecular pathways.

Although the histologic context cannot be replaced at this time, it still provides an important basis for interpreting a molecular mutation in terms of the expected biological characteristics of a given tumor type, degree of cellular differentiation and expected

clinical behavior. For example, the presence of a BRAF V600E mutation in a patient with melanoma has a very different therapeutic implication than having the same mutation in a patient with colorectal carcinoma.

As such, the pathologist of the future will have to function in two capacities simultaneously: as a morphologist (i.e., one who understands the structural characteristics of tissues), and as a molecular interpreter (i.e., one who understands the "code" that exists within each cell).

H. The Emotional Landscape of Diagnosis

A glass slide represents a person's experience of waiting for answers, the unknown, and the balance between hope and fear. "Unknown Primary" can represent a void in both a psychological sense (the absence of something) and clinically (the lack of a source).

As a result, the pathology staff stand silently as part of this patient and family's narrative. They are engaged in an empathetic process, as well as intellectually driven, as they attempt to determine where a malignancy originated. Hours are devoted to morphological correlation, performing staining procedures, and reviewing the slides again and again. These processes are human gestures that reflect the search for the truth about the patient's cancer.

When the original location of a malignancy is identified, there is a sense of relief as if the patient is finally able to be identified by their voice after being surrounded by people they do not know.

Although the pathology staff may not have identified the original site of the malignancy, they can use the report to provide clinical guidance based on probability, truth, and the comfort of knowing that there are boundaries to the uncertainty.

I. The Philosophical Closure - Truth Within Disguise

While all subjects possess metaphors, the most enduring metaphor in pathology is that of disguise. As it develops, cancer has provided an example of identity, and of transformation; it has demonstrated how close the line is between being and appearing.

When looking at a dedifferentiated carcinoma, one is not viewing a disease; one is viewing a great allegory of biology; one is viewing the manner in which the identity of cells can deteriorate under stress, the manner in which memories of past experiences can fade, and the manner in which systems that once worked in concert to produce order

become disordered. However, even though the system is now anarchic, there exists a pattern or an echo of what existed as the source.

Diagnosis, as such, is both scientifically and philosophically based. It involves a conversation with the unknown, a reflection on form, function, and failure. The identification of the primary site of the tumor is more than simply another clinical challenge; it is a demonstration of the cognitive and adaptive capabilities of humans to respond to biologic changes.

Cancer does disguise itself, but it cannot disguise itself forever. The residue of the truth is always contained within every deception; it is this residue that the pathologist seeks; he or she pursues this residue with patience, compassion and persistence.

Ultimately, therefore, the microscope becomes not only a tool for viewing objects, but also a method of self-examination. The microscope shows us that the truth is layered; that appearances deceive; and that seeking clarity is a moral responsibility. Identifying the original site of a malignancy is to introduce coherence to chaos; it is to tell a story to the nameless; it is to find a home for the homeless.

And thus, the study of the malignant disguises will continue to evolve, not only in laboratories and hospitals, but in the ongoing dialogue between what we see, and what we understand.

References

[1] Fidler IJ. The pathogenesis of cancer metastasis: the 'seed and soil' hypothesis revisited. Nature Reviews Cancer. 2003;3(6):453–458.

[2] Nguyen DX, Bos PD, Massagué J. Metastasis: from dissemination to organ-specific colonization. Nature Reviews Cancer. 2009;9(4):274–284.

[3] Hainsworth JD, Greco FA. Cancer of unknown primary site: new treatment paradigms in the era of precision medicine. American Society of Clinical Oncology Educational Book. 2018;38:20–25.

[4] Van der Weyden L, Arends MJ, Campbell AD, Bradley A. Tumor heterogeneity and metastasis. Cold Spring Harbor Perspectives in Medicine. 2020;10(9):a037143.

[5] Obenauf AC, Massagué J. Surviving at a distance: organ-specific metastasis. Trends in Cancer. 2015;1(1):76–91.

[6] Driessens G, Beck B, Caauwe A, Simons BD, Blanpain C. Defining the mode of tumour growth by clonal analysis. Nature. 2012;488(7412):527–530.

[7] Nikiforov YE, Nikiforova MN. Molecular genetics and diagnosis of thyroid cancer. Nature Reviews Endocrinology. 2011;7(10):569–580.

[8] Pavlidis N, Khaled H, Gaafar R. A mini review on cancer of unknown primary site: a clinical puzzle for the oncologists. Journal of Advanced Research. 2015;6(3):375–382.

[9] Tot T. The cytokeratin profile of breast carcinomas. Histopathology. 2002;40(2):112–118.

[10] Bridgewater J, van Laar R, Floore A, Van ‘t Veer L. Gene expression profiling may improve diagnosis in patients with carcinoma of unknown primary. British Journal of Cancer. 2008;98(8):1425–1430.
[11] Varadhachary GR, Raber MN. Cancer of unknown primary site. New England Journal of Medicine. 2014;371(8):757–765.
[12] Travis WD, Brambilla E, Nicholson AG, et al. The 2021 WHO classification of lung tumors: impact of advances since 2015. Journal of Thoracic Oncology. 2021;16(5):553–572.
[13] Moran S, Martínez-Cardús A, Boussios S, Esteller M. Methylation profiling in cancer diagnosis and personalized therapy. Clinical Epigenetics. 2017;9:105.
[14] Thiery JP, Acloque H, Huang RYJ, Nieto MA. Epithelial–mesenchymal transitions in development and disease. Cell. 2009;139(5):871–890.
[15] Ku SY, Rosario S, Wang Y, Mu P, Seshadri M, Goodrich ZW, et al. Rb1 and Trp53 cooperate to suppress prostate cancer lineage plasticity, metastasis, and antiandrogen resistance. Science. 2017;355(6320):78–83.
[16] Quail DF, Joyce JA. Microenvironmental regulation of tumor progression and metastasis. Nature Medicine. 2013;19(11):1423–1437.
[17] Henry NL, Hayes DF. Cancer biomarkers. Molecular Oncology. 2012;6(2):140–146.
[18] Nayar R. Diagnostic challenges of poorly differentiated malignancies: the role of morphology, immunohistochemistry, and molecular tests. Diagnostic Histopathology. 2020;26(6):227–238.
[19] Drilon A, Laetsch TW, Kummar S, DuBois SG, Lassen UN, Demetri GD, et al. Efficacy of larotrectinib in TRK fusion–positive cancers in adults and children. New England Journal of Medicine. 2018;378(8):731–739.
[20] Pavlidis N, Pentheroudakis G. Cancer of unknown primary site: biological and clinical characteristics. Annals of Oncology. 2012;23(Suppl 10):x119–x122.

Deep Science Publishing, 2025
https://doi.org/10.70593/978-93-7185-400-9

DeepScience
Open Access Books

Chapter 7: Infectious Versus Neoplastic: The Infective Impersonators

You will learn early in your training as a diagnostic pathologist that appearances can be misleading, and form and structure (tissues and cells), rarely provide clear information. Tuberculosis, fungal diseases and parasitic infestations have a way to disguise themselves as malignant processes so well that even seasoned observers will stop dead in their tracks and question what they see. Infectious impersonators serve as a reminder that the lines between infectious pathology and neoplastic development are blurry, and determined by many factors including the context in which they develop, the local environment, and how the host responds.

Tuberculosis represents the model example of misleading pathology. Extrapulmonary tuberculosis creates confusion for clinicians and pathologists. Granulomatous lesions in lymph nodes, vertebrae, liver, and even the central nervous system can resemble carcinoma or lymphoma. Radiographically, a mass in the mediastinum or liver can appear virtually indistinguishable from a metastasis. Histologically, the defining characteristics of TB (epithelioid histiocytes, Langhans giant cells, caseous necrosis) may be obscured, distorted or absent due to secondary inflammation, fibrosis, or coexisting pathology. On occasion, TB lesions may induce atypical reactive epithelial proliferation and form glandular or papillary structures that convincingly mimic adenocarcinoma. One of the most intriguing and confusing diagnoses for a pathologist is when an infection mimics a tumor. Therefore, the pathologist is required to translate the morphologic language of the morphology into the dialect of an infectious agent, by combining ancillary studies with clinical correlation to distinguish reality from fantasy. Although the Ziehl-Neelsen stain is far from perfect, it has been a cornerstone for many years and helps identify the presence of acid fast bacilli, which makes the diagnosis. In addition, fungal infections add further variables to the equation.

Fungal infections introduce additional variables. For example, pulmonary aspergillosis may present as a mass lesion, with invasion of surrounding tissue and blood vessels. Similarly, mucormycosis is known for its aggressive angiogenic behavior, producing

necrotic nodules that mimic highly malignant neoplasms. Histoplasmosis and cryptococcosis mimic malignancies as well, with granulomatous or pseudo-tumor like lesions in multiple organs. At times, microscopic evaluation reveals few, degenerated, or poorly visualized organisms that require PAS or GMS to visualize them. The ability of pathogens to mimic neoplasia is not coincidental; rather it has evolved through selective pressures to survive within a host, to incorporate itself into the tissue architecture, and to avoid immune mediated destruction.

Finally, parasitic pseudoneoplasms round out the variety of deceptions. Echinococcal cysts grow to become space-occupying lesions, with laminated walls and daughter cysts that occasionally resemble cystic neoplasms. Calcified nodules produced by cysticercosis can resemble metastatic deposits in muscle or CNS tissue. Similarly, schistosomal granulomas and fibrotic masses induced by filariasis can also mimic tumor-like lesions. In all of these examples, chronic inflammation, tissue remodeling and fibrosis create confusing patterns for even the most experienced observer. The parasite has no intention to mislead, however the host response inadvertently molds the lesion into one that mimics the morphology of cancer. The pathologist's job is therefore to decipher the pathogen's signature and the host's handwriting, to distinguish one from the other.

Misdiagnosis of an infectious lesion as a neoplasm can result in unnecessary surgical interventions, chemotherapy, and increased morbidity. Conversely, failure to identify cancer in preference to presumed infection can delay diagnosis and reduce prognosis. The fine line between prudence and decisiveness, between suspicion and confirmation is the skill of the diagnostician. It requires patience, knowledge, and a great deal of respect for biological subtlety.

Histopathology serves as both microscope and narrator. Granulomatous structures must be interpreted in the context of cytologic detail, i.e., the type of epithelioid cells, the pattern of giant cells, the degree of necrosis, and the distribution of inflammatory infiltrate. For example, caseating necrosis is a hallmark of TB, but similar necrotic patterns may occur in fungal infections, necrotic tumors, or metastases that have undergone infarction. Therefore, morphology alone is inadequate and ancillary tests are required. Special stains, IHC, and molecular diagnostics each contribute additional layers of confidence. PCR can detect mycobacterial DNA, whereas culture or antigen detection can confirm an infective etiology.

Similarly, integrating radiologic, clinical, and laboratory information is essential. The interpretation of a pulmonary mass in a patient who presents with fever, weight loss, and night sweats is significantly different than interpreting an incidental lesion found in an asymptomatic individual. Imaging can reveal characteristics that suggest an infective process over neoplasia (cavitation, calcification, or vascular invasion), however none are

specific. Travel history, serologic findings, and the patient's degree of immunocompetence provide valuable contextual information, but they do not constitute definitive evidence. The pathologist will ultimately need to synthesize all the information at hand, and be adaptable and humble in light of the ambiguities inherent in many cases.

Infectious disease mimics not only represent a story of simple mimicry but also illustrate some deeper conceptual principles. Both infectious pathogens and cancerous cells employ tissue architecture, blood vessel access, and host immune responses to facilitate growth. Both generate mass effects, elicit stromal reactions, and disrupt normal physiological pathways within affected tissues. Infectious diseases can therefore be considered a biologic "dress rehearsal" for cancer, because they occupy space, compete for limited host resources, and survive despite host immunity. Recognizing this relationship underscores pathology as more than a static collection of entities — it is a dynamic relationship between an organism and its environment, and each lesion is the product of a negotiated compromise between those two elements.

From a radiographic standpoint, a mass located in the mediastinum or liver may appear to be virtually indistinguishable from a metastasis. Histologically, while characteristic of epithelioid histiocytes, Langhans' giant cells, and caseous necrosis can be identified in tuberculosis, they may be obscured by secondary inflammation, fibrosis, or coexistent pathology. Some forms of tuberculous lesions can induce reactive epithelial proliferation, resulting in the formation of glandular or papillary structures that may lead the observer to mistakenly conclude the presence of adenocarcinoma. As such, the pathologist must utilize a combination of special stains and clinical correlation to identify whether a lesion is of infectious or neoplastic origin. Ziehl–Neelsen staining, despite some limitations, has been used historically to detect acid-fast bacilli, thereby identifying the presence of Mycobacterium tuberculosis.

Fungal infections further complicate the differential diagnosis. For example, pulmonary aspergillosis may present as a mass lesion that invades the surrounding tissues and vascular channels. Similarly, mucormycosis is characterized by its aggressive angioinvasive properties, producing necrotic nodules that may mimic high-grade malignancy. Histoplasmosis and cryptococcosis can both create granulomatous or pseudo-tumor patterns in the affected organs, making differentiation from neoplastic processes challenging. The organisms involved in these infections can be difficult to distinguish from cellular debris when they are sparse, degraded, or poorly preserved in tissue sections. Staining methods such as PAS and GMS can help make the organisms more apparent in tissue sections. This ability of fungi to mimic neoplastic processes is not incidental, but rather results from selective pressure that exists to enable these organisms to survive within a host, adapt to the host's tissue architecture, and evade host immune responses.

Parasitic pseudoneoplasms represent yet another component of this spectrum of deception. For example, echinococcal cysts may develop as space-occupying lesions and their laminated walls and daughter cysts may be mistaken for cystic neoplasms. Calcified nodules developed in muscle and brain tissue as a consequence of cysticercosis can be mistaken for metastatic deposits. Schistosomal granulomas and fibrotic masses produced by filariasis can be similarly mistaken for tumor-like structures. In each case, the chronic inflammatory response of the host and the resultant tissue remodeling and fibrosis may produce morphologic features that can confuse even experienced observers. The parasite itself does not intentionally attempt to deceive; instead, the host response inadvertently transforms the parasite into a form that resembles a malignant process. As such, the pathologist's task is to identify the parasite's signature along with the host's "signature" and to determine which one is represented by the observed features.

The clinical implications of these disguises are significant. Misidentification of an infectious process as a neoplasm can result in unnecessary surgical procedures, improper use of chemotherapy, and considerable morbidity. Alternatively, failure to identify a neoplasm due to suspected infection can lead to delayed therapy and negatively impact the prognosis. The distinction between cautiousness and decisiveness, between suspicion and confirmation, is the art of the diagnostician. It requires patience, knowledge, and a profound appreciation for the subtleties of biological relationships.

Histopathology in this context represents both the microscope and the narrative. Each granulomatous lesion must be examined based on the cytologic details of the reaction: the type of epithelioid cell present, the pattern of giant cells, the presence of necrosis, and the distribution of the inflammatory infiltrate. For example, caseous necrosis is a hallmark of tuberculosis; however, necrotic patterns may be seen in other conditions, including fungal infections, necrotic tumors, or infarcted metastases. Histopathology alone is insufficient; additional methodologies must be employed to establish a definitive diagnosis. Special stains, immunohistochemistry, and molecular diagnostics offer additional levels of diagnostic assurance. Molecular methods, such as PCR assays, can detect the DNA of Mycobacteria, whereas fungal cultures or antigen detection can confirm the infectious agent.

In addition to histopathology, the pathologist must evaluate the interplay among radiologic, clinical, and laboratory data. A pulmonary mass in a systemically ill patient (with signs of infection, including fever, weight loss, and night sweats) should be interpreted differently than a pulmonary mass found incidentally in an asymptomatic person. Specific radiologic features (cavitation, calcification, or vascular invasion) can suggest infection over neoplasia; however, none of these features are pathognomonic. Laboratory testing (serologic tests), travel history, and the patient's level of immunocompetence provide supportive or contradictory evidence, but none of these provide definitive proof. The pathologist must combine all of the available information

to arrive at an interpretation of the lesion, while demonstrating flexibility and humility in the face of uncertainty..

In addition to the challenges presented by these types of infections, the pathology community needs to incorporate a variety of diagnostic modalities such as microbiology, molecular diagnostics and advanced staining into their traditional morphological practices. While traditional methods of identifying Mycobacterium tuberculosis (e.g. Ziehl-Neelsen stain), fungal pathogens (e.g., Gomori methenamine silver stain) and parasites (e.g., histochemical stains) have been used for years, they are not additive to the diagnostic process. They are needed to determine whether or not the lesions identified through the use of these stains may mimic neoplastic processes. These findings can be subtle. A small amount of fungal organisms, sparse numbers of mycobacteria and degenerative forms of parasites can appear similar to amorphous cellular debris. Molecular-based assays such as PCR for Mycobacterial DNA or fungal ribosomal RNA sequencing can increase the confidence of the pathologist in his/her ability to make a definitive diagnosis when morphology has provided inconclusive results.

The examples of fungi as described earlier, further exemplify the potential of the above-mentioned lesions to mimic the masses of neoplastic diseases. Species of fungi such as Aspergillus, Mucor, Histoplasma and Cryptococcus are capable of creating large enough mass lesions within tissues that may be confused with neoplastic disease not only in terms of size but also in terms of biological behavior. For example, an invasive aspergilloma growing in the lung tissue can invade blood vessels and cause necrosis and hemorrhage, leading to necrotic areas that may be indistinguishable from those seen in highly malignant carcinomas using radiographic means.

Thus, the pathologist must be extremely vigilant at all stages of the diagnostic process. The pathologist cannot rely solely on morphology or gross examination; the complexity of infection requires the integration of multiple layers of information that includes clinical correlation, patient history, imaging studies and laboratory data to support the diagnosis. For example, a single mass lesion located in the lung of a patient who lives in a region where tuberculosis is endemic cannot be assumed to be a primary lung carcinoma without other supporting evidence. Similarly, a space occupying lesion in the brain could potentially represent a fungal abscess rather than a metastasis. Each architectural abnormality, necrosis and inflammatory cell infiltration provides clues as part of a broader story line that requires careful analysis of the total story to determine its significance.

Additionally, the emphasis on integrating traditional morphology with modern technology (microbiology, molecular diagnostics, advanced staining techniques) is emphasized by these infections. The traditional methods of diagnosing tuberculosis (acid-fast staining for tubercle bacilli), diagnosing fungal infections (methenamine-

silver staining for fungal hyphae) and detecting parasitic structures (histochemical staining) are not supplemental to the diagnostic process; they are necessary to demonstrate the presence of the infectious agent if the lesion has the potential to be mistaken for a neoplasm. The subtleties of the findings in many of these cases cannot be overstated. Many fungal organisms will be present in small numbers, mycobacteria will be present in small numbers and degenerating parasitic structures will appear like amorphous cellular debris. In such cases, molecular assays (such as PCR for Mycobacterial DNA or fungal ribosomal RNA sequencing) can provide increased diagnostic confidence for the pathologist and allow him/her to confirm suspicions that morphology alone cannot resolve..

Fungal infections also exemplify the capability of certain infectious agents to mimic neoplastic processes not only in terms of gross anatomy and physiology, but also in terms of biology. Likewise, mucormycosis can involve bone and soft tissue with the development of expansile lesions mimicking a sarcomatous tumor. Histoplasmosis and cryptococcosis (especially in an immunosuppressed host) can develop diffuse or nodular organ involvement which mimics metastasis. That we have witnessed time and again: the remarkable flexibility of infectious organisms, and the mental strain placed on us as pathologists who are required to read not simply what is there but also what is not there:the subtle absence of mitotic atypia, cellular pleomorphism, or true neoplastic arrangement that distinguishes infection from malignancy[6,7].

Added to this is the group of parasitic inflammatory pseudoneoplasms. The hydatid cyst, the cysticercus, granuloma due to filarial parasite and the pseudotumour in Filariasis also cause chronic inflammation, fibrosis and mass effect with simulation of benign or malignant neoplastic growth in almost anywhere on body. The immune response itself is implicated in the masquerade molding lesions of architectural grandeur while pretending coherence. Parasites can cause daughter cysts, laminated membranes, and calcification within the same kind of masses (lesions) as neoplastic (cancerous) cysts, sarcomas, or metastatic (distant site spread) calcifications. The pathologist must do more than diagnose an infection; the pathologist must try to determine how the dynamic process of immune response, tissue repair and remodeling, and cellular adaptation leads to the first step of creating the mass.

Lesions caused by infections have the potential to teach the pathologist far more than simple technical skills. These types of lesions teach the pathologist to be critical thinkers, patient, and humble. These types of lesions encourage the pathologist to look at the larger picture and create questions. Are the masses formed due to an actual cancerous process, or a reaction to the infection? Am I confident that the atypical cells forming the masses are indeed neoplastic (cancerous) or reactive histiocytic? How does the clinical history, epidemiology, and laboratory data support my microscopic findings?

Each case provides a new example of how the convergence of biology, environment, and evolution creates a unique story for the pathologist to observe the interactions of organisms rather than a simple translation of slide information.

When the pathologist is trying to differentiate between a "true" tumor and an infectious mimic (a process in which an infection imitates a tumor), the pathologist is involved in a scientific and philosophical exercise. In essence each lesion is a conversation between a pathogen, the host (infected individual), and the observer (pathologist). The pathogen presents its message with characteristics influenced by evolutionary pressures and host responses. The pathologist must listen carefully and interpret the message from the pathogen based on the evidence obtained using a variety of methods. Therefore, the process of establishing a diagnosis is not merely a classification but an interpretation, an ethics, and a human experience. It acknowledges that biology can be deceptive and therefore caution and reliance upon evidence-based reasoning should be exercised during the decision-making process of establishing a diagnosis.

To a large extent, tuberculosis, fungal infections, and parasitic pseudoneoplasms (parasites that form tumors) turn the pathology laboratory into a stage for observing the art of biological disguise/mimicry. In addition, these diseases remind us that appearance can be misleading and that the distinction between disease processes can be fluid. Ultimately, finding the truth in a diagnosis will require a combination of scientific objectivity, compassion, and intellectual curiosity. The microscope, the stain used, the molecular assay used, and the clinical notes all combine to provide the pathologist with a tapestry of knowledge to assist the pathologist in distinguishing whether a mass is caused by an infection or a neoplasm, deception or reality..

References

[1] Purohit MR, Mustafa T. Laboratory diagnosis of extrapulmonary tuberculosis in resource-constrained settings: challenges and opportunities. *PLOS Neglected Tropical Diseases*. 2020;14(4):e0008376.

[2] Burrill J, Williams CJ, Bain G, Conder G, Hine AL, Misra RR. Tuberculosis: a radiologic review. *Radiographics*. 2007;27(5):1255–1273.

[3] Sharma SK, Mohan A. Extrapulmonary tuberculosis. *Indian Journal of Medical Research*. 2004;120(4):316–353.

[4] Kousha M, Tadi R, Soubani AO. Pulmonary aspergillosis: a clinical review. *European Respiratory Review*. 2011;20(121):156–174.

[5] Guarner J, Brandt ME. Histopathologic diagnosis of fungal infections in the 21st century. *Clinical Microbiology Reviews*. 2011;24(2):247–280.

[6] Chatterjee KD. *Parasitology: Protozoology and Helminthology*. 13th ed. CBS Publishers; 2019.

[7] Mukhopadhyay S. Role of histopathology in the diagnosis of infectious diseases. *Modern Pathology*. 2007;20(S2):S88–S103.
[8] Lee JY. Diagnosis and treatment of extrapulmonary tuberculosis. *Tuberculosis and Respiratory Diseases*. 2015;78(2):47–55.
[9] Wheat LJ, Azar MM, Bahr NC, Spec A, Relich RF, Hage C. Histoplasmosis. *Infectious Disease Clinics of North America*. 2016;30(1):207–227.
[10] Dutta AK, Dutta M, Chaudhuri A. Parasitic granulomas simulating neoplastic lesions: clinicopathologic observations. *Tropical Parasitology*. 2015;5(1):45–49.

Deep Science Publishing, 2025
https://doi.org/10.70593/978-93-7185-400-9

DeepScience
Open Access Books

Chapter 8: Pulmonary Pathology: Distinguishing Diffuse Alveolar Damage, Organizing Pneumonia and Adenocarcinoma Spectrum

While the Lung appears to have a standard injury process; every stage of injury will have it's own timing. In the exudative stage there is a leaky capillary with fluid accumulation (edema), and then the proliferative stage where type II pneumocytes start replacing damaged tissue. Finally, the fibrotic phase involves structural changes to the lung's architecture through scar formation that may result in permanent deformation.

Thus, microscopic examination of diffuse alveolar damage (DAD) demonstrates both injury and potential recovery and serves as a reminder that the lung will initiate the complex and sometimes aberrant repair process subsequent to injury. However, the repair process may also inadvertently create a substrate for future malignant transformations.

Organizing Pneumonia (OPN) also shares a similar conceptual area and is characterized by the abnormal organization of the alveoli with fibroblastic plugs filling the alveolar spaces and extending into bronchioles. However, the overall framework of the lung remains intact. OPN is an example of the lung's ability to regenerate and attempt to restore normal architecture after injury and is an example of the cell's ability to attempt to restore continuity. However, the histopathological presentation of OPN may also cause confusion to the experienced pathologist. The fibroblastic proliferation may form nodular aggregates resembling adenocarcinomas, and in some cases the interface of the OPN with the interstitium may exhibit atypical epithelial proliferation making it difficult to differentiate between repair and neoplasia. Radiographically, OPN may present as patchy consolidation that may migrate over time consistent with the concept that injury and repair are dynamic processes and not static presentations.

To recognize the above differences and nuances require both technical expertise and a sense of timing and awareness of the temporal aspect of disease.

Unlike DAD and OPN, the adenocarcinoma spectrum represents the utilization of the body's repair mechanisms to produce unchecked proliferation. Type II pneumocytes and club cells have the capability of undergoing neoplastic transformation when their genetic and epigenetic regulatory processes fail. The spectrum of adenocarcinoma ranges from atypical adenomatous hyperplasia, representing a slight architectural and cytological abnormality, to minimally invasive adenocarcinoma to frank invasion and disruption of alveolar architecture. It is fascinating to see how adenocarcinoma utilizes the same repair mechanisms to support the growth of tumors: fibroblastic proliferation, production of extracellular matrix, and alveolar epithelial regeneration are utilized to support the growth of the tumors and create a surface that superficially resembles that of organizing pneumonia.

The most significant issue is establishing how all of this works together. For example, the hyaline membrane of DAD may be near a proliferative fibroblast lesion and cause confusion in identifying what was happening. The reactive epithelial atypia can occur in areas of OPN and lead to an identification of adenocarcinoma. Tumors can grow in a lepidic fashion and spread through alveolar septa and mimic the architectural features of normal repair and regeneration. Therefore, the pathologist needs to identify the subtle clues of nuclear morphology, mitotic activity, stromal reaction and spatial relationship, to differentiate between injury and neoplasia and between a reparative process and a malignant one.

Immunohistochemistry and molecular analysis allow clinicians to explore additional themes in greater detail than do the stories told by the histologic features of these diseases. In the case of adenocarcinomas, markers such as TTF-1 and Napsin-A allow for identification of the lineage of the tumor, while Ki-67 and p53 can be used to determine the proliferative rate of the tumor cells and degree of genetic instability. Molecular studies can identify specific driver mutations in genes such as EGFR, KRAS, and ALK that can be used to differentiate true neoplasia from reactive proliferation. Like all diagnostic techniques, however, the use of immunohistochemistry and molecular studies involves interpretation rather than absolute determination, as there is considerable overlap in the expression of some markers between regenerative epithelium in areas of organized pulmonary necrosis (OPN) and type II pneumocyte hyperplasia after diffuse alveolar damage (DAD). At the end of the day, however, the clinician's eye and experience will always play a role in interpreting these data.

These approaches to understanding the biology of disease are not merely forms of classification, but also serve as forms of biological philosophy. The lung illustrates the complex interplay between repair and malignancy and demonstrates how the distinctions between the two are not fixed, but rather are flexible and shaped by cellular plasticity, local microenvironmental signals, and systemic influences. Thus, injury leads to regeneration, regeneration makes one susceptible to injury, and in the presence of certain

molecular changes, injury can lead to malignancy. Each slide viewed through the microscope represents a conversation with time and reflects the relationships among injury, response, and transformation.

The clinical context provides additional depth to this conversation. For example, patients who present with acute hypoxemic respiratory failure may have DAD secondary to infection or drug toxicity. A migratory pattern of consolidation may reflect cryptogenic organizing pneumonia (COP). Ground-glass opacifications that slowly expand may represent early adenocarcinoma. Clinical findings, laboratory results, and patient history all contribute to the development of a clinical narrative that guides the pathologist's interpretation of the tissue slides. If the pathologist fails to consider these clinical narratives, he/she risks misinterpreting the entire story and confusing the epiphenomena of repair with neoplastic processes.

In addition, the lung serves as a living example of the potential consequences of misdirected repair. Prolonged fibroblastic proliferation during the fibrotic phase of DAD can result in architectural changes in the lung that support neoplastic transformation. Similarly, chronic COP, particularly when the patient has multiple episodes of injury leading to further episodes of COP, may lead to atypical epithelial proliferation, which exemplifies the continuum of inflammation to dysplasia. Furthermore, adenocarcinomas can utilize reparative pathways to create a microenvironment that superficially resembles COP, thereby highlighting the dual nature of survival and destructive mechanisms that utilize reparative mechanisms to promote destruction.

This conceptual model highlights the fact that diagnosis in pulmonary pathology is not simply a technical exercise but an interpretive activity. Each biopsy and each resected specimen is a chapter in the ongoing story of cellular communication, host response, and environmental effects. The overlapping narratives of DAD, COP, and the spectrum of adenocarcinoma illustrate the potential intersection of repair with malignancy, injury with transformation, and the pathologist with both the role of interpreter and philosopher.

The relationships among injury, repair, and malignancy in pulmonary pathology can be viewed as a continuous progression rather than separate distinct events. DAD is never a single event; it exists in three phases (exudative, proliferative, and fibrotic) that may coexist within the same lung and produce heterogeneous conditions that parallel the complexities of the clinical disease process in patients with DAD. In this manner, alveolar epithelial cells attempt to repair the damage and orchestrate the proliferation of type II pneumocytes and recruitment of macrophages, fibroblasts, and endothelial progenitor cells to create an environment that is both protective and misleading. The hyperplastic areas created by proliferation of type II pneumocytes can simulate neoplastic proliferation and can also exhibit atypical nuclear morphology resulting from oxidative stress or hypoxia. It is thus important for pathologists to understand the

distinction between hyperplasia and neoplasia based on both the context and pattern of the histopathology: that not all atypia is neoplasia and that hyperplasia can mimic cancer.

Pulmonary pathology therefore illustrates how the boundaries between repair and malignancy are fluid and influenced by cellular plasticity, microenvironmental signals, and systemic influences.

Diagnosing the spectrum of Diffuse Alveolar Damage (DAD) (Diffuse Alveolar Hemorrhage (DAH) or Exudative Phase) and Organizing Pneumonia (OP) and Adenocarcinoma (AC) provides the pathologist with a significant diagnostic challenge because all three processes share common cell types and similar morphologic features. Therefore, an interdisciplinary approach incorporating clinical, radiologic, and pathological evaluation is necessary to provide accurate diagnoses and classification of these three diseases.

Organizing Pneumonia (OP) represents the body's ability to repair itself after injury. The fibroblastic plugs that form in the alveolar space during OP are formed in such a way as to preserve alveolar architecture and function. Although the plugs themselves are generally non-neoplastic, in some cases they can grow together so as to obscure their benign nature. A critical component of diagnosing OP is to assess the relationship of the fibroblastic plugs to the surrounding epithelium. Assessing the nuclei of the fibroblasts, number of mitotic figures, and presence of stromal invasion into the surrounding tissues are the primary methods used to distinguish between the plugs of a benign repair process and those associated with a neoplasm. Additionally, assessing the distribution of the fibroblasts in the area of the damaged tissue and whether or not the structural integrity of the alveolar spaces are preserved will aid in identifying whether the repair process has progressed to a neoplasm.

Organizing Pneumonia (OP) and Adenocarcinoma (AC) share many similarities. Both processes use Type II pneumocytes and club cells to facilitate repair of the bronchiolar airspaces. Both can undergo neoplastic transformation as a result of genetic and/or epigenetic alterations. Additionally, the progression from hyperplastic adenomatous changes to lepidic growth pattern to invasive adenocarcinoma is a gradual process involving the transformation of normal repair mechanisms to promote the formation of a neoplasm. Furthermore, the process of transforming from a normal repair process to a neoplasm is often mimicked by Adenocarcinomas that display lepidic growth patterns, thereby complicating the differential diagnosis of even the most experienced pathologists. Thus, an interdisciplinary approach utilizing radiologic-pathologic correlation, morphologic assessment, immunohistochemical staining, and molecular studies are needed to accurately diagnose and classify Adenocarcinoma..

Radiologic-pathologic correlation is an important tool used to distinguish DAD, OP, and AC. DAD typically presents as bilateral ground glass opacities, consolidation, and septal

thickening due to the exudative and proliferative phases of the disease process. OP presents as patchy consolidation or nodular opacities that may migrate due to the dynamic nature of the repair process. AC typically presents as persistent ground glass nodules, consolidation with spiculated margins, or mixed solid and ground glass lesions depending upon the degree of invasion. By utilizing a combination of radiologic findings and pathological features and clinical history, the likelihood of misclassifying the disease process decreases.

The ability of immunohistochemistry to distinguish between repair and malignancy is significant. Immunohistochemistry can establish the lineage of adenocarcinoma through identification of lineage-specific markers (TTF-1 and Napsin-A), and it can help to determine whether the proliferation index of cells (Ki-67) is indicative of neoplastic vs. reactive hyperplasia. Immunohistochemistry can help to identify the presence of driver mutations (EGFR, KRAS, and ALK) that provide definitive proof of malignancy. Nevertheless, molecular studies are not perfect, and some regenerating pneumocytes can express similar markers due to extreme injury or chronic inflammation. Therefore, the pathologist's interpretation of the biopsy results continues to be based on their expertise and knowledge of both morphology and molecular studies, as well as their review of the patient's clinical data.

The lung embodies the paradoxical nature of repair conceptually, since all three processes, DAD, OP, and AC, coexist along a continuum with respect to cellular plasticity, microenvironmental cues, and host response. Injury can lead to regeneration, regeneration can increase vulnerability to injury, and increased vulnerability can lead to malignant transformation. The study of the continuum of DAD, OP, and AC will enhance our understanding of the biological principles that govern tissue homeostasis and improve the accuracy of diagnosis. Additionally, the study of the continuum of DAD, OP, and AC highlights the importance of temporal context; that is, a single biopsy sample may only provide a snapshot of a dynamic process.

Finally, the treatment options for DAD, OP, and AC illustrate the convergence of repair and malignancy. Management of DAD typically consists of supportive care, avoidance of further injury, and promotion of resolution of injury. Treatment of OP typically involves corticosteroids to regulate the repair process. Treatment of AC is determined by molecular characterization and/or surgical intervention and/or systemic therapy. Misdiagnosis of the type of lesion present in the initial evaluation can result in overtreatment of benign reparative processes or undertreatment of early malignancies, which emphasizes the clinical relevance of accurate morphologic assessment.

In conclusion, the pathologist is not only a classifier, but also a narrator. Each biopsy sample tells a story of cellular conflict, destruction and repair, adaptation and misdirection. The microscopic architecture of each sample contains both temporal and

spatial information that reflects previous injuries and possible future transformations. Hyaline membranes, fibroblastic plugs, and lepidic growth patterns do not represent static entities, but rather dynamic indicators of biological communication. The observation and interpretation of these morphologies requires technical skills and conceptual understanding: an appreciation of the lung as a system that continuously balances injury, repair, and neoplastic transformation..

Additionally, there are remaining features of the normal architecture and repair processes of the lung within invasive adenocarcinomas, that remind us of how neoplastic pathways originate. Tumor cells use the pre-existing structures of the alveoli to promote their own growth, and retain some architectural features that provide clues to the relationship of the malignant process to its regenerative origins. While reparative processes in DAD and OP demonstrate that excessive reparative processes can appear neoplastic and thus illustrate the dual nature of tissue plasticity, the reparative processes are distinguishable from neoplasia due to the lack of invasion in the former.

A comprehensive, multi-disciplinary approach incorporating clinical, radiologic, and pathological findings provides the most effective method to differentiate DAD, OP, and AC. Histopathology, immunohistochemistry, molecular analysis, radiography, and clinical data all contribute different aspects to the overall picture of disease. Each modality offers a unique contribution: morphology provides identification of form, immunohistochemistry and molecular studies identify lineage and potential, imaging determines location and timing, and clinical data establish the context in which the disease process occurs. Thus, mastering pulmonary pathology is both technical and philosophical, and includes interaction with the material, temporal, and conceptual aspects of disease.

As one moves further into the pulmonary environment, it becomes apparent that the differences between repair and malignancy are not absolute, but rather relative, and dependent on the interactions of cellular plasticity, microenvironmental signals, and temporal dynamics. The alveolar epithelium demonstrates a remarkable ability to regenerate in cases of DAD. Type II pneumocytes proliferate to regenerate the alveolar surface and orchestrate the repair of the lung with macrophages and fibroblasts to restore tissue integrity. However, this regenerative capability introduces ambiguity into the diagnostic process. For instance, hyperplastic pneumocytes may display enlarged nuclei, mild atypia, or prominent nucleoli that may alone suggest early adenocarcinoma. The pathologist's task is to position these findings within a context that clearly indicates a reparative process versus a neoplastic transformation.

OP also illustrates the regenerative capabilities of the lung. The fibroblastic plugs that develop in the alveolar ducts and bronchioles in OP are an organized attempt to repair the lung parenchyma. These plugs maintain the alveolar architecture and provide a

scaffold for epithelial regeneration. Rarely, the epithelium covering these plugs may exhibit reactive changes, including cytologic atypia that may suggest carcinoma. Whether a reparative process or a neoplasm exists will depend on the spatial distribution of the process, the temporal sequence of the process, and the presence or absence of invasive growth.

Radiologic correlation with histology assists in distinguishing between reparative and neoplastic processes. Patchy consolidation and/or transient nodular opacity radiographically support dynamic reparative processes rather than neoplastic growth.

The overlap in morphological characteristics of OP and RH highlights the necessity of using a comprehensive approach to diagnosis. Immunohistochemical markers (TTF-1, Napsin-A, and Ki67) confirm the lineage of the lesions and provide information about the rate of proliferation, whereas molecular testing for mutations in EGFR, KRAS, or ALK define the neoplastic characteristics of the lesions.

Conceptually, the intersection of repair and malignancy has several implications. First, it emphasizes that tissue injury and regeneration are not only physiologically responsive processes, but may also provide the nidus for neoplastic transformation. Repeated episodes of chronic diffuse alveolar damage, organizing pneumonia, or prolonged epithelial hyperplasia may, over time, alter local stromal composition, influence immune surveillance, and increase levels of oxidative stress, and thereby increase susceptibility to malignancy. Second, it reminds clinicians and pathologists of the importance of vigilance when diagnosing; misdiagnosis may result in either overtreatment of benign reparative lesions, or failure to treat early malignancy. Third, it underscores the importance of temporal and spatial awareness in histopathology; a single static section captures only a moment in time in a dynamic biologic process and requires careful consideration of the contextual information.

These considerations will direct the therapeutic approach to patient care. Treatment of diffuse alveolar damage is primarily supportive, aimed at reducing ongoing injury and facilitating repair of damaged alveoli. OP is highly responsive to corticosteroids, consistent with the reparative and inflammatory nature of the disease. Treatment of adenocarcinoma is directed based upon the molecular characterization of the tumor; surgical resection, targeted therapy, or systemic chemotherapy are directed based upon the genetic landscape of the tumor. Therefore, misinterpretation at the histopathologic level can have significant clinical implications and highlight the role of the pathologist not only as diagnosticians, but as an integral member of patient management.

Each alveolus, each fibroblastic plug, and each lepidic tumor represents a story of cell decision-making, interaction with the environment, and progression through time. Hyaline membranes in DAD represent the sequelae of acute injury; fibroblastic plugs in OP represent attempts at restitution that have been organized; and the lepidic or invasive

growth of adenocarcinoma represent the hijacking of repair mechanisms. Together, they represent a spectrum in which repair and malignancy intersect, in which the distinction between physiological restoration and malignant proliferation is tenuous, and in which the expertise, experience, and conceptual understanding of the pathologist are the final arbitrators.

Pulmonary pathology provides an illustrative paradigm of a broader principle in biology that processes developed for maintenance and repair can, under specific perturbations, be commandeered by disease. The lung, in its constant struggle to protect itself from environmental insult, injury and repair, is an example of the malleability of tissue and its potential for manipulation. Recognizing these patterns is both a technical skill and an intellectual exercise requiring the integration of morphology, immunohistochemistry, molecular data, radiologic images, and clinical context.

Thus, the differentiation of DAD, OP, and the spectrum of AC is both a scientific and philosophical pursuit. It requires attention to detail, an understanding of the nuances of biology, and the ability to synthesize disparate lines of evidence. Each lesion represents a testament to injury, participation in repair, and potential precursors to malignancy. Through careful observation and thoughtful interpretation, the pathologist understands the lung's response to injury is a continuum, rather than a series of discrete events.

In addition, there exists a dialectical relationship in every slide, biopsy, and radiographic image: between injury and repair, between the host and its environment, between form and function, and finally between life's tenacity and the possibility of malignancy. Mastery of pulmonary pathology goes beyond merely identifying these entities and recognizing the continuum in which they exist, where repair intersects with malignancy, and understanding emerges not from observing individual elements in isolation, but from the integration of multiple lines of evidence and conceptual understanding..

References

[1] Katzenstein AL, Bloor CM, Leibow AA. Diffuse alveolar damage: the role of pathology in understanding ARDS. *Human Pathology*. 1976;7(1):1–12.

[2] Ware LB, Matthay MA. The acute respiratory distress syndrome. *New England Journal of Medicine*. 2000;342(18):1334–1349.

[3] Thille AW, Esteban A, Fernandez-Segoviano P, Rodriguez JM, Aramburu JA, Penuelas O, et al. Comparison of histopathology of diffuse alveolar damage and organizing pneumonia in ARDS. *Intensive Care Medicine*. 2013;39(2):271–278.

[4] Beasley MB. Pulmonary pathology: patterns of injury and repair. *Modern Pathology*. 2000;13(1):1–10.

[5] Epler GR. Bronchiolitis obliterans organizing pneumonia. *New England Journal of Medicine*. 2001;344(6):421–429.

[6] Yousem SA, Dacic S. Distinguishing adenocarcinoma from organizing pneumonia: histologic and molecular considerations. *Archives of Pathology & Laboratory Medicine*. 2010;134(4):608–616.
[7] Travis WD, Brambilla E, Noguchi M, Nicholson AG, Geisinger K, Yatabe Y, et al. International multidisciplinary classification of lung adenocarcinoma: concepts and criteria. *Journal of Thoracic Oncology*. 2011;6(2):244–285.
[8] Rekhtman N. Lung adenocarcinoma: pathology and molecular pathology. *Seminars in Diagnostic Pathology*. 2010;27(3):133–146.
[9] Pelosi G, Pastorino U, Papotti M. Lung adenocarcinoma spectrum: morphological and molecular perspectives. *Virchows Archiv*. 2010;456(2):115–127.
[10] Bishop JA, Xu B, Illei PB, Westra WH. TTF-1 and Napsin A expression in lung adenocarcinomas and mimics. *American Journal of Surgical Pathology*. 2010;34(5):814–822.
[11] Sica G, Yoshizawa A, Travis WD. Adenocarcinoma and repair: interpreting morphology in context. *Histopathology*. 2007;51(2):179–190.
[12] Petersen I, Polyak K. Repair, regeneration, and cancer: lessons from the lung. *Cancer Cell*. 2010;18(5):414–416.
[13] Rossi G, Cavazza A, Spagnolo P, Colby TV. Lung injury and repair: clinical and pathological correlation. *Respiration*. 2007;74(6):564–575.
[14] Katzenstein AL, Fiorelli RF. Idiopathic pulmonary fibrosis: cellular and molecular mechanisms. *American Journal of Surgical Pathology*. 1994;18(5):487–503.
[15] Travis WD. Lung adenocarcinoma: where repair meets malignancy. *Modern Pathology*. 2013;26(1):S65–S76.
[16] Colby TV. Pulmonary pathology: reflections on repair and neoplasia. *Archives of Pathology & Laboratory Medicine*. 2006;130(6):834–842.
[17] Han X, Chen H, Wang J, et al. Molecular profiling in early-stage lung adenocarcinoma: implications for diagnosis and therapy. *Journal of Thoracic Oncology*. 2019;14(6):1015–1027.
[18] Travis WD, Brambilla E, Burke AP, Marx A, Nicholson AG. WHO classification of lung tumors. 4th ed. Lyon: IARC Press; 2015.
[19] Sholl LM, Hirsch FR. Molecular diagnostics and immunohistochemistry in pulmonary adenocarcinoma. *Archives of Pathology & Laboratory Medicine*. 2015;139(10):1232–1240.
[20] Thunnissen E, Kerr K, Herth F, et al. Early-stage lung adenocarcinoma: histologic patterns and prognostic implications. *Journal of Thoracic Oncology*. 2014;9(5):701–712.
[21] Travis WD, Brambilla E. Pathology of lung cancer: insights into repair and neoplastic transformation. *Lancet Respiratory Medicine*. 2013;1(3):242–252.
[22] Beasley MB, Colby TV, Carrington CB. Diffuse alveolar damage: the pathologist's perspective. *American Journal of Surgical Pathology*. 2002;26(8):1031–1038.
[23] Epler GR, Colby TV. Organizing pneumonia: clinicopathologic features. *Seminars in Respiratory and Critical Care Medicine*. 2000;21(1):7–19.
[24] Travis WD, Brambilla E, Nicholson AG. Lung adenocarcinoma: morphology, classification, and prognostic implications. *Journal of Clinical Pathology*. 2015;68(10):797–808.
[25] Yousem SA. Reactive epithelial changes in pulmonary injury and repair. *Modern Pathology*. 2000;13(9):1025–1033.

[26] Katzenstein AL, Fiorelli RF. Chronic injury and the risk of neoplastic transformation in the lung. *American Journal of Surgical Pathology*. 1994;18(5):487–503.
[27] Travis WD. Conceptual reflections on repair and malignancy in pulmonary pathology. *Modern Pathology*. 2013;26(Suppl 1):S65–S76.
[28] Mukhopadhyay S, Katzenstein AL. Diagnostic challenges in lung pathology: repair versus neoplasia. *Archives of Pathology & Laboratory Medicine*. 2011;135(5):698–707.
[29] Travis WD, Brambilla E, Noguchi M. Adenocarcinoma spectrum: morphology, molecular features, and clinical correlation. *Journal of Thoracic Oncology*. 2013;8(7):891–902.
[30] Travis WD. Histologic patterns of diffuse alveolar damage and organizing pneumonia: interpretive strategies. *Human Pathology*. 2001;32(5):443–450.
[31] Travis WD, Brambilla E, Nicholson AG. Pathology and biology of lung adenocarcinoma: repair meets malignancy. *Lancet Oncology*. 2013;14(6):e246–e254.
[32] Travis WD, Brambilla E, Burke AP. Pulmonary pathology: an integrated approach to injury, repair, and neoplasia. *Archives of Pathology & Laboratory Medicine*. 2014;138(10):1324–1338.

Deep Science Publishing, 2025
https://doi.org/10.70593/978-93-7185-400-9

DeepScience
Open Access Books

Chapter 9: Hepatobiliary Mimicry, Cholangiocarcinoma and Its Imposters: Regenerative Nodules, Ductular Reactions, and Neoplastic Transitions

For centuries, the liver has been perceived as a paradoxical organ - capable of repairing itself through regeneration but also vulnerable to malignant transformation. This paradox exists within the liver's biliary system, consisting of winding biliary canals and sinuous biliary ducts, which together comprise a world of repair, inflammation, and neoplasia where they are often difficult to distinguish from one another. For clinicians and pathologists alike, this world is at once fascinating and dangerous. The complexity of this world is perhaps best illustrated by the challenge of distinguishing between cholangiocarcinomas and their many histologic mimics (i.e., regenerative nodules, ductular reactions), including the earliest stages of neoplastic transformation that render distinctions between repair and malignancy increasingly ambiguous.

Cholangiocarcinomas arise from the epithelial lining of the bile ducts, which present with a great variety in terms of tumor biology. Therefore, cholangiocarcinoma should be viewed neither as a single disease nor as a single pathological process. Rather, each subtype of cholangiocarcinoma (e.g., intrahepatic, perihilar, distal) speaks its own unique language of histopathology. However, beneath this variability lies an overarching theme: cellular degeneration that leads to the loss of normal cellular regeneration. Normally, the biliary epithelial cells have a silent cross-talk with hepatocytes and hepatic stellate cells . Under chronic injury, these biliary epithelial cells may acquire the ability to speak the language of immortality. It starts, as so many betrayals swindle the brain into doing, disguised as repair.

When chronic cholestatic injury or viral hepatitis assaults the liver, the parenchymal architecture strives for renewal. Hepatocytes, though remarkably regenerative, cannot always bear the brunt of sustained injury. In their place, the ductular reaction emerges - a proliferation of small duct-like structures at the portal-parenchymal interface, driven by hepatic progenitor cells residing in the canals of Hering[3]. These progenitor cells

possess a unique plasticity: under favorable signals, they regenerate hepatocytes or biliary cells; under sustained cytokine stress, they may instead imitate malignancy. The histological picture of a ductular reaction can thus resemble that of well-differentiated cholangiocarcinoma , both display glandular or ductular profiles embedded in fibrous stroma, both express cytokeratins, and both may arise amidst chronic fibrosis[4].

Ductular reactions (the first form of mimicry) resemble neoplasms because they grow in a manner and architecture similar to their cancerous counterparts. Both have small, anastomosing ducts with surrounding myofibroblast activation and infiltration of inflammatory cells. Pathologists therefore need to use additional diagnostic techniques to assess for nuclear polarity, the presence of stromal invasion, and the retention of the underlying reticulin structure of the liver to determine if these ductular reactions represent a normal response to injury or a neoplastic process. In addition, ductular reactions do not invade the underlying liver architecture but instead proliferate along pre-existing hepatic structures. In contrast, neoplastic growth (e.g., cholangiocarcinoma) does invade the surrounding liver, causes scarring and distorts the underlying architecture of the liver. However, in the early stages of neoplastic development, the difference between ductular reactions and cholangiocarcinoma is often difficult to discern.

Regenerative nodules, which develop in cirrhotic livers as part of the body's attempt to repair damaged areas of the liver, add another layer to the complex issue of distinguishing benign from malignant processes in the liver. Regenerative nodules are typically found in cirrhotic livers, are surrounded by fibrotic bands, and sometimes exhibit atypical cytologic and architectural characteristics that could be misinterpreted as malignancy. Therefore, when these nodules occur adjacent to bile ducts or contain a peripheral zone of ductular cells, they can mimic small duct type cholangiocarcinomas.

This clinical mimicry also presents a problem for imaging studies. Imaging studies such as ultrasound, CT scans and MRIs depend upon contrast uptake and tissue density to distinguish benign from malignant lesions. Since regenerative nodules and cholangiocarcinomas can both appear as enhancing masses in cirrhotic livers and since both exhibit overlapping vascular patterns, the imaging findings may lead to invasive biopsy, thereby requiring the pathologist to interpret the microscopic findings as both an art and a science.

The pathologist's microscope provides a reflection of the ambiguous nature of biology. At the microscopic level, ductular reactions and early neoplastic foci can exhibit the same cytokeratin profiles.. Immunohistochemical markers such as CK7 and CK19 are expressed in both, reflecting their shared lineage. The presence of epithelial–mesenchymal transition markers, like vimentin, further blurs boundaries, as regenerative epithelia transiently adopt these during wound healing[9]. Only the patterns of invasion,

the loss of cell polarity, and the desmoplastic stromal response provide clues to malignancy. Yet even desmoplasia, that fibrotic halo of cancer, can emerge in chronic injury as part of repair. The narrative of hepatobiliary pathology thus becomes one of cellular intentions misread.

As one navigates through the concept of neoplastic transition, a question arises: when does regeneration cease to be repair and begin to be rebellion? In the chronically injured liver, the interplay of cytokines, growth factors, and oxidative stress creates a microenvironment conducive to transformation. Hepatic progenitor cells, under repeated mitotic pressure, may accumulate mutations in oncogenic pathways , notably in KRAS, IDH1, or ARID1A : leading to dysplastic proliferation that precedes frank carcinoma[10].

Mimicry is a unique form of deception in the world of medicine. Mimicry involves a condition that has characteristics of multiple diseases, leading to confusion about what disease the person is actually experiencing. For example, there is a disease known as biliary intraepithelial neoplasia (BilIN), which has characteristics of both a benign condition and a malignant one.

Another disease is primary sclerosing cholangitis (PSC). PSC has many characteristics of a benign condition, but over time the condition can develop into a malignant one. PSC can also be connected to IBD in the form of ulcerative colitis. This is an inflammatory condition of the colon (lower part of the digestive tract), and PSC is an inflammatory condition of the bile ducts which is frequently seen in combination with UC.

Chronic viral hepatitis is a condition that is a long-term infection caused by a virus that damages your liver. Viral hepatitis is one of the most frequent reasons why people lose their livers and develop liver cancer. Over time, this damage to liver cells will create fibrosis (scarring), but for some people, this will lead to a condition known as cirrhosis. Cirrhosis occurs when there is extensive scarring of the liver due to years of inflammation and dying liver cells; this creates an increased likelihood of developing liver cancer.

Liver cirrhosis is a medical term used to describe the scarring of the liver due to inflammation and/or liver cell death over many years.. The liver loses its ability to function properly and is replaced by scar tissue. The scarring of the liver can lead to a buildup of fluid in the abdomen and other complications.

Liver cancer occurs when abnormal cells grow in the liver. Liver cancer is often caused by long-term liver damage. Liver cancer can occur in anyone, regardless of age.

Cholangiocarcinoma (CCA) is a rare and aggressive type of cancer. CCA originates in the bile ducts and is difficult to diagnose. It is usually diagnosed late in the progression of the disease. The symptoms of CCA include pain, weight loss, jaundice and dark urine.

As stated previously, the liver's regenerative capacity is both a benefit and a detriment. The liver is able to regenerate quickly, but the rapid growth of new liver cells provides an environment in which malignant cells can rapidly grow.

A key area of study for the treatment of liver cancer is the use of targeted therapy. Targeted therapy is a type of drug that is designed to attack specific proteins that are responsible for the development of cancer. Some examples of targeted therapy drugs include sorafenib and erlotinib. Sorafenib is used to treat liver cancer and erlotinib is used to treat lung cancer.

References

[1] Sato K, Marzioni M, Meng F, Francis H, Glaser S, Alpini G. Ductular reaction in liver diseases: pathological significance and mechanisms. J Hepatol. 2018;69(2):426–435.

[2] Sanada Y, Kawashita Y, Okada S, Matsumoto S, Yoshioka T, Sasaki M, et al. Macroscopic subtypes and clinical–pathological features of intrahepatic cholangiocarcinoma. Liver Int. 2014;34(6):897–906.

[3] Guest RV, Boulter L, Dwyer BJ, Kendall TJ, Man TY, Minnis-Lyons SE, et al. Understanding liver regeneration to bring new insights for cholangiocarcinogenesis. J Hepatol. 2017;67(1):168–182.

[4] Libbrecht L, Roskams T. Hepatic progenitor cells in human liver tumor development. J Pathol. 2006;208(3):395–404.

[5] Banales JM, Marin JJG, Lamarca A, Rodrigues PM, Khan SA, Roberts LR, et al. Cholangiocarcinoma 2020: the next horizon in mechanisms and management. Nat Rev Gastroenterol Hepatol. 2020;17(9):557–588.

[6] Moeini A, Sia D, Bardeesy N, Mazzaferro V, Llovet JM. Cell of origin in biliary tract cancers and clinical implications. Nat Rev Gastroenterol Hepatol. 2021;18(8):557–572.

[7] Ohfuji S, Misu M, Taguchi K, Ichikawa K, Shirota K. Cholangiocarcinoma of possible hepatic progenitor cell origin. Vet Q. 2012;32(4):218–222.

[8] Choi JH, Kim MJ, Lee MJ, Kim DG, Lee KB. Recent advances in pathology of intrahepatic cholangiocarcinoma. Cancers (Basel). 2024;16(5):932–948.

[9] Sorrentino G, Romito R, Zambelli F, Russo M, Magni R, Cordiglieri C, et al. Microenvironmental control of the ductular reaction: balancing repair and disease progression. Cell Death Dis. 2025;16(1):1–13.

[10] Guest RV, Kendall TJ, Minnis-Lyons SE, Newsome PN. Morphomolecular pathology and genomic insights into the cell(s) of origin of liver cancers. Ann Transl Med. 2025;13(4):215–229.

[11] Lou C, Chen Y, Zhang X, Tang Q, Luo Z, Wu Y, et al. Heterogeneity and plasticity of cholangiocytes in liver injury and regeneration. Gut. 2025;74(2):253–269.

[12] Gupta V, Singh S, Patel R, Mehra P, Nundy S. Portal fibrosis and the ductular reaction: insights into the regenerative–fibrotic interface. Gastroenterology. 2025;168(3):721–735.

[13] Rosenberg N, De Vito C, Lleo A, Invernizzi P. Combined hepatocellular–cholangiocarcinoma derives from hepatic progenitor cells in chronic disease settings. J Hepatol. 2022;77(4):1037–1048.
[14] Vicent S, Lieshout R, Spaan CN, Ottenhoff R, de Vos R, van den Bosch MAAJ, et al. Experimental models to unravel molecular mechanisms of hepatic progenitor contribution to carcinogenesis. Liver Int. 2019;39(6):1122–1134.
[15] Chansky K, Abu Dayyeh BK, Kamath PS. Imaging overlap between regenerative nodules and intrahepatic cholangiocarcinoma in cirrhotic livers. Clin Radiol. 2023;78(1):45–56.
[16] Bridgewater J, Galle PR, Khan SA, Llovet JM, Park J, Patel T, et al. Multidisciplinary management and resection challenges in intrahepatic cholangiocarcinoma. Lancet Gastroenterol Hepatol. 2023;8(7):602–617.
[17] Li Y, Zhang W, Xu J, Chen J, Zhu W, Wang Q, et al. Therapeutic targeting of Notch and Wnt signaling in cholangiocarcinoma stem-like cells. Mol Cancer Ther. 2022;21(9):1431–1445.
[18] Kinoshita M, Uchida Y, Nakashima H, Nakashima M, Shono S, Habu Y, et al. Crosstalk between stromal microenvironment and hepatic progenitor cells during fibrosis and carcinogenesis. Hepatology. 2021;74(5):2702–2718.
[19] Sirica AE, Gores GJ, Groopman JD, Selaru FM, Strazzabosco M, Wei Wang X, et al. Pathobiological classification and molecular biomarkers of cholangiocarcinoma. Hepatology. 2019;69(4):1803–1815.
[20] Nakamura H, Arai Y, Totoki Y, Shirota T, Elzawahry A, Kato M, et al. Genomic sequencing identifies IDH1, FGFR2, and KRAS mutations as diagnostic discriminators in cholangiocarcinoma. Nat Genet. 2015;47(12):1473–1482.
[21] Kendall TJ, Newsome PN. Evolutionary mimicry of regenerative programs in cholangiocarcinoma: a philosophical view of oncogenesis. Semin Liver Dis. 2023;43(2):205–218.
[22] Roskams T, Desmet VJ. The role of hepatic progenitor cells in regeneration and malignant transformation. Histol Histopathol. 2008;23(1):41–59.

Deep Science Publishing, 2025
https://doi.org/10.70593/978-93-7185-400-9

DeepScience
Open Access Books

Chapter 10: Renal Pathology: Glomerular Shadows of Systemic Disease (Diabetic Nephropathy, Lupus Nephritis, and Vasculitic Overlap)

The kidney is a storyteller, though it does not speak in words. It speaks in whispers of proteinuria, in the pale cast of edema, in the microscopic signatures of immune traffic across its glomerular tuft. To the untrained eye, it is a silent organ. To the pathologist, it speaks in eloquent terms of systemic disease. In its glomeruli, diabetes, autoimmunity and vasculitic fury are printed on canvas of capillaries and mesangium with indelible paint [1].

Diabetic nephropathy, lupus nephritis and vasculitic overlapping syndromes have become leading figures in the evolving field of renal pathology. While each has its unique "fingerprint," the echoes of all three overlap; therefore, to some degree the identification of these diseases is both scientific and interpretive. The glomerulus, which is an intricate and fragile organ, does not have the ability to protest against or escape from systemic attacks..

A. The Glomerulus: A Canvas of Systemic Messages

The glomerulus can be described as simple; a tuft of capillaries wrapped by a layer of podocytes (the structural support) covered by endothelial cells, nourished and filtered by the basement membrane, and held together by the mesangial matrix. While the description is an oversimplification, each layer of the glomerulus is capable of independent and interdependent changes that allow for the maintenance of glomerular filtration under normal physiological conditions. Endothelial cells provide an antithrombotic surface, the basement membrane filters on the basis of molecular size, and the podocytes serve as the final barrier to filtration. However, when systemic disease invades, these functions are disrupted.

Systemic diseases enter into the glomerulus at different times and through different mechanisms. Diabetes begins to invade the glomerulus silently over a period of years or decades. During this time, the basement membrane is slowly thickened and the mesangium expands due to non-enzymatic glycosylation of proteins from the blood, and eventually, the glomerulus is constricted with glycation products. Lupus also invades the glomerulus, but it does so quickly and aggressively. Immune complexes are rapidly deposited on the walls of the capillary loops and in the mesangial core creating lesions that are consistent with lupus nephritis. Vasculitis attacks the glomerulus with an aggressive inflammatory process, destroying the architectural structure of the glomerulus before it is even realized that damage is occurring.

B. Diabetic Nephropathy: A Slow Conversation with Sugar

Diabetes has been identified as one of the most persistent systemic disorders in terms of its potential for causing renal dysfunction. Diabetes is not typically an acute disease process. Instead, diabetes is a silent process that has been present in the body for years, sometimes even decades. Diabetes causes gradual alterations in molecular communication between components of the glomerular unit. Through the process of non-enzymatic glycosylation of proteins in the blood, diabetes alters the selectivity of the basement membrane. As a result of this alteration, the basement membrane becomes thick and unselective, losing its ability to filter molecules based on their size. At the same time, the podocytes lose contact with the glomerular basement membrane, and as they do, spaces form where albumin can escape into the urine.

The early microscopic signs of diabetic nephropathy include mesangial expansion. Mesangial expansion is the initial structural change to occur in response to diabetes. It is generally very difficult to identify using light microscopy because of its subtlety. As the disease progresses, nodular sclerosis develops and forms Kimmelstiel-Wilson nodules that represent areas of chronic hyperglycemic injury. The afferent and efferent arterioles frequently develop hyaline arteriolosclerosis, and both of these changes further reduce the vascular supply to the glomeruli and increase the pressure on them.

Proteinuria is the clinical sign of diabetic nephropathy that occurs earliest. Initially, proteinuria may be detectable in small amounts, but as the disease advances, the amount of protein lost in the urine increases significantly. The loss of protein into the urine results in decreased filtration capabilities of the kidney. However, the kidneys have a remarkable capacity to continue filtering at a reduced rate, even after injury to the glomeruli has occurred. Eventually, sclerosis will destroy the architecture of the glomerulus, and at this point, serum creatinine levels will begin to rise and uremia will become apparent. Because the onset of uremia is delayed until late in the course of the disease, many patients with diabetic nephropathy suffer from significant renal failure

before symptoms of uremia are evident, and therefore, the majority of patients with diabetic nephropathy are diagnosed late in the course of the disease.Diabetic nephropathy is not just a story about sugar. You know, about the dialogue between glucose and endothelial signaling--between oxidative stress and mesangial survival15. AGEs interact with receptors that promote inflammation and fibrosis[16]. Vascular permeability is modulated by transforming growth factor beta and vascular endothelial growth factor 17. The sensitive podocyte is overpowered, when a sentinel of integrity goes off duty, floats away and vanishes into the (urinary) space 18.

Glomerular basement membrane thickening, mesangial expansion, nodular sclerosis and arteriosclerosis are typical signs of the disease in pathology practice. Under the electron microscope, there is a smooth thickened basement membrane and blunting of foot processes[19]. Immunofluorescence only demonstrates linear staining of albumin, and immune complex deposition is absent. This differentiation is important when distinguishing from other sclerosing lesions[20].

C. Lupus Nephritis: An Immune Storm

Whereas diabetic nephropathy is a slow whisper, lupus nephritis is a tempest. The glomerular microcosm becomes a battlefield for autoimmunity when systemic lupus erythematosus takes it in hand. Circulating immune complexes seem to find the glomerulus a fine place to rest -- it has slow blood flow, and quite complex filtration barriers * [21]. Once deposited, these complexes initiate a complement cascades with inflammatory cell recruitment, and turn the delicate tuft into a battle ground[22].

Lupus nephritis wears many faces. It may present as a benign mesangial hypercellularitywith limited clinical importance to an overwhelming mass of kidney tissue with diffuse proliferative destruction. This is faced by classes I through VI in ISNISN/RPS classification. Mesangial proliferative disease is frequently silently subclinical whereas diffuse or focal proliferative disease may result in renal failure over months[23].

On microscopy the capillary loops thicken, the mesangial matrix increases and crescents may appear[24]. Wire loop lesions, formed by large subendothelial immune deposits, are direct evidence of active lupus nephritis[25]. Immunofluorescence shows the so-called Full house pattern –IgG, IgA, IgM, C3 and C1q lighting up the glomerulus like a constellation[26]. To note: one study also provides electron microscopic evidence of the subendothelial, mesangial and foot-process deposits[27].

Clinically, lupus nephritis presents with proteinuria, haematuria, hypertension and various degrees of renal dysfunction[28]. It is an expression of a systemic autoimmune disease, the kidney being only its most articulate spokesman. But lupus nephritis is also

a master of disguise. Some lesions have the appearance of membranous nephropathy, others proliferative glomerulonephritis. The pathogenesis, however, remains immune complex mediated[29].

Treatment frequently focuses on immune modulation: corticosteroids⁄ immunosuppressants ⁄ biologics working to suppress the immune tempest[30]. However, despite current treatment modalities, LN continues to be a major cause of morbidity in SLE[31].

D. Vasculitic Overlap: When Inflammation Becomes Siege

There are states in which inflammation does not leak or slink but rather assaults. This is well demonstrated in ANC Associated vasculitis, polyarteritis nodosa and associated syndromes. Here the glomerulus does not witness immune complex deposition but rather a direct onslaught of inflammation[32]. Neutrophils, guided by autoantibodies against cytoplasmic antigens, attack small vessels, causing fibrinoid necrosis[33].

The lesions are often pauci-immune which means immunofluorescence reveals little or no immune deposits. Yet histologically they are devastating[34]. Capillary walls rupture, crescents form in Bowman's space, and the glomerular tuft collapses. This form of injury progresses rapidly, often leading to acute kidney injury within weeks[35].

Vasculitic injuries do not follow a predictable timeline, nor do they involve the complex orchestration of lupus nephritis. Rather, they occur quickly and severely. Vasculitis presents clinically as rapidly progressive glomerulonephritis (RPGN) with hematuria, proteinuria, and rising serum creatinine levels. Often, the systemic manifestations of vasculitis ,such as pulmonary hemorrhage, sinusitis, or neuropathy; provide additional clues regarding the presence of a systemic inflammatory process, indicating that the renal manifestations are likely part of a broader systemic process.

Microscopically, pathologists recognize vasculitis through fibrinoid necrosis, crescent formation and minimal immune deposition. Immunohistochemistry and serology may also help identify specific ANCA patterns, thereby establishing a link between histological findings and serological fingerprints.

E. The Intersections and the Shadows

Although the mechanisms underlying diabetes-induced nephropathy, lupus nephritis, and vasculitis are distinct, the histological signatures of these diseases may share some commonalities. Diabetic nephropathy can induce nodular sclerosis that closely resembles the membranoproliferative patterns observed in other diseases. Similarly,

lupus nephritis can exhibit membranous changes that resemble those seen in other forms of kidney disease. Furthermore, vasculitis can present as necrotizing lesions that coexist with the most active lupus nephritis

The glomerulus itself provides no clear information regarding the cause of a particular disease pattern; however, the pattern observed in the glomerulus should be correlated with the systemic manifestations of the disease identified by both clinicians and pathologists working together. The relationship between the glomerulus and systemic manifestations is a source of tension that underscores the scientific and human aspects of renal pathology.

F. Histology as Testimony

Ultimately, regardless of whether the primary insult was caused by diabetes, lupus or vasculitis, the resultant inflammatory response leads to glomerulosclerosis and interstitial fibrosis. The long-term effects of any of the aforementioned insults lead to detachment of podocytes, alterations to the basement membrane and scarring of nephron's as well as the above mentioned late-stage findings. This is why many types of kidney disease produce similar findings at biopsy. Therefore, it is the journey taken to develop the late-stage findings and not the findings themselves that change..

G. Conceptual Understanding and Clinical Harmony

A pathologist viewing a renal biopsy sample is essentially walking into a courtroom where the glomerulus serves as the silent witness. The hallmark of diabetic nephropathy is thickening and nodularity of the basement membranes and mesangium. The hallmark of lupus nephritis is immune deposits and proliferative lesions indicative of an autoimmune process. The hallmark of vasculitis is necrosis and crescent formation indicative of an inflammatory process invading the glomerulus.

However, it is essential that the pathologist remain humble and recognize that the biopsy sample represents a single snapshot of the disease process. Timing of the biopsy, previous treatments and presence of comorbidities may affect how the patient presents clinically in terms of disease

Examples include a patient with lupus that has overlapping diabetic changes and a diabetic who develops ANCA vasculitis. When the disease is textbook, it follows one pattern, but when dealing with real world pathology, it does not always follow textbook patterns..

H. Beyond the Microscope

Ultimately, renal pathology is much more than just looking at slides and performing stains. Renal pathology is the study of how systemic diseases use the kidney as a canvas. Every glomerulus, if looked at closely enough, tells a story of injury, adaptation, and eventual scarring. The kidney does not create these stories, it merely documents them. Layer upon layer, like the rings in a tree trunk, the kidney documents the disease process.

Diabetes tells its story quietly over time, until the damage becomes apparent. Lupus tells its story loudly early in the course of the disease, but may be treatable.. Vasculitis strikes swiftly and demands an urgent ear. Together, they remind us that systemic disease rarely respects organ boundaries. The glomerulus, ever silent, becomes the stage where their shadows fall.

Epilogue

I am always amazed in medicine at how we are taught to label diseases by their cause. What pathology teaches us is to read tissues as stories. The glomerulus is a victim and witness in the kidney. Diabetic nephropathy, lupus nephritis and vasculitic overlap are not only diseases, they are models; chronic, immune or inflammatory. The physician can begin listening to what the kidney has been telling them by understanding the rhythms of these diseases (chronic), their association with other events (immune) and their tempo (inflammatory)

References

[1] Couser WG. Glomerulonephritis. Lancet. 1999;353(9163):1509–1515.

[2] Tervaert TW, Mooyaart AL, Amann K, Cohen AH, Cook HT, Drachenberg CB, et al. Pathologic classification of diabetic nephropathy. J Am Soc Nephrol. 2010;21(4):556–563.

[3] Haraldsson B, Nystrom J, Deen WM. Properties of the glomerular barrier and mechanisms of proteinuria. Physiol Rev. 2008;88(2):451–487.

[4] Forbes JM, Cooper ME. Mechanisms of diabetic complications. Physiol Rev. 2013;93(1):137–188.

[5] Hahn BH. Lupus nephritis. Curr Opin Rheumatol. 2012;24(5):561–568.

[6] Jennette JC, Falk RJ, Bacon PA, Basu N, Cid MC, Ferrario F, et al. 2012 revised International Chapel Hill Consensus Conference nomenclature of vasculitides. Arthritis Rheum. 2013;65(1):1–11.

[7] Alicic RZ, Rooney MT, Tuttle KR. Diabetic kidney disease. Clin J Am Soc Nephrol. 2017;12(12):2032–2045.

[8] Fioretto P, Mauer M. Histopathology of diabetic nephropathy. Semin Nephrol. 2007;27(2):195–207.

[9] Pagtalunan ME, Miller PL, Jumping-Eagle S, Nelson RG, Myers BD, Rennke HG, et al. Podocyte loss and progressive glomerular injury in type II diabetes. J Clin Invest. 1997;99(2):342–348.
[10] Steffes MW, Osterby R, Chavers B, Mauer SM. Mesangial expansion as a central mechanism for loss of kidney function in diabetic patients. Diabetes. 1989;38(9):1077–1081.
[11] Kimmelstiel P, Wilson C. Intercapillary lesions in the glomeruli of the kidney. Am J Pathol. 1936;12(1):83–97.
[12] Scholey JW, Meyer TW. Control of glomerular hypertension and the progression of renal disease. J Am Soc Nephrol. 1997;8(9):1498–1504.
[13] Mogensen CE. Microalbuminuria predicts clinical proteinuria and early mortality in maturity-onset diabetes. N Engl J Med. 1984;310(6):356–360.
[14] Perkins BA, Ficociello LH, Silva KH, Finkelstein DM, Warram JH, Krolewski AS. Regression of microalbuminuria in type 1 diabetes. N Engl J Med. 2003;348(23):2285–2293.
[15] Brownlee M. Biochemistry and molecular cell biology of diabetic complications. Nature. 2001;414(6865):813–820.
[16] Schmidt AM, Hori O, Brett J, Yan SD, Wautier JL, Stern D. Cellular receptors for advanced glycation end products. Arterioscler Thromb. 1994;14(10):1521–1528.
[17] Kanwar YS, Sun L, Xie P, Liu FY, Chen S. A glimpse of various pathogenetic mechanisms of diabetic nephropathy. Annu Rev Pathol. 2011;6:395–423.
[18] Wiggins JE. Podocytes and glomerular function with aging and diabetes. Semin Nephrol. 2012;32(4):324–333.
[19] Mauer SM, Steffes MW, Ellis EN, Sutherland DE, Brown DM, Goetz FC. Structural-functional relationships in diabetic nephropathy. J Clin Invest. 1984;74(4):1143–1155.
[20] Fioretto P, Steffes MW, Mauer M. Glomerular structure in nonproteinuric IDDM patients with various levels of albuminuria. Diabetes. 1994;43(11):1358–1364.
[21] Appel GB, Radhakrishnan J, D'Agati V. Secondary glomerular disease. Am J Kidney Dis. 1998;31(6):945–958.
[22] Weening JJ, D'Agati VD, Schwartz MM, Seshan SV, Alpers CE, Appel GB, et al. The classification of glomerulonephritis in systemic lupus erythematosus revisited. J Am Soc Nephrol. 2004;15(2):241–250.
[23] Bajema IM, Wilhelmus S, Alpers CE, Bruijn JA, Colvin RB, Cook HT, et al. Revision of the ISN/RPS classification for lupus nephritis. Kidney Int. 2018;93(4):789–796.
[24] D'Agati VD, Appel GB. Lupus nephritis: pathology and pathogenesis. Semin Nephrol. 1999;19(2):173–180.
[25] Cameron JS. Lupus nephritis. J Am Soc Nephrol. 1999;10(2):413–424.
[26] Madaio MP. Lupus nephritis: immunopathology. Semin Nephrol. 2007;27(1):21–29.
[27] Magil AB. Ultrastructural features of lupus nephritis. Am J Kidney Dis. 1988;12(2):166–177.
[28] Hahn BH, McMahon MA, Wilkinson A, Wallace WD, Daikh DI, Fitzgerald JD, et al. American College of Rheumatology guidelines for screening, treatment, and management of lupus nephritis. Arthritis Care Res (Hoboken). 2012;64(6):797–808.
[29] Schwartz MM, Lan SP, Bernstein J, Hill GS, Holley KE, Lewis EJ. Morphologic patterns of glomerular injury in lupus nephritis. Kidney Int. 1989;35(4):716–725.

[30] Rovin BH, Adler SG, Barratt J, Bridoux F, Burdge KA, Chan TM, et al. KDIGO 2021 clinical practice guideline for the management of glomerular diseases. Kidney Int. 2021;100(4S):S1–S276.
[31] Almaani S, Meara A, Rovin BH. Update on lupus nephritis. Clin J Am Soc Nephrol. 2017;12(5):825–835.
[32] Falk RJ, Jennette JC. ANCA small-vessel vasculitis. J Am Soc Nephrol. 1997;8(2):314–322.
[33] Little MA, Nightingale P, Verburgh CA, Hauser T, De Groot K, Savage C, et al. Early mortality in systemic vasculitis. Ann Rheum Dis. 2010;69(6):1036–1043.
[34] Hilhorst M, Wilde B, van Paassen P, Winkens B, van Breda Vriesman PJ, Cohen Tervaert JW. Proteinase 3–ANCA vasculitis versus myeloperoxidase–ANCA vasculitis. J Am Soc Nephrol. 2015;26(10):2314–2327.
[35] Jennette JC, Nachman PH. ANCA glomerulonephritis and vasculitis. Clin J Am Soc Nephrol. 2017;12(10):1680–1691.
[36] Hogan SL, Nachman PH, Wilkman AS, Jennette JC, Falk RJ. Prognostic markers in patients with antineutrophil cytoplasmic autoantibody–associated microscopic polyangiitis and glomerulonephritis. J Am Soc Nephrol. 1996;7(1):23–32.
[37] Watts RA, Scott DG. Epidemiology of the vasculitides. Semin Respir Crit Care Med. 2004;25(5):455–464.
[38] Kitching AR, Anders HJ, Basu N, Brouwer E, Gordon J, Jayne DR, et al. ANCA-associated vasculitis. Nat Rev Dis Primers. 2020;6(1):71.
[39] Jayne D, Rasmussen N, Andrassy K, Bacon P, Tervaert JW, Dadoniene J, et al. A randomized trial of maintenance therapy for vasculitis associated with antineutrophil cytoplasmic autoantibodies. N Engl J Med. 2003;349(1):36–44.
[40] Couser WG. Pathogenesis of glomerular damage in glomerulonephritis. Nephrol Dial Transplant. 1998;13(Suppl 1):10–15.

Deep Science Publishing, 2025
https://doi.org/10.70593/978-93-7185-400-9

DeepScience
Open Access Books

Chapter 11: Dermatopathology, The Imitative Interface: Drug Eruptions, Autoimmune Blistering, and Lymphoma Simulants

In comparison to many of the other subspecialties of pathology; dermatopathology is an area of study based on similarity; as skin is a highly visual and communicative organ; it has been a very large canvas for copy cat art. When viewed under a microscope, it is often difficult to distinguish the various diseases of the skin from one another. Each disease appears to take on the appearance of others, creating a mysterious identity that challenges the observer's ability to view their surroundings (perceptual vision) and their ability to feel and understand the subject matter (interpretive empathy). In order to be proficient in dermatopathology one must learn to "see" beyond the mask. The written language beneath the skin is expressed through inflammation, necrosis, acantholysis and cellular choreography. As such, the pathologist must not only possess discipline, but also imagination in order to decipher the written language.

The pathologist examining the specimen under a microscope is a silent author between the biological sciences and storytelling.. What looks like a spongiotic vesicle may whisper allergy to the observer, but equally the possibility of drug hypersensitivity. One possible explanation for what appears to be lymphocyte infiltration into the skin is that it could be nothing more than a reactive, imitative phenomenon, rather than an actual lymphoma. The boundary where pathology and art meet, and the true diagnosis is revealed through thoughtful observation of the tissue.

This chapter will examine the skin's three "great imitators": drug eruptions; autoimmune blistering diseases; and lymphoma lookalikes. These are examples of the full spectrum of dermatopathological mimicry from short-lived, clinically relevant, and pharmacologically-mediated disorders to autoimmune betrayals of the skin, through reactive infiltrates, to neoplastic pretenders..

A. The Skin as an Organ of Expression

Skin is a communicative organ. It communicates the existence of an internal imbalance, of an immune system imbalance, and of an environmental chemical trespass. The thin layer of the epidermis is constantly being rebuilt. Beneath the epidermis is the dermis which contains blood vessels, nerves, and immune sentinels. The entire unit is cushioned beneath the subcutaneous fat layer. While in healthy states, these layers work in concert, in diseased states, they become the backdrop for intense, uncontrolled conversations.

All dermatologic disease involves some degree of breakdown in communication between cells. Drugs, antibodies, and neoplastic lymphocytes can be present in the skin as part of this communication process. The skin will respond based upon pattern of injury, spongiotic, lichenoid, vesiculobullous, granulomatous, or pseudo lymphomatous. It is up to the dermatopathologist to both recognize these patterns and differentiate them from coincidence..

B. Drug Eruptions — The Skin's Pharmacologic Protest

No organ has a greater democratization of its responses to drugs than the skin. Multiple drugs can produce an eruption ranging from antibiotics to anticonvulsants to NSAIDS to chemotherapy. These eruptions create an impressive level of mimicry – they mimic infectious processes, autoimmune diseases, and neoplastic diseases.

Drug reactions occur when the immune system identifies therapeutic agents or their metabolites as foreign substances and mounts a surveillance response to remove those perceived foreign substances. When a T cell is activated, it generates an inflammatory reaction that becomes visible on the skin.

Drug reactions have different microscopic morphologies. The most frequent form is the morbilliform reaction (measles rash), and this reaction has a microscopically evident perivascular lymphocytic infiltration that sometimes includes eosinophils. Damage to the interface is very limited and there is no obvious loss of the epidermis. On the other hand, lichenoid drug reactions generate a dense collection of lymphocytes overlying the dermo-epidermal junction similar to what is observed in lichen planus. When one is aware that the reaction is caused by a drug, additional indicators that support this are the presence of eosinophils, parakeratosis, and focal basal cell necrosis.

Certain drugs, such as anticonvulsants, sulfonamides, and allopurinol may induce severe cutaneous adverse reactions that result in either Stevens-Johnson syndrome or toxic epidermal necrolysis. These reactions cause the full-thickness of the epidermis to become necrotic and separate completely from the dermis resulting in extensive regions of exposed skin. Microscopic changes associated with these reactions are also extreme:

the necrotic keratinocytes fall out of the epidermis like dead leaves and subepidermal clefts develop as the epidermal layer deteriorates.

Other types of drug eruptions exist. Fixed drug eruptions display remarkable spatial consistency in their formation of lesions. At each subsequent exposure to the drug causing the eruption, the lesion develops at the exact site where the previous lesion was located. Each lesion under the microscope displays basal cell degeneration, pigment incontinence, and an interface infiltrate of necrotic keratinocytes. Melanophages remain for extended periods of time after the clinical activity of the lesion has resolved, creating a long-lasting memory of the lesions' activity.

Additionally, drug-induced pseudolymphomas can appear clinically identical to cutaneous T-cell lymphoma. The infiltrate formed by the drug can resemble that found in cutaneous T-cell lymphoma and can be thick, atypical, and band-like; however, the infiltrate will resolve if the offending drug is stopped.

A strong clinicopathologic correlation is required to diagnose drug reactions. The dermatopathologist needs to combine the findings obtained through microscopy with information regarding the timing of drug administration and the patient's clinical history.. Often, the distinction between a benign reaction and a potentially life-threatening reaction depends on this integration of historical context.

Drug reactions serve as a reminder that pathology is dynamic and contextual. A biopsy, no matter how perfectly performed, cannot tell the entire story without the language of time and history.

C. Autoimmune Blistering Diseases — When Self Becomes Stranger

When the Immune System Betrays Itself

While drug eruptions represent an external provocation of the skin, autoimmune blistering diseases represent an internal betrayal of the skin. In these conditions, the immune system loses tolerance to the skin structures that maintain the integrity of the skin.. Antibodies, instead of defending the host, target adhesion molecules in the epidermis or at the basement membrane. The result is blistering, a literal separation of the skin’s layers, a visible manifestation of immunologic misunderstanding[8].

The spectrum is broad , pemphigus vulgaris, pemphigus foliaceus, bullous pemphigoid, cicatricial pemphigoid, and dermatitis herpetiformis each with distinct molecular targets but overlapping appearances.

In pemphigus vulgaris, antibodies are directed against desmoglein 3, a cadherin component of desmosomes. These desmosomes act as molecular rivets binding

keratinocytes together. When the rivets are attacked, cells detach, leading to acantholysis. Under the microscope, this manifests as a suprabasal cleft with floating, rounded keratinocytes , the so-called “row of tombstones” appearance. The blister roof consists of the stratum corneum and upper epidermis, fragile and easily ruptured[9].

Pemphigus foliaceus targets desmoglein 1, resulting in more superficial acantholysis. The blister forms in the granular layer, leading to crusted erosions rather than intact bullae. These patients often present with widespread exfoliation rather than deep blisters.

At the other end of the spectrum lies bullous pemphigoid, in which autoantibodies target hemidesmosomal antigens, particularly BP180 and BP230, that anchor the basal layer to the dermis. The separation here is subepidermal, and the roof remains intact, giving rise to tense bullae. Microscopically, one sees an eosinophil-rich infiltrate beneath the epidermis, with the basement membrane lifted like a curtain. Direct immunofluorescence demonstrates linear deposition of IgG and C3 along the basement membrane zone, glowing like a horizon of autoimmunity[10].

Cicatricial pemphigoid has the same split promoting mechanism and commonly involves mucosal surfaces with resultant scarring. The immune target could be, for instance laminin 332 or one of the other anchoring complex constituents. On the other hand, dermatitis herpetiformis is cutaneous manifestation of gluten sensitive enteropathy mediated by IgA antibodies against epidermal transglutaminase. Its papillary dermal tips bristle with neutrophilic microabscesses and granular IgA deposition on IF makes the Dx[11].

However, in all their diversity they share one guiding principle: antibody-mediated loss of contact. They each represent a different stop along the epidermal–dermal interface, and they each teach how form underpins susceptibility.

Autoimmune blistering diseases can mimic infections, drug eruptions or neoplasms from a clinical standpoint. Net like acantholysis or basal vacuolation with only subtle change may be seen in early biopsies that are easily misdiagnosed. This is why often 2 biopsies, 1 for routine histology and the other for direct immunofluorescence, are necessary..

These are situations which show how shaky our self-image can be. They learn that the line between protection and self-destruction is as thin as the basement membrane itself.

D. Lymphoma Simulants — When Inflammation Pretends to be Malignancy

Lymphoid infiltrates: the lymphoma mimickers Of all cutaneous mimics, some of the most difficult to diagnose are the lymphoid infiltrates that mimic lymphoma. As a sentinel organ, the skin contains a large population of immune cells to sense and respond to antigens. When triggered, these cells have the ability of gathering in arrangements

nearly resembling neoplastic proliferation. This is where telling pseudolymphoma apart from a true lymphoma can be quite an artistic challenge; and not merely at the histologic level but also in terms of immunophenotypic and molecular characterization[12].

Drug, infective, tattooed, arthropodbitten and idiopathic immune dysregulation cutaneous pseudolymphomas have been reported. Histology shows dense nodular infiltrates of small lymphocytes, plasma cells and histiocytes. The architecture can involve germinal centers, supporting a reactive process. But atypical cells and epidermotropism can muddy that.

Mycosis fungoides, is the most frequent cutaneous T-cell lymphoma. Risks and Benefits Mycosis fungoides may be deceptive even in early stages, showing minimal epidermotropism and only not strikingly atypical features. Immunohistochemistry assists, but even then there is overlap. On molecular studies, pesudolymphomas often continue to express its polyclonality, whereas true lymphomas exhibit the monoclonality of T-cell receptor rearrangement. There are exceptions, however — another of those reminders that biology rarely takes place entirely as described in textbooks.

B-cell pseudolymphomas, especially those occurring after insect bites or infection with Borrelia, can mimic primary cutaneous marginal zone lymphoma. Here, architectural pattern and distribution of follicles as well as the presence of reactive germinal centers and expression of polyclonal immunoglobulins drive diagnosis.

Available alongside our results is also a report on drug-induced reactive lymphoid reactions as a separate entitiy, which can abate following withdrawal of :Results of the above-mentioned performance analysis are available at4064 Table 5: Benchmark comparison of two synthetic datasets. Antidepressants, anticonvulsants and antihypertensive drugs are known culprits. Microscopically, dense atypical lymphocytic infiltrates with eosinophils and plasma cells may be seen. These may be disturbing to the unsuspecting eyes but, the clinical time line is the answer to all truth[13].

Sometimes the question of inflammatory vs. neoplastic is a philosophic one. The immune system in the skin, which constantly monitors, can appear temporarily malignant during exuberant responses. Whereas indeed real lymphoma is immune autonomy (the breaking of the order) and monocle identity.

Diagnostic techniques such as polymerase chain reaction–based clonality assays and flow cytometry plus next-generation sequencing add further definition to our knowledge. But with all those tools, the last analysis is based on pattern recognition in correlation with clinical and experience. The microscope today is still the philosopher’s lens — one of certainty approached though not, alas, reached.

E. The Unifying Thread — Mimicry and Meaning

Skin pathology is fundamentally based upon mimicking. Drugs and/or a deficiency in autoimmunity or infection and neoplasm can produce the exact same picture as interface dermatitis. Therefore, while eosinophils may indicate allergy, they are also found with lymphoma or pemphigoid. Keratinocytes may be necrotic and suggest either viral damage or drug sensitivity. For that reason, no single histological finding will be diagnostic (by itself) for a given condition.

The ambiguous nature of skin does not reveal weakness - it reveals wisdom. While the histological (microscopic) aspects of skin have been subjected to very little selective pressure throughout its evolutionary history to provide for an extensive vocabulary to define the many insults to which it is exposed, there are fewer but also more flexible terms available to describe these insults. The definitions of the words used in this vocabulary depend on context - and they can be as poetic as poetry.

That is the paradox referred to as the "imitative interface," where more obviously identifiable diseases often appear similar, while less similar diseases can appear to be almost identical to one another. To truly understand dermatopathology is to move from merely describing patterns to interpreting those patterns, and to interpret the emotional quotation of inflammation and follow the path of the immune system's intent.

Teach your students that the slide is NOT the disease - it is a shadow of a dialogue between the immune response and the affected tissues. Each spongiotic vesicle, each necrotic keratinocyte, and each atypical lymphocyte represents a word in that dialogue.

E. The Human Aspect

Behind each lesion is a person; a biopsy that shows a drug eruption may be from a patient with cancer phobia, an autoimmune blistering disease can be a torturous disease for a young woman that uses her skin as a battleground by her immune system and the lymphoid infiltrate can be a representation of a person with the ever-present possibility of developing lymphoma.

A pathologists work is to be precise; however, precision must include compassion. It is not merely a description that completes a report, it has consequences. The difference between describing a lesion as "suggestive of drug reaction" and "suggestive of lymphoma" can greatly affect a person's life. Dermatopathology is therefore not just observational, it is ethical interpretation.

Precision of communication relates to precision of thought. Delivering a clear and readable report is being respectful of the patient's story. The purpose is not to appear intelligent, it is to show why it is exciting to be.

G. Reflections on Patterns, Patience, and Perception

Dermatopathology rewards patience. There is much complexity in the patterns of dermatopathology and it takes time to train the eye. The observer must learn to alternate back and forth, as when viewing a stereoscopic photograph in which the image caught by the right eye is different from the image caught by the left eye: in such a view it necessitates both eyes or fusion of the brain becomes impossible.

Drug reactions you learn the poem of the complaint of how the skin reacts to foreign chemicals. Autoimmune blistering you learn the tragedy of misrecognition. Among the lymphoma mimics, you see the theater of confusion. 0These three forms of mimicry together constitute a trinity and each teaches humility. These are reminders that certainty in pathology is a process of bargaining rather than an act of pronouncement.

To know dermatopathology is to experience the essence of life. The skin is the most outward representation of our inner spirit; it responds, reacts and is resilient. Simultaneously the skin provides protection while also communicating with the world around it. Through the microscope we find out through images what life has previously shown us: that the truth often exists in many different forms and that beauty is rarely simple.

Dermatopathology therefore finds itself at the crossroads of art and science. The field requires the same level of discipline as science, yet the creative imagination of the artist. The image, in this case, is nothing less than a representation of life itself. Drug eruptions, autoimmune blistering, and lymphoma mimics do not represent diseases or illnesses, but rather serve as a test of discrimination. At the interface of mimicry, one does not receive instructions, but instead receives opportunities... these opportunities challenge the viewer to look closer, to listen more intently and to ask not simply "what I am seeing", but "why".

Thus the epidermis - mimic of all things else - represents the manuscript of a philosopher. It teaches us that biology is rarely ever absolute; that immunity can serve as either a protector and an adversary; that form is language; and that the road to healing begins with entry: Let there be true recognition.

Still in every single tissue-section, there is a morally contested issue: to recognize is to care, and (I assume) vice versa. Thus dermatopathology is therefore not limited to glass slides; it seeks to reach into the very core of medicine..

References

[1] Elder DE. Lever's Histopathology of the Skin. 11th ed. Philadelphia: Wolters Kluwer; 2014.

[2] Weedon D. *Weedon's Skin Pathology*. 4th ed. London: Churchill Livingstone; 2016.

[3] Calonje E, Brenn T, Lazar A, Billings SD. *McKee's Pathology of the Skin*. 5th ed. Elsevier; 2020.

[4] Pichler WJ. Drug-induced exanthema. *Allergy*. 2003;58(9):854–863.

[5] Shiohara T, Kano Y. Drug-induced hypersensitivity syndrome (DIHS): a reaction induced by a complex interplay among herpesviruses and antiviral and antidrug immune responses. *Allergol Int*. 2006;55(1):1–8.

[6] Mockenhaupt M, Schöpf E. Epidemiology of Stevens–Johnson syndrome and toxic epidermal necrolysis. *Semin Cutan Med Surg*. 1996;15(4):235–243.

[7] Cerroni L, Zenahlik P, Hofler G, Kaddu S, Smolle J, Kerl H. Pseudolymphomas of the skin: a clinicopathologic study of 82 cases. *Am J Surg Pathol*. 1997;21(10):1175–1186.

[8] Stanley JR. Autoantibodies against adhesion molecules in autoimmune blistering diseases. *J Invest Dermatol*. 1989;92(4 Suppl):59S–65S.

[9] Hertl M, Eming R, Veldman C. Pemphigus vulgaris and foliaceus. *Autoimmunity*. 2006;39(7):611–617.

[10] Schmidt E, Zillikens D. The diagnosis and treatment of autoimmune blistering skin diseases. *Dtsch Arztebl Int*. 2011;108(23):399–405.

[11] Zone JJ. Dermatitis herpetiformis. *N Engl J Med*. 2005;352(3):231–238.

[12] Cerroni L. Cutaneous pseudolymphoma and cutaneous lymphoma: Facts and controversies. *Clin Dermatol*. 2010;28(5):568–574.

[13] Willemze R, Jaffe ES, Burg G, Cerroni L, Berti E, Swerdlow SH, et al. WHO–EORTC classification for cutaneous lymphomas. *Blood*. 2005;105(10):3768–3785.

Deep Science Publishing, 2025
https://doi.org/10.70593/978-93-7185-400-9

DeepScience
Open Access Books

Chapter 12: Neuropathology: The Subtle Boundaries of Degeneration and Neoplasia

The illness is often silent or unclear in the dark corridors of the brain. Illness does not clearly announce itself by how it will look, feel, smell or taste in the tissue responsible for thought and memory. This tissue communicates through shadow, shade, tone and cells which don't just change their shape they also become different beings. Speaking the language of neuropathology means to decipher the "whispers" rather than hearing the "shouts". Neuropathology is a delicate dance along the fine line between degeneration and neoplasia (cancer); injury and regeneration; and what may be temporary versus what will be fatal

Central to this field are entities which have an incredible similarity to one another: reactive gliosis; demyelination; and low grade gliomas.. All present the identical spectrum of astrocytic proliferation, nuclear atypia and architectural distortion. Yet their meanings differ profoundly: one speaks of healing, another of decay, and the last of unbridled autonomy. The task of the pathologist is to distinguish care from corruption, to discern when the brain is trying to heal and when it has lost control[2].

A. The Brain as a Landscape of Repair

Unlike other organs, the brain does not regenerate easily. Neurons, once lost, are seldom replaced. Yet the nervous system possesses its own custodians , astrocytes and microglia , which rise in quiet rebellion when injury strikes. This orchestrated reaction, known as reactive gliosis, is both shield and signal. It encapsulates the wound, secretes protective molecules, and restores homeostasis.

In reactive gliosis, astrocytes undergo hypertrophy. Their processes become thick and entangled, their cytoplasm glows with glial fibrillary acidic protein. Under the microscope, the field becomes a delicate forest of branching filaments. Some nuclei enlarge and take on irregular shapes, at times mimicking neoplastic atypia.

This illusion is further exaggerated by the presence of gliosis surrounding regions of necrosis/demyelination. The distinction between reactive versus neoplastic glial elements is blurred. A collective clustering of nuclei, variability in cell size, and hyperchromaticity may create the impression that there exists neoplasm. However, the changes seen in gliosis occur in unison and not randomly.. The architecture of the parenchyma is preserved; the cellular choreography remains disciplined.

In contrast, a low grade astrocytoma introduces subtle disorder. The nuclei may seem gentle, even innocent, but their arrangement betrays intention. They infiltrate beyond boundaries, disperse through white matter tracts, and replace normal neuropil with a quiet insistence.

Thus, the first lesson of neuropathology is not morphology but context. The same cell, viewed in isolation, may belong to repair or rebellion. Only by listening to the surrounding landscape ,the pattern of myelination, the presence of neurons, the distribution of vessels , can one tell whether the brain is healing or transforming.

B. Reactive Gliosis — The Brain's Reparative Script

Reactive gliosis is the neural counterpart of fibrosis, though infinitely more graceful. It represents the final common pathway of diverse insults - trauma, ischemia, infection, demyelination, and even distant tumor infiltration.

The astrocyte, normally quiescent, becomes the protagonist. It proliferates, secretes extracellular matrix proteins, and reestablishes the blood–brain barrier. Its cytoplasmic arms intertwine, forming a glial scar. This scar is both a protector and a barrier, it prevents spread of injury but also impedes axonal regrowth.

Histologically, the spectrum ranges from mild hypertrophy to dense gliotic scarring. In early stages, nuclei enlarge but remain oval; in late stages, they elongate and overlap, forming fascicles that may resemble astrocytoma. Immunohistochemistry becomes crucial. In gliosis, the astrocytes express strong GFAP positivity but retain orderly boundaries.

Their proliferation index, determined using Ki-67, is low, usually less than one percent.

However, their proliferation index is difficult to determine in long-standing lesions because, when they occur, the glial scar thickens and vascular proliferation takes place. Furthermore, reactive endothelial changes, perivascular lymphocytes, and occasional mitoses may also complicate distinguishing between regeneration and neoplasia. Ultimately, the observer will need to rely upon the distribution and intention of gliosis (which respects structure) and neoplasia (which invades it).

Clinically, gliosis may accompany older infarcts, multiple sclerosis plaques, or viral encephalitis. Gliosis may mimic tumors on imaging studies, demonstrating as hyperintense foci on MRI. Therefore, only through examining tissue does one discover whether it has been damaged or invaded by neoplasm. In this respect, reactive gliosis is a form of the brain's resilience, providing a "quiet handwriting" on the "parchment of injury."

C. Demyelination -- The Elegy of White Matter

Reactive gliosis provides the glial response to damage; demyelination provides evidence of lost insulation. Myelin is the lipid sheath encasing axons and provides a means for efficient transmission. When myelin is destroyed, transmission is disrupted as well as the identity of the axon. Once insulated by myelin, the axon becomes susceptible to degeneration.

Demyelination may result from immune mediated mechanisms, such as those occurring in multiple sclerosis; or may result from toxic, infectious, or metabolic processes. Regardless of the mechanism, the microscopic findings associated with demyelination share common characteristics including pale staining of the white matter, macrophage infiltration, and preservation of the axons. Macrophages filled with myelin debris cluster the parenchyma like custodians clearing a battle field.

Perivascular lymphocytes accumulate in early demyelinating lesions around the veins creating cuffs. Astrocytes located adjacent to the demyelinating zone become reactive, and microglia proliferate. As time passes, the myelin debris is cleared, and a gliotic scar remains.

Both demyelination and low-grade glioma may exhibit some similar features. For example, the demyelinating lesion may appear expansive with increased cellular density and irregular borders. Both conditions may demonstrate T2 hyperintensity without apparent mass effect on MRI. At the histological level, reactive astrocytes within demyelinating zones may appear atypical and foamy macrophages may be misidentified as tumor cells.

Use of special stains and immunostains assist in distinguishing between demyelination and neoplasia. Loss of myelin is evident with Luxol Fast Blue staining, and preservation of axons is demonstrated with neurofilament staining. The combination of these two staining methods confirm demyelination versus destruction of tissue. In contrast, neoplasia disrupts both the myelin sheath and the axons. A useful tool for distinguishing reactive vs neoplastic glial cells is the Ki-67 proliferative index. The index is typically lower than expected with respect to demyelination, while the index is variable in cases of neoplasia.

There is also an emotional component associated with the destructive capability of demyelination, due to the fact that demyelination is both destructive and has the possibility of being reversible. Gliomas represent a progressive form of disease, whereas demyelinating lesions have the capacity to recover and partial restoration of conduction can be achieved through remyelination. As such, demyelination illustrates the capacity of the brain to attempt to redeem itself

D. Low Grade Glioma -- The Quiet Invader

Low-grade gliomas reside within a space that is neither entirely normal nor entirely malignant. Low-grade gliomas expand at a slow rate, they invade the surrounding tissue diffusely and often coexist with functioning neurons. Therefore, the risk associated with low-grade gliomas does not stem from their ability to rapidly increase in size but rather from their tendency to persist.

There are several types of low-grade gliomas based on histology including: diffuse astrocytoma, oligodendroglioma, and mixed glioma. Although each of these exhibit some degree of cytologic atypia, all three display unequivocal invasion into the surrounding tissue. As such, the surrounding neuropil becomes increasingly diluted and neurons can be found in isolation in a sea of glial cells. Gliomas do not cause a thickening of tissue as occurs with gliosis; instead gliomas cause a thinning of tissue as the tumor replaces the tissue.

Astrocytes in diffuse astrocytoma have elongated, fibrillary processes and their nuclei are irregular but not grotesque. Oligodendrogliomas present with what is described as a "fried egg" appearance due to the fixation-related clearing of the cytoplasm of the cells. In addition, capillaries branch out throughout the lesion forming a fine vascular network.

Establishing a differential diagnosis between a low-grade glioma and either reactive gliosis, or demyelination requires an integration of data. No single feature used in isolation will provide a definitive diagnosis. However, a combination of the following factors (i.e., pattern of invasion, lack of clear boundaries, lack of maintenance of normal tissue architecture) will indicate the presence of neoplastic activity.

Immunohistochemical analyses can provide further information in the identification of gliomas. For example, while gliomas are GFAP positive, there is variability in the intensity of the staining. Molecular markers are also critical in providing a definitive diagnosis of glioma, especially in determining the oligodendroglial lineage and prognosis. Molecular markers are generally absent in reactive lesions.

In addition to the molecular markers used to identify gliomas, the Ki-67 proliferation index provides a quantitative measure of neoplastic activity. There is generally a very

low level of proliferative activity in reactive gliosis, a transient level of proliferative activity in demyelination, and a high and increasing level of proliferative activity in glioma. The presence of rare mitotic figures are also an important factor in establishing a diagnosis of glioma.

The clinical course of low-grade glioma closely follows its pathological characteristics in terms of slow but persistent invasion into the surrounding neural tissue and inability to completely remove the tumor surgically. Over time, years in fact, the tumor can undergo malignant transformation to anaplastic forms referred to as secondary glioblastoma.

As such, the pathologist acts as a temporal witness to assess both the morphological characteristics of a lesion and the ultimate fate of the lesion. It may appear to be benign today, but will likely be malignant tomorrow. Thus, every histopathological examination represents a picture in a sequence of events..

E. The Science of Differential Diagnosis

The delicate art of separating gliosis from demyelination and low-grade gliomas requires both a strong reliance on scientific principles as well as a great deal of intuitive thinking.

Even when using parameters for evaluation, there will always be some degree of ambiguity. The most experienced neuropathologists admit that even when they evaluate a lesion, it may exist in an area of overlap and they cannot provide an instant classification. In cases such as this, multi-disciplinary review, incorporating information from imaging studies and molecular data, becomes essential.

Feature	Reactive Gliosis	Demyelination	Low Grade Glioma
Etiology	Response to injury	Immune or toxic insult	Neoplastic proliferation
Architecture	Preserved	Disrupted but reparative	Infiltrative, distorted
Astrocytes	Hypertrophic, GFAP strong	Reactive, mixed with macrophages	Atypical, variable GFAP
Macrophages	Minimal	Prominent, lipid laden	Absent or sparse
Molecular markers	Negative	Negative	IDH1, 1p/19q, ATRX
Ki-67 index	<1%	<3%	3–10%
Clinical course	Stable	Relapsing or remitting	Progressive

F. The Human Perspective

Each brain biopsy is carried out with a patient who is temporarily at a crossroads in their life. There could be gliosis from a young patient having seizures, and yet the young patient fears there could be a tumor. Multiple sclerosis, a lifetime of relapse and adaptation may occur because of a single demyelinating plaque. A low-grade glioma may enable the patient to live nearly as they would if they were normal for years until it becomes deadly.

For the neuropathologist, this is not only a technical issue but also a moral one. The ability to differentiate repair from neoplasia will determine whether or not the patient has hope. The written word within the laboratory report radiates outward and determines how a patient will be treated, how he/she will feel and ultimately what their destiny will be.

Therefore, neuropathology must demonstrate both precision and compassion. The microscope can only tell you parts; it is the empathetic relationship with the patient that ties the parts together and relate them to the whole. The brain is not just an organ, it is the home of the individual; its illness requires language that acknowledges both the biological and the essence of the patient..

G. Philosophy of Boundaries

The boundaries between degeneration and neoplasm are not clear-cut, but are rather blurred. Cellular response in the microscope is unclear, representing the spectrum of the brain's adaptive strategies. Gliosis and glioma, demyelination and malignancy: These are not just diagnoses, but metaphors of perseverance.

- The activated glia illustrate the technique of surviving.
- The demyelinated axon illustrates the biology of being vulnerable and repairing.
- The low-grade glioma illustrates the risk of autonomous behavior that cannot be controlled by itself.
- Studying these processes is to observe the brain communicating back through time to heal, to create, to keep alive the fight against forgetting.

Ultimately, To see those patterns is to develop an art that transcends anatomy. It requires patience, humility and imagination to listen to what we do not wish to hear. In the pale landscape of white matter and the flexible fibers of glial tissue is the story of humanity's most complex organ -- always poised in a state of transition between order and disorder, always hesitating between memory and forgetting, between life and transformation..

References

[1] Ellison DW, Love S, Chimelli L. Neuropathology: A Reference Text of CNS Pathology. 4th ed. Elsevier; 2021.

[2] Love S, Perry A, Ironside J. Greenfield's Neuropathology. 10th ed. CRC Press; 2018.

[3] Sofroniew MV, Vinters HV. Astrocytes: biology and pathology. Acta Neuropathol. 2010;119(1):7–35.

[4] Pekny M, Nilsson M. Astrocyte activation and reactive gliosis. Glia. 2005;50(4):427–434.

[5] Zamanian JL et al. Genomic analysis of reactive astrogliosis. J Neurosci. 2012;32(18):6391–6410.

[6] Louis DN, Perry A, Reifenberger G, von Deimling A et al. The 2021 WHO classification of CNS tumors. Acta Neuropathol. 2021;142(4):563–592.

[7] Komori T. The 2021 WHO classification of tumors of the central nervous system. Brain Tumor Pathol. 2022;39(1):1–17.

[8] Sofroniew MV. Molecular dissection of reactive astrogliosis. Trends Neurosci. 2009;32(12):638–647.

[9] Burda JE, Sofroniew MV. Reactive gliosis and the multicellular response to CNS damage. Neuron. 2014;81(2):229–248.

[10] Liddelow SA, Barres BA. Reactive astrocytes: production, function, and therapeutic potential. Immunity. 2017;46(6):957–967.

[11] Hamby ME, Sofroniew MV. Reactive astrocytes in the neural repair process. Cold Spring Harb Perspect Biol. 2010;2(7):a001438.

[12] Migheli A, Attanasio A, Schiffer D. GFAP expression in reactive astrocytes. J Neuropathol Exp Neurol. 1991;50(4):377–387.

[13] Franklin RJ, Ffrench-Constant C. Regeneration in the CNS. Nat Rev Neurosci. 2017;18(12):753–766.

[14] Lassmann H. Mechanisms of demyelination. Brain Pathol. 2014;24(3):289–297.

[15] Lucchinetti CF et al. Inflammatory demyelination in multiple sclerosis. Ann Neurol. 2000;47(6):707–717.

[16] Prineas JW, Parratt JD. Demyelination revisited. Brain. 2012;135(Pt 7):1984–2023.

[17] Kotter MR et al. Remyelination and the repair of MS lesions. Nat Rev Neurol. 2011;7(9):514–524.

[18] Reuss DE, von Deimling A. Molecular diagnostics of CNS tumors. Acta Neuropathol. 2015;129(5):643–658.

[19] Huse JT, Holland EC. Targeting brain cancer. Science. 2010;329(5987):1488–1490.

[20] Kleihues P, Cavenee WK. Pathology and Genetics of Tumours of the Nervous System. WHO; 2007.

[21] Parsons DW et al. An integrated genomic analysis of human gliomas. Science. 2008;321(5897):1807–1812.

[22] Weller M et al. Glioma. Nat Rev Dis Primers. 2015;1:15017.

[23] Huse JT, Snuderl M, Jones DT. Low grade gliomas: diagnostic perspectives. J Neuropathol Exp Neurol. 2017;76(6):453–466.

[24] Perry A, Brat DJ. Practical surgical neuropathology. Elsevier; 2017.

[25] Budka H. Humanistic aspects of neuropathology. Clin Neuropathol. 2001;20(1):1–6.

[26] Ironside JW. Reflections on neuropathologic interpretation. Histopathology. 2018;72(1):3–13.
[27] Love S. The poetic nature of glial pathology. Brain Pathol. 2020;30(4):625–632

Deep Science Publishing, 2025
https://doi.org/10.70593/978-93-7185-400-9

DeepScience
Open Access Books

Chapter 13: The Immunohistochemical Compass while navigating Through Phenotypic Shadows: Principles and pitfalls of IHC interpretation in overlapping morphologies.

Let me walk you through a fictional but plausible scenario.

You examine a biopsy from a lung lesion showing spindle cells. The differential includes malignant melanoma, sarcomatoid carcinoma, and a sarcoma. Morphology alone cannot decide. You order immunostains: cytokeratin (AE1/AE3), vimentin, S100, HMB45, desmin, TTF1, and so on.

On the slide you see a group of spindle cells, many positive for vimentin strongly, a subset weakly positive for cytokeratin, scattered S100 positivity in a few cells, but negative for HMB45, and negative for desmin, TTF1 negative. The cytokeratin positivity is focal, weak, and mostly perinuclear. The S100 is patchy and weak. What do you think?

You must not rush to call this carcinoma simply because of weak cytokeratin. Consider that in many poorly differentiated tumors cytokeratin may be lost or attenuated, or aberrantly expressed.[15–16] The weak, patchy nature suggests caution. Perhaps this is a melanoma variant with partial cytokeratin expression. Or a sarcoma with aberrant epithelial marker. To resolve further, you might add Melan A, SOX10, pancytokeratin, EMA, and others, paying attention to the pattern: if cytokeratin is truly membranous and diffuse in many cells, that supports carcinoma. If S100 and SOX10 are strong and diffuse, that points melanoma. If muscle markers are entirely negative, sarcoma weak.

You would also check internal controls , are normal epithelial cells on the slide positive for cytokeratin? If not, perhaps the staining failed or the run was flawed. Always check the positive internal and external controls.[17] If controls fail, the entire interpretation is suspect.

Thus your compass turns, and with each additional marker and reassessment, you gradually approach a stable direction , not by a single arrow, but by overlaying many small arrows.

A. The Invisible Traps — Common Pitfalls

As we wander, traps lie hidden. Let me recount some classic pitfalls, in narrative form.

One evening, a pathologist stained for a nuclear antigen. The signal was absent. He concluded loss of expression. But the next day, after adjusting antigen retrieval, the signal reappeared. The earlier negative was a false negative owing to epitope masking.[18] Fixation conditions, choice of retrieval buffer, and retrieval time all weigh heavily.[19] Had he prematurely declared a negative, he misread the forest.

Another time, someone used a high concentration of primary antibody. The slide glowed almost uniformly. They thought the antigen was ubiquitous. But upon further dilution, the pattern sharpened and only certain cells remained positive; the earlier was non-specific binding.[20] Strong binding is seductive, but it can mask specificity. Fritschy warned that non-specific binding or cross-recognition of epitopes may mislead.[21]

Then there is the danger of cross-reactivity. An antibody intended for one protein may bind an isoform, homolog, or unrelated protein in some tissues. One case in a breast tumor showed staining for insulin-degrading enzyme (IDE) when endogenous peroxidases were incompletely quenched; the positive was artifactual.[22] Or an antibody might bind to biotin in the tissue if using an avidin-biotin system, yielding false positivity.[23] These traps are subtle; they reward only vigilance.

Another trap is diffusion artifact: the staining spreads beyond the true boundary, smearing the edge and giving false impression of positivity in adjacent cells. This can happen when chromogen development runs too long or when tissues are loosely adherent. The correct boundary is lost.[24] Also, background from sticky extracellular matrix can adsorb antibody Fc portions or non-specific interactions, making background “texture” in tissue.[25]

In multiplex stains, chromogen interference or signal suppression may occur: one reaction overshadows another, or color mixing confuses the eye.[26] A negative in one marker may not be true but masked by the stronger chromogen of another. If you interpret multiplex incorrectly, you can misread coexpression.

A final trap is interpretive bias. You see a suspicious cell and unconsciously force the stain to match your preconception. You ignore the weak negative because your mind expects positivity. Always remain skeptical and re-examine negative and borderline cells.

B. The Rules of the Compass — Principles to Uphold

Let me distill principles that keep your compass honest.

First, validation is sacred. Before adopting an antibody or protocol, one must validate it in known positive and negative tissues. One must titrate dilution, test retrieval, test across known controls. Never assume vendor claims hold in your hands.[27] Use internal controls — normal cells on the same section that are known to express (or not express) the antigen. If those do not work, your run is invalid.[28]

Second, panel thinking : never trust a single marker in isolation in ambiguous cases. Use complementary markers, with overlapping and contrasting expression, to triangulate. No single arrow , multiple arrows. Always interpret in context of morphology.

Third, pay attention to localization. The subcellular location matters: nuclear, cytoplasmic, membranous, granular, Golgi, apical. A nuclear marker that stains cytoplasm is suspect; a cytoplasmic enzyme that appears membranous may be mislocalized.[29] Always assess whether the staining is in the correct compartment.

Fourth, assess intensity and proportion. Few weak cells are less convincing than many strongly stained cells. Use semi-quantitative scoring only cautiously. What matters is pattern, not just percentage.

Fifth, respect the negative. A negative is as informative as a positive , when properly controlled. A true negative (with functioning controls) means absence of expression, but a false negative means a blindfolded compass. Always raise the possibility of technical failure when you see negatives.

Sixth, remember context. The biology of the tissue, the expected differentiation, the morphology should guide your choice of markers and your interpretation. If something is wildly contrary to the morphology, treat it with suspicion.

Seventh, beware amplification artifacts. Amplification systems may boost weak true signals, but may also magnify background noise. Use them only when necessary, and calibrate their power.[30]

Eighth, document protocol and reproducibility. Any IHC slide must come with a written protocol: fixation, retrieval, dilution, incubation times, detection systems. Without this, others cannot reproduce your result and your conclusions are unstable.[31] Fritschy argued for minimal method reporting to allow reproducibility.[21]

Ninth, rely on holistic consistency. If one stain outlier conflicts drastically with the majority of stains and morphology, do not accept it blindly. Re-examine, repeat, or exclude suspicious stains.

If you hold these rules in mind, your compass will be steadier through the murk.

C. A Voyage of Two Cases

Allow me to narrate two vignette-like cases to illustrate.

Case A: A hepatic lesion with polygonal cells. Morphology suggests hepatocellular carcinoma or metastatic carcinoma. You stain for HepPar1, arginase-1, CK7, CK20, GPC3, and TTF1. The slide shows strong HepPar1 positivity in many cells, arginase positive, GPC3 moderate, CK7 negative, CK20 negative, TTF1 negative. This composite suggests hepatocellular carcinoma. But within you wonders: could a metastasis from lung aberrantly express HepPar1? Very unlikely if TTF1 is negative and morphology matches. The strong positive internal control (normal hepatocytes on the slide) reassure you. You accept the diagnosis, but cautiously.

Case B: A lung tumor with glandular architecture but areas of solid growth. You stain for TTF1, Napsin A, CK7, CK20, p63, CK5/6. The glands are CK7 positive, TTF1 positive, Napsin A positive , conventional adenocarcinoma. But in solid areas p63 is weakly positive in some cells. Does that mean squamous differentiation? Not necessarily. The p63 positivity is patchy, weak, and lacks the expected morphology. You suspect non-specific staining or cross-reactivity. You check internal control: basal bronchial cells are strongly p63 positive ,so your p63 reagent works, but the tumor cells are likely not true p63+ squamous. You maintain adenocarcinoma. If you misinterpreted p63 as definitive squamous, you might misclassify adenosquamous carcinoma.

In both cases, the compass is the weave of markers, internal controls, morphology, and cautious weighting.

D. When the Compass Falters — Troubleshooting

What do you do when the signals are muddled? Let me narrate how to troubleshoot.

If you see no staining at all , check whether your controls also failed. If yes, the run failed: reagent inactivation, blocked primary, bad detection. If controls are okay but target is negative, then you may have a true negative ,or your antigen retrieval is insufficient. Try alternate retrieval buffers or enzymatic digestion.

If background is high everywhere, first check blocking: insufficient quench of peroxidases, incomplete blocking of Fc or biotin, or sticky ECM interaction. Sometimes reducing the primary antibody concentration helps. Or shorten chromogen development time. Reduce amplification. Use more stringent washes.

If you see diffuse weak staining in all cells, that may be non-specific. Try titrating the antibody lower, or increasing stringency of washes or competitor blocking. Or choose a different clone.

If spotty staining in unexpected cells (e.g. mast cells, macrophages) , consider antibody adsorption by granules, Fc receptor binding, or cell type nonspecific binding. In FFPE, mast cell granules are notorious for adsorption.[32] In frozen sections, Fc receptor binding is more dangerous.[33] You may need additional blocking (e.g. serum, Fc block). Or ignore isolated weak positivity unless consistent.

If staining appears in wrong compartment (nuclear antigen in cytoplasm), suspect mislocalization artifact, cross-reactivity, or overdevelopment. Reassess, maybe repeat with a different clone or shorter chromogen time.

If multiplex color conflict arises, try sequential staining on separate slides or choose chromogens with nonoverlapping spectra. Always validate multiplex carefully.

If one slide gives contradictory internal controls (e.g. normal cells negative), discard that slide. It is a failed run. Never trust interpretation from a run with failed internal controls.

When in doubt, repeat. Try a different antibody clone, different retrieval conditions, or different detection chemistry. The repetition forces you to question your assumptions.

E. The Compass in New Frontiers — Advances & Caution

Our narrative would be incomplete without acknowledging newer frontiers — multiplex IHC, digital quantification, 3D IHC, and AI-assisted analysis. But these expand capability even as they demand greater care.

Multiplex IHC (multiple antibodies on one slide) holds great promise to detect coexpression and spatial context. But cross-interference, steric hindrance, chromogen bleed, competition for epitopes, and interpretive complexity loom. You must validate each combination and ensure signals are truly independent.[34] The compass now has more needles, but their interactions may distort balance.

Deep IHC for 3D tissues (whole organ slices) attempts to immunolabel intact tissues in three dimensions. But penetration gradients, quenching, diffusion limits, and nonuniform labeling bedevil it.[35] The compass in deeper tissue may drift. Standardization and benchmarking remain urgent.

Digital pathology and AI aim to read and quantify stains more objectively. They may detect subtle gradients, patterns invisible to the eye. But they rely on properly curated training sets; if your staining artifacts or misclassifications feed into their model, the AI may be perpetually biased. Also, digital thresholds must be tuned to the real biology. The compass becomes algorithmic, but with new sources of error.[36]

Thus even as our compass evolves, the principles remain: validate, cross-check, interpret holistically. The new tools do not relieve responsibility; they amplify it.

F. A Coda — How to Train Your Compass in Practice

Let me end with a few reflections and advice, in narrative form, on how a pathologist or researcher may internalize this compass.

When learning IHC, begin with well characterized tissues and known controls. Practice a marker series where you know the expected outcome. Notice how varying retrieval conditions change results. Learn how intensity, background, and signal to noise shift.

Always document your protocol rigorously , fixative type and time, retrieval buffers, times, antibody clones and dilutions, incubation times, detection system. That is the diary of your journey; without it, no one can follow your path.

In ambiguous cases, slow down. Do not let pressure push you to immediate interpretation. Step away from morphology alone; stare at the immunostain critically. Ask yourself: do internal controls work? is localization correct? is intensity believable? is there pattern coherence across markers? Is anything inconsistent with expected biology? If yes , repeat, reconsider.

Build a habit of ordering panels rather than single markers. In difficult cases, choose markers that offer contrast (one positive in A but negative in B, another vice versa) rather than mere repeats. Always cast a net wide initially, then narrow.

In your reports, when you have to opine in overlap, express uncertainty , e.g. “favor carcinoma over sarcoma, but possibility of sarcomatoid melanoma cannot be excluded; recommended correlation with molecular test or repeat biopsy.” Never overstate. The compass may point strongly but sometimes the way is dark.

Finally, keep your humility. We interpret molecular shadows cast by proteins; we never see the cell’s full identity. The compass is our tool, not our master. Stay alert to artifacts, cross-reactivity, and surprises. Always question the unexpected result, and when doubtful, repeat or confirm by orthogonal methods (molecular, ultrastructure, additional stains)

Thus concludes our conceptual voyage through the immunohistochemical compass , the art of navigating phenotypic shadows, the perils of overlapping morphologies, the deep principles that guard accuracy, and the traps that beckon misinterpretation. May your compass grow ever steadier, your eyes ever more discerning, and your stories on tissue slides ever more truthful.

References

[1] Ramos-Vara JA. Technical aspects of immunohistochemistry. Vet Pathol. 2005;42(4):405–26.

[2] Taylor CR, Levenson RM. Quantification of immunohistochemistry—issues concerning methods, utility and semiquantitative assessment II. Histopathology. 2006;49(4):411–24.

[3] Cattoretti G, Becker MH, Key G, Duchrow M, Schlüter C, Galle J, et al. Monoclonal antibodies against recombinant parts of the Ki-67 antigen (MIB 1 and MIB 3) detect proliferating cells in microwave-processed formalin-fixed paraffin sections. J Pathol. 1992;168(4):357–63.

[4] Shi SR, Key ME, Kalra KL. Antigen retrieval in formalin-fixed, paraffin-embedded tissues: an enhancement method for immunohistochemical staining based on microwave oven heating of tissue sections. J Histochem Cytochem. 1991;39(6):741–8.

[5] Taylor CR, Shi SR, Chaiwun B, Young L, Imam A, Cote RJ. Strategies for improving the immunohistochemical staining of various intranuclear prognostic markers in formalin-paraffin sections: androgen receptor, estrogen receptor, p53 protein, proliferating cell nuclear antigen, and Ki-67 antigen. Hum Pathol. 1994;25(3):263–70.

[6] Leong ASY, Gilham PN. The effects of progressive formaldehyde fixation on the preservation of tissue antigens. Pathology. 1989;21(4):266–8.

[7] Ramos-Vara JA, Miller MA. When tissue antigens and antibodies get along: revisiting the technical aspects of immunohistochemistry—the red, brown, and blue technique. Vet Pathol. 2014;51(1):42–87.

[8] Nadji M, Morales AR. Immunoperoxidase: part I. The techniques and its pitfalls. Lab Med. 1983;14(12):767–70.

[9] Elias JM. Immunohistopathology: a practical approach to diagnosis. ASCP Press; 2003.

[10] Cordell JL, Falini B, Erber WN, Ghosh AK, Abdulaziz Z, MacDonald S, et al. Immunoenzymatic labeling of monoclonal antibodies using immune complexes of alkaline phosphatase and monoclonal anti-alkaline phosphatase (APAAP complexes). J Histochem Cytochem. 1984;32(2):219–29.

[11] Nonaka D, Chiriboga L, Rubin BP. Sox10: a pan-schwannian and melanocytic marker. Am J Surg Pathol. 2008;32(9):1291–8.

[12] Miettinen M, Wang ZF, Lasota J. DOG1 antibody in the differential diagnosis of gastrointestinal stromal tumors: a study of 1840 cases. Am J Surg Pathol. 2009;33(9):1401–8.

[13] Ordóñez NG. Value of cytokeratin immunostaining in tumor diagnosis: a review and update. Appl Immunohistochem Mol Morphol. 1998;6(4):157–63.

[14] Wick MR. Immunohistology of undifferentiated malignant neoplasms: a differential diagnostic approach. Semin Diagn Pathol. 2000;17(3):194–203.

[15] Han J, Lee OJ, Lee JW, Park WY, Kim YJ. Cytokeratin expression in undifferentiated carcinomas: diagnostic pitfalls. Korean J Pathol. 2003;37(4):243–8.

[16] Oertel YC. Pitfalls in immunohistology: a review of problem areas and possible solutions. Ann Diagn Pathol. 2000;4(3):154–61.

[17] Dako. Immunohistochemistry guidebook. Agilent Technologies; 2017.

[18] Shi SR, Shi Y, Taylor CR. Antigen retrieval immunohistochemistry: review and future prospects in research and diagnosis over two decades. J Histochem Cytochem. 2011;59(1):13–32.
[19] Bogen SA, Vani K, Sompuram SR. Molecular mechanisms of antigen retrieval: antigen retrieval reverses steric interference caused by formalin-induced crosslinks. Lab Invest. 2009;89(7):807–16.
[20] Taylor CR. Standardization in immunohistochemistry: the role of antigen retrieval in molecular morphology. Biotech Histochem. 2006;81(1):3–12.
[21] Fritschy JM. Is my antibody-staining specific? How to deal with pitfalls of immunohistochemistry. Eur J Neurosci. 2008;28(12):2365–70.
[22] Matos LL, Trufelli DC, de Matos MG, da Silva Pinhal MA. Immunohistochemistry as an important tool in biomarkers detection and clinical practice. Biomark Insights. 2010;5:9–20.
[23] Rait VK, Xu H, Sanchez R, Van Nostrand AW, Wang N, Pao A, et al. Multiple factors contribute to biotin interference in immunohistochemistry. Arch Pathol Lab Med. 2004;128(9):1056–60.
[24] Nadji M, Morales AR. Immunoperoxidase, Part II: the techniques and its pitfalls. Lab Med. 1983;14(12):771–3.
[25] Gown AM. Diagnostic Immunohistochemistry: What Can Go Wrong and How to Prevent It. Arch Pathol Lab Med. 2002;126(12):1440–2.
[26] Toth ZE, Mezey E. Simultaneous visualization of multiple antigens with tyramide signal amplification using antibodies from the same species. J Histochem Cytochem. 2007;55(6):545–54.
[27] Bordeaux J, Welsh A, Agarwal S, Killiam E, Baquero M, Hanna J, et al. Antibody validation. BioTechniques. 2010;48(3):197–209.
[28] Rimm DL. What brown cannot do for you. Nat Biotechnol. 2006;24(8):914–6.
[29] Miettinen M. Diagnostic Immunohistochemistry: Theranostic and Genomic Applications. 5th ed. Elsevier; 2022.
[30] Bobrow MN, Harris TD, Shaughnessy KJ, Litt GJ. Catalyzed reporter deposition, a novel method of signal amplification: application to immunoassays. J Immunol Methods. 1989;125(1-2):279–85.
[31] Taylor CR. The total test approach to standardization of immunohistochemistry. Arch Pathol Lab Med. 2000;124(7):945–51.
[32] Elston CW, Ellis IO. Assessment of histological grade. In: The Breast. Elsevier; 2018. p. 295–302.
[33] Gown AM, Vogel AM, Hoak D, Gough M, McNeal JE. Monoclonal antibodies in diagnostic pathology. Am J Surg Pathol. 1986;10(2):83–92.
[34] Stack EC, Wang C, Roman KA, Hoyt CC. Multiplexed immunohistochemistry, imaging, and quantitation: a review, with an assessment of Tyramide signal amplification, multispectral imaging and multiplex analysis. Methods. 2014;70(1):46–58.
[35] Richardson DS, Lichtman JW. Clarifying tissue clearing. Cell. 2015;162(2):246–57.
[36] Steiner DF, MacDonald R, Liu Y, Truszkowski P, Hipp JD, Gallas BD, et al. Evaluation of the use of digital pathology and artificial intelligence by pathologists. JAMA Netw Open. 2020;3(8):e2010319.

Deep Science Publishing, 2025
https://doi.org/10.70593/978-93-7185-400-9

DeepScience
Open Access Books

Chapter 14: Molecular Pathology involving Genomic Truths Behind Morphologic Lies: Gene signatures, fusion transcripts, and next-generation sequencing in resolving dilemmas.

I start with a scene: Picture a pathologist at the microscope, looking at an ordinary-appearing slide of tissue but recognizing that it contains an unseeable drama. The anatomy appears typical, the cells look just as they should, the shape quietly telling one tale. But within that silence may also lurk a genomic insurrection, an invisible counterrevolution of genes warping truth. This is the irony of molecular pathology: genomic realities behind morphologic fiction.

As we navigate this landscape, allow me to accompany you on a journey through gene signatures, fusion transcripts and next-generation sequencing, not as arid methodologies but actors in a drama of uncovering the secret identity of disease

Now you may be wondering what a gene signature is. Imagine a choir of genes, each singing its note. In health, some sing in harmony; in disease, others rise or fall. A gene signature is a pattern of expression across many genes that, taken together, distinguishes one biological state from another. It may whisper that a tumor is aggressive or benign. The secret lies not in a single note but in the chorus. Yet many signatures are unstable,when a new tumor is sampled, the choir may rearrange. Researchers stabilized signatures by integrating network information or grouping genes in subnetworks so that the pattern stays reproducible[7]. Clinicians use these signatures today to predict prognosis or to define molecular subtypes in cancers[8].

Now let us turn to fusion transcripts. They are words formed when two gene messages are stitched into one chimeric sentence. The classical example is the BCR-ABL fusion in chronic myeloid leukemia[9], a rearrangement producing an abnormal protein that drives proliferation. It's not possible beforehand to predict that fusion from morphology alone. Also EWS-FLI1 in Ewing sarcoma or fusion driver in secretory carcinoma, such as ETV6-NTRK3, are the demonstration of an hidden molecular identity not visible

macroscopically[10],[11]. Fusions like these are the equivalent of a cross--bred accent in a cell's voice: The hybrid indicates that something in its speech has gone haywire and needs to be righted. But some fusions are truly new, others extremely rare, and none can be deduced from morphology.

Then along comes next-generation sequencing, the Sherlock Holmes of the genomic age.[12] It massively reads DNA or RNA, and looks for mutations, copy number variants and fusion junctions all at once. It unmasks what morphology conceals. in oncology has transformed how we diagnose cancer (and now) how we treat cancer. no longer is the story of pathology told solely through stains and slides. there is a new chapter in the story; a genomic chapter.

Take an example. a tumor looks like most carcinomas. however, through high-coverage, targeted sequencing, you learn about a previously unknown fusion between genes A and B. if you determine that the gene fusion is likely to be an oncogene then you need to re-think your diagnosis. the lesion may be diagnosed as a molecularly-defined disease that will respond to a particular class of drugs. the "morphologic fabrication" is revealed by the genomic truth.

still, the road ahead is not without some speed bumps. on the dna side of things, there are literally thousands of fusions involving long stretches of repetitive filled-in introns making probe design challenging. on the rna side, there are no introns. fusions occur at the junctions of exons. therefore, sensitivity increases when any rna-based platform is used. one study found that targeted rna sequencing increased the diagnostic yield from 63% to 76% over conventional methods. however, rna is fragile and degradation during the preservation of tissue can result in false negatives.

Behind every fusion discovery stands bioinformatics - the silent narrator. millions of short reads must be analyzed and interpreted. to find a fusion, algorithms look for split reads and discordant pairs. tools such as STAR-Fusion, Arriba and FusionCatcher carry out this analysis. however, not all events detected by algorithms are true positives. artifacts, read-throughs and paralogous alignments can masquerade as fusions. therefore, manual review is critical.

Gene signatures provide an additional way to resolve diagnostic dilemmas when morphology fails. suppose two tumors look identical under light microscopy but behave very differently. a validated prognostic signature can distinguish the aggressive from the indolent. even in small biopsy samples in which morphology is altered, molecular signatures can identify the tumors' identities.

technology, while powerful, creates a burden. ngs generates vast amounts of data and identifying variants of uncertain significance remains a major challenge. the reliability of ngs results is influenced by factors including sequencing depth, tumor purity and

uniformity of coverage. cost, turn-around-time and informatics infrastructure remain barriers to widespread adoption. despite these limitations, the clinical benefit is well-established. for example, in a large sequencing study, gene fusions were identified in 36.5% of 652 patients, and each led to changes in treatment decisions.

To responsibly interpret these data, one needs to go beyond numbers. every genomic report should include information linking the sample's histological origin to the sample's quality, the assay's design and the evidence supporting every variant linked to a disease. this represents the molecular pathologists' new profession.

when morphology provides a plausible but ambiguous image, genomics provides facts. the story becomes richer: one layer at microscopic scales and another using decoded sequence reads. sometimes the genome and eye agree; other times they disagree.But both are necessary for truth.

So this is our reconciliation. Morphology is the first impression; gene signatures give the background; fusion transcripts reveal the motor, and next generation sequencing presents the entire play. Today’s pathologist must be a storyteller in histology and code. And in that union is the future of precision medicine, where genomic truth ceases to lurk behind the morphologic falsehood and is visible for all who can speak its tongue..

References

[1] Lin XJ, Fang JH, Yang XJ, et al. Hepatocellular carcinoma cell-secreted exosomal microRNA-210 promotes angiogenesis in vitro and in vivo. *Mol Ther Nucleic Acids.* 2018;11:243–252.

[2] Bussolati G, Leonardo E. Morphologic misdiagnosis in pathology: limits of morphology and the role of molecular testing. *Virchows Arch.* 2020;476:139–150.

[3] van ’t Veer LJ, Bernards R. Enabling personalized cancer medicine through analysis of gene-expression patterns. *Nature.* 2008;452:564–570.

[4] Golub TR, Slonim DK, Tamayo P, et al. Molecular classification of cancer: class discovery and class prediction by gene expression monitoring. *Science.* 1999;286:531–537.

[5] Perou CM, Sørlie T, Eisen MB, et al. Molecular portraits of human breast tumours. *Nature.* 2000;406:747–752.

[6] Ramaswamy S, Golub TR. DNA microarrays in clinical oncology. *J Clin Oncol.* 2002;20:1932–1941.

[7] Chuang HY, Lee E, Liu YT, et al. Network-based classification of breast cancer metastasis. *Mol Syst Biol.* 2007;3:140.

[8] Paik S, Shak S, Tang G, et al. A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer. *N Engl J Med.* 2004;351:2817–2826.

[9] Rowley JD. A new consistent chromosomal abnormality in chronic myelogenous leukaemia. *Nature.* 1973;243:290–293.

[10] Delattre O, Zucman J, Plougastel B, et al. Gene fusion with an ETS DNA-binding domain caused by chromosome translocation in human tumours. *Nature.* 1992;359:162–165.
[11] Tognon C, Knezevich SR, Huntsman D, et al. Expression of the ETV6–NTRK3 gene fusion as a primary event in human secretory breast carcinoma. *Cancer Cell.* 2002;2:367–376.
[12] Mardis ER. Next-generation sequencing platforms. *Annu Rev Anal Chem.* 2013;6:287–303.
[13] Roychowdhury S, Chinnaiyan AM. Translating genomics for precision cancer medicine. *Annu Rev Genomics Hum Genet.* 2014;15:395–415.
[14] Frampton GM, Fichtenholtz A, Otto GA, et al. Development and validation of a clinical cancer genomic profiling test. *Nat Biotechnol.* 2013;31:1023–1031.
[15] Mertens F, Antonescu CR, Mitelman F. Gene fusions in soft tissue tumors: recurrent and overlapping pathogenetic themes. *Genes Chromosomes Cancer.* 2016;55:291–310.
[16] Stransky N, Cerami E, Schalm S, et al. The landscape of kinase fusions in cancer. *Nat Commun.* 2014;5:4846.
[17] Benayed R, Offin M, Mullaney K, et al. High yield of RNA sequencing for targetable kinase fusions in lung adenocarcinomas with no driver mutation. *Clin Cancer Res.* 2019;25:4712–4722.
[18] Wu G, Diaz AK, Paugh BS, et al. The genomic landscape of diffuse intrinsic pontine glioma and pediatric non-brainstem high-grade glioma. *Nat Genet.* 2014;46:444–450.
[19] Tothill RW, Shi F, Paiman L, et al. Impact of RNA degradation on fusion detection by next-generation sequencing. *J Mol Diagn.* 2021;23:264–275.
[20] Haas BJ, Dobin A, Stransky N, et al. STAR-Fusion: fast and accurate fusion transcript detection from RNA-Seq data. *bioRxiv.* 2017;120295.
[21] Venet D, Dumont JE, Detours V. Most random gene expression signatures are significantly associated with breast cancer outcome. *PLoS Comput Biol.* 2011;7:e1002240.
[22] Roy S, Coldren C, Karunamurthy A, et al. Standards and guidelines for validating next-generation sequencing bioinformatics pipelines. *J Mol Diagn.* 2018;20:4–27.
[23] Zehir A, Benayed R, Shah RH, et al. Mutational landscape of metastatic cancer revealed from prospective clinical sequencing of 10,000 patients. *Nat Med.* 2017;23:703–713.

Deep Science Publishing, 2025
https://doi.org/10.70593/978-93-7185-400-9

DeepScience
Open Access Books

Chapter 15: Histologic Impressionism: The Pathologist's Brushstroke of Judgment by Balancing empiricism and intuition in the diagnostic act.

Before the microscope the pathologist is as a painter before a blank canvas. The field of view is a mosaic of colors and textures, pinks from cytoplasm, blues from nuclei, the dim lines of architecture. In that landscape, one is looking not for beauty, but for meaning. Every slide tells a human story in abstraction, one part of the body transmuted into form and hue. And in that translation resides the mystique of judgement, for pathology is not just a science of identification but an art of interpretation[1],[2].

The process of all diagnosis begins with empiricism; a systematic observation and comparison. The experienced eye is aware of form, shape, pattern, and inconsistency. It also understands when cells lose their polarized state, when organs/glands malfunction, and when systems of the body are expressing an onco-density or disease density. Prior to this empiric base, however, there lies intuition where that universal, unconscious aspect of the observer has an inkling that something is amiss prior to reason's completion of a thought. That is why many experienced pathologists will pause, examine further, and simply say, "It feels cancerous. The senior pathologist tends to stop, look again and then just say, "It feels malignant." This is not mysticism, but an unconscious blending of decades worth of visual memory. It is superstition in THIS realm that becomes the silent partner of empiricism, and they are not to be separated.

And the art of histology arises from that gap between observation and intuition. It is not approximation or sloppiness, but awareness that perception brings with it construal. And just as the artist identifies light from the tone of the moment, it is experience that dictates what cellular patterns are actually seen by a pathologist. The section of tissue is never neutral; it solicits the observer to produce meaning. The business of diagnosis is, therefore, not mechanical, but creative; it is a continuous conversation between what the eye perceives and what the mind envisages[4].

It is very characteristic that classical training does exhibit pathology as a concatenation of criteria. Each disease has its architecture, its cellular demeanor, its stromal environment. But real seeing has too much vitality for any rulebook. The brain does not evaluate an image by number of nuclei, or mitoses; it captures the gestalt. This is part of digital algorithms' difficulty with replicating human judgment[5]. They can count and categorize but they cannot hear harmony or dissonance. The human eye just has so much background of context and can jump places that no rules based system ever gets near to.

It may be said that the microscope is an instrument, yet to the pathologist it is also his mirror!. This is also a reflection of the person viewing it as well as the tissue. As fatigue builds, as we have expectations about what we want to see, and as we allow emotions to influence our perception, we begin to see what we perceive we should see. This means that pathology is subjective and requires self-awareness. What you know how to see is just as important as what you see. A pathologist must develop mental neutrality; he/she must not be invested in a specific outcome, so as to provide the most candid opinion possible based upon the slide he/she examines. The ability to do this successfully is to manage your subjectivity without losing all of your instincts (instincts draw on a disciplined naivety).

Each diagnosis is a dialogue between the structure of the disease and the hints provided by the slide. The slide does not tell us what is happening; rather it provides us with some information regarding potential areas of interest to further investigate. For example, an adenocarcinoma could initially present as a loss of cellular polarity, slight elongation of the nucleus, or a few scattered mitotic figures. The pathologist must be attentive to these "hints" provided by the slide.

Overreliance on rigid criteria leads to a loss of the intuitive nature of perception; conversely, too great an emphasis on relying on one's gut feeling and past experiences results in a lack of scientific objectivity. Finding this delicate balance between the two takes many years of study and practice. With each case, the pathologist continues to refine his/her ability to maintain both confidence and uncertainty simultaneously.

The process of making a diagnosis has a rhythm. At first, the area of the slide is viewed very generally as a painter views their canvas prior to defining their overall composition. Once the general area of concern has been identified, the pathologist focuses in more closely to examine specific details such as the arrangement of cells, the appearance of the nuclear membranes, the texture of the chromatin, etc. Finally, the pathologist will step back again and consider whether the individual characteristics of the cells fit together to define the whole slide. This movement of focusing in on specific details and then stepping back to view the slide as a whole is similar to the method used by artists to assess the proportions of their paintings. This type of rhythm is indicative of mastery in pathology.

What distinguishes an amateur from a professional in pathology is not merely the ability to visually identify features of a disease, but the ability to recognize patterns. After years of clinical experience, a physician may enter a patient's room and within minutes they can sense a dissonance in a case that does not fit with their previous experiences. The initial impression that arises is not wild guessing, but rather a synthesis of years of accumulated visual memories. Each earlier exposure creates a residual memory trace in the brain that forms a large network of associations that allows the physician to quickly recall and recognize familiar patterns. When the physician enters the eyepiece and begins to view the slide, this network of associated memories becomes active, compares, matches and rejects various images until a final image is established. Although the process is largely subconscious, it is based on the integration of memory and evidence, and it is the integration of memory and evidence that establishes expertise.

However, pathological interpretation is not isolated from culture or language. Terms such as "hobnail," "comedo," and "signet ring" are analogies derived from everyday life, which serve to help the pathologist organize perceptions. Using such analogies, the pathologist develops a common visual knowledge base among other pathologists. Such terms do not add ornament to description; they instruct the mind to imagine the unseen. The vocabulary of morphology is a vocabulary of metaphorical exactness, each term represents an invitation to observe more closely.

However, the modern molecular diagnostic world challenges this traditional skill. Molecular panels, transcriptome signatures, and DNA sequencing technologies demonstrate aspects of the tumor biology that were previously inaccessible through morphological techniques. A lesion that appears to be benign may contain genetic mutations that predict a high likelihood of malignant transformation.. Conversely, a tumor of frightening appearance may carry a mutation of indolence. Does this make morphology obsolete? Far from it. The eye remains the gatekeeper of context. It tells us where to look, which area of tissue best represents the process, which structure might mislead the machine. Morphology and molecular data must coexist like melody and harmony. One without the other is incomplete[9].

Histologic impressionism thus becomes a philosophy of practice. It acknowledges that every visual judgment carries interpretation, that empiricism must be enriched by intuition, and that certainty in diagnosis arises not from formula but from comprehension. The slide is a question, and the pathologist is both witness and narrator. Through disciplined looking, the chaotic becomes ordered, and through humility, order remains provisional.

In daily practice the interplay between empiricism and intuition is constant. Consider a small biopsy from the lung. The tissue is crushed, torn and distorted. Specific criteria/ons for adenocarcinoma may not be met. But the examinant sees irregular nuclei, incomplete

gland development, and a certain pattern of mucin. The impulse comes: this is cancer. Ancillary stains confirm the suspicion. Here intuition guided empiricism. In other cases, a lesion suspected to be malignant may, on further review or consideration of the process as reactive. The mind needs to abstain from wanting to see patterns and to reflect on the evidence. The most dangerous errors in pathology are those which occur because our intuition was just a fraction of a second faster than fact. The wise pathologist learns to listen to the gap of silence between the knowledge he or she thinks they have and the point at which he or she feels confident.

Teaching this type of balance is very difficult. Students always want certainty, formulas that assure them of correct results. However, pathology will not allow for that type of closure. Every case is unique; every situation is unique. While students cannot be taught how to find the answers in pathology, they can be taught the art of observing: looking at things long enough, recognizing the absence of something as well as its presence, and learning to be patient. An apprenticeship in pathology is an apprenticeship in perception itself. As time goes on, the observer's gaze becomes less active, less reactive, and more precise.

The similarities between painting and pathology are not metaphors, but are structurally similar. Impressionist painters sought to capture fleeting light (transient) instead of solid forms (static). They also trusted their own perceptions, even when those perceptions conflicted with the "rules" of academia. Pathology seeks the living truth of tissue, whereas pathology criteria seek only the criteria of the tissue. The diagnosis is never made by one instant of recognition, but through the accumulation of many small, discrete moments of recognition that ultimately produce conviction. However, the stroke of judgment, analogous to the painter's brush stroke, is composed of countless, unseen strokes of observation.

As with art galleries, pathology fills classrooms and microscopes as artists fill galleries. As with art galleries each person looks slightly differently. Through discussion we refine our perceptions. In a collective "gaze," the group creates an agreement. This type of collaborative process is analogous to the art critique process, whose ultimate purpose is not to add anything to the artwork, but to reveal it. This type of collaboration has helped to sustain the discipline of pathology. It reinforces the idea that no single perspective has the absolute truth, and that humility in front of the specimen is perhaps the most advanced sense of awareness.

When empiricism is attempted without the aid of intuition, then pathology is reduced to simple arithmetic. When intuition is used in isolation of empiricism, then it can easily slide into pure illusion. Before any readings are done, there is the living act of interpretation. The microscope ceases to be a machine and it becomes an instrument of culture between evidence and imagination. Like artists, pathologists discover that

mastery is not about control, but about receptiveness. The tissue reveals itself to those who are willing to look beyond the surface.

Ultimately, histologic impressionism is an ethics of observation.. It requires the observer to be present to what is in front of the eye. Every nucleus, or vessel, or fiber there bears the record of life. To look good is to respect that life. The pathologist's judgment, like the painter's brush stroke, is exacting and humane. It is the convergence of science and art, empiricism and intuition, discipline and novelty. And then, when the last diagnosis is laid down upon the paper it isn't really a label at all but there the magic moment of understanding! There has been beneath those cold abstraction, stain and structure, a human form whose tale the observer has now learned.

References

[1] Bussolati G, Leonardo E. Morphologic misdiagnosis in pathology: limits of morphology and the role of molecular testing. *Virchows Arch.* 2020;476:139–150.

[2] Kumar V, Abbas AK, Aster JC. *Robbins and Cotran Pathologic Basis of Disease.* 10th ed. Philadelphia: Elsevier; 2020.

[3] Damasio AR. *The Feeling of What Happens: Body and Emotion in the Making of Consciousness.* New York: Harcourt; 1999.

[4] Ackerman LV. The evolving art of diagnostic pathology. *Am J Surg Pathol.* 1981;5:121–128.

[5] Komura D, Ishikawa S. Machine learning methods for histopathological image analysis. *Comput Struct Biotechnol J.* 2018;16:34–42.

[6] Ramalho LNZ, Zucoloto S. The pathologist's perception and subjectivity in diagnosis. *Hum Pathol.* 2016;55:25–32.

[7] Tan PH, Ellis IO. The role of experience in histopathological diagnosis: lessons from breast pathology. *Histopathology.* 2015;67:1–13.

[8] Willis RA. *The Spread of Tumours in the Human Body.* London: Butterworth; 1973.

[9] Louis DN, Perry A, Wesseling P, et al. The 2021 WHO classification of tumours of the central nervous system: a summary. *Acta Neuropathol.* 2021;142:141–161.

[10] Weedon D. *Weedon's Skin Pathology.* 5th ed. Edinburgh: Churchill Livingstone; 2020.

Deep Science Publishing, 2025
https://doi.org/10.70593/978-93-7185-400-9

DeepScience
Open Access Books

Chapter 16: Error, Uncertainty, and the Ethics of Equivocality: Communicating doubt, reporting variants, and preserving diagnostic integrity.

Whenever a pathologist looks down the microscope, there is always beside them a silent shadow of doubt. It doesn't prosecute, it follows along with. For it is not only diseases that are named in naming a disease; one also names life. Error in pathology is not a failure of vision but an intimation of human mortality, a hint that knowledge, no matter how exacting, is limited[1],[2].

There's always a moment before every report, when the pathologist pauses. The slide seems to look so familiar, the architecture nearly conclusive, but some holds back from coming to a close. Such resistance is the voice of uncertainty, and it is deeply ethical. and to understand it is not a flaw, but integrity. The theoretical basis of our modern diagnostic pathology has evolved over hundreds of years through the accumulation of observations. Yet each phrase is weighted with the seriousness of treatment, prognosis, and emotion. When a physician diagnoses the word carcinoma, he or she is prepared to change his/her life. This weight transforms a purely technical exercise into a moral commitment.

Error is an inherent part of the fabric of medicine. Error is the cost of medicine's complexity. Tissues can distort due to fixation, cells may overlap, and artifacts can disguise themselves as meaningful. The pathologists' task is not to eliminate error; rather, it is to navigate error with humility. Ignorance does not do nearly as much damage as the unwillingness to acknowledge uncertainty. There is a form of heroic humility in admitting ignorance.

In the long process of learning to become a pathologist (it is an apprenticeship toward security), which will never succeed for those lacking in self-confidence, the student discovers that certainty is a mirage of their initial training. Students want the clear-cut answers: "this is benign," "this is malignant." However, as the students gain experience,

the two categories begin to blur together. The spectrum of morphology is not merely binary, it is continuous. There exists a vast geographic area of variety between normal and abnormal. Reality is not bound by the limits defined by textbooks. That which appears abnormal could be reactive; that which appears benign can hide genetically violent behavior. ("The microscope does not find atoms," he writes in that essay, "any more than the telescope finds stars.")

The probabilistic nature of pathology is typically disguised beneath the rhetoric of certainty. Reports are written in declarative sentences as if the slide was issuing the conclusion. Beneath the pathologist's steady declarations of fact lie a web of judgment: visual, conceptual, and emotional. An experienced pathologist knows that all conclusions are provisional, and depend upon context and association. One of the great ethical dilemmas facing the profession is how to convey this nuance without compromising the patient's trust in the pathologist.

A pathologist must continually weigh the need for clarity against the need for caution when writing a report. The physician needs to know for certain, while the pathologist seeks to provide evidence. What amount of responsible doubt can reasonably be built into a system? If too little, then the pathologist may omit something critical. If too much, then communication will break down.. The art is in constructing words that are honest and useful. It is a study-cypher to which the terms features are indicative of or findings support applies as an ethical ruler. The practice of ethics is executed through language itself[7].

Error doesn’t just happen on the independent eye. It’s what comes out of systems, from the rigors that come with time, from the expectations of velocity, and from heavy institutional habits. in large laboratories slides change quickly from one observer to another. Fatigue becomes invisible. The temptation to hurry is relentless. But all errors are an alert: it is not the technology that keeps diagnostic integrity alive as much as the moral attitude of attentiveness[8]. To see truly requires stillness.

Uncertainty, when acknowledged, protects both patient and practitioner. When denied, it becomes danger. Consider the ambiguous lesion: a small focus of cellular irregularity in a limited biopsy. To call it carcinoma could put a patient through unnecessary treatment; to label it benign might delay an intervention. At that point, humility is not fear or weakness; it is wisdom. To get to the right question, one must be willing to live in the space of uncertainty.

Rather than being seen as evasive (obfuscatory), the language of equivocation is, in fact, a language of caution. It provides an opportunity to describe the complexity of biology. While a term like atypia of undetermined significance may appear unsatisfying, it reflects the same commitment to precision that guides the pathologist's actions.

Molecular pathology redefines what is considered "uncertainty." Molecular diagnostics provide evidence of genetic mutations whose implications are unclear (unknown significance) and the behaviors of gene fusions that do not fit into our current classification systems. The mistakes of the past of morphology (such as misinterpreted slides and missed patterns) are eclipsed by the uncertainty of data. The genome tells us far too much and our minds struggle to make sense of the pieces of information. Reporting a variant becomes an act of philosophical containment: description of what is known, admission of what isn't and the eschewing of prophecy dressed up as science[11].

Uncertainty is not just a sign of being unprepared, it is a form of emotional weakness. Behind each microscopic image is a human who feels pressured to be flawless. Confidence is what Medicine values. Pathology is one area where there is no value placed on hesitancy. This is due to the fact that all medical areas require an individual to be comfortable with ambiguity. Young pathologists need to understand that the inability to arrive at a definitive answer is not a lack of ability, it is a demonstration of intellectual honesty. It is not a failure when I do not know. Instead, it is a commitment to the truth and is therefore an honorable act.

Compassion and Courage, rather than just courage, are the virtuous responses to the feelings of uncertainty within pathology. It is permissible to seek another opinion, to review previous slides or to seek additional testing. We would prefer not to see this type of behavior, not because we are so easily intimidated by the unknown, but because it is not respectful to the sample or the patient that sample represents. Only a truly professional individual has the courage to reopen a case and question their initial findings and conclusions. The dangers associated with certainty are greater than the shame of changing your mind.

Nobility in the use of equivocality is the art of maintaining two opposing ideas without the break between them. Equivocality allows medicine to exist at the crossroads of clarity and mystery. Ambiguous language utilized in pathology reports serve as a buffer between the clinical team and the fantasy of being omnipotent. This allows clinical teams to understand the risks involved. Such a statement as that which the features may represent either high-grade dysplasia or incipient carcinoma is more in the nature of an invitation to collaborate than an order. It is in line with the dialogue aspect of medicine[14].

There is a temporal ethics of mistake as well. A mistake of today will be corrected tomorrow, but with the condition that one is open to re-evaluating. With digital archives and multi-disciplinary reviews, the conversations between yesterday's and today's diagnoses are now open. Every prevention corrected is a sanctuary of knowledge built inside the specialty. The courage to erase one's words is as much an ethical move as the courage to set them down in the first place[15].

Pathologists dwell in dialogue with uncertainty. They did not merely read tissues, however; they read silences. Between the cells exists time, decay and unsaid history of illness. Each lesion is both different and the same. This duality generates humility. It reminds the observer that they are interpreters, not owners, of truth. The ethical pathologist is one who never forgets that the specimen once belonged to someone who trusted medicine to see rightly. One must respect that trusting us with their bodies as the first step in this journey of discovery, requires us to acknowledge that there will be times we see things incompletely

To err is human, to hide the truth of that error is inhuman. Transparency is now a moral obligation once errors are recognized; therefore the pathologist should be willing to have open discussions regarding uncertainty with all parties: clinicians, colleagues, and in some cases, the patient(s). To provide illumination rather than justification for what occurred during the examination process, which serves to create a more humane approach to the practice of medicine by changing shame to a joint understanding, thus making the ethics of ambiguity applicable to both the diagnostic process and to the overall culture of healthcare.

The use of machine learning brings new dimensions to the issue of error. Algorithms do not experience self-doubt. Algorithms calculate probabilities but they are unable to experience hesitancy. Their conclusions are based on data. Data, however, are derived from human judgment. Therefore artificial intelligence does not carry forward human prejudice, nor does it bring forward human conscience. Therefore the pathologist's imaginative capabilities to address ethical issues remain relevant in our digital age. Machines can count, but only humans can care. Caring is about being able to have the ability to ask questions of yourself

As I reflect on my time spent peering through the lens of the microscope, I am reminded that a diagnosis is not an announcement, but a discussion. A glass slide does speak, softly; the pathologist listens and responds with doubt. It is in that silent exchange that science meets conscience. What comes out of the laboratory is not simply an interpretation of this tissue sample, but a record of the moral work that has gone into seeing.. Each of these word, including benign and malignant and indeterminate do carry -tacitly- the human signature of a man trying to force his way between knowledge, hubris/pomposity/assertion.

In the end, the ethics of equivocality are a reminder that medicine is not an overcoming of doubt but a pensive allies it. Not for perfect certainty but accountable understanding. To be in error and to know it, to be certain yet uncertain, to believe an d at the same time suspend belief, not singly but together — these are not paradoxes but truth. The microscope, however exact, does not relieve us of mystery; it is enough for the senses..

References

[1] Croskerry P. The importance of cognitive errors in diagnosis and strategies to minimize them. Acad Med. 2003;78:775–780.

[2] Berner ES, Graber ML. Overconfidence as a cause of diagnostic error in medicine. Am J Med. 2008;121:S2–S23.

[3] Pellegrino ED. The moral foundations of the patient–physician relationship: the essence of medical ethics. J Med Philos. 1993;18:5–22.

[4] Garland JS. The clinical problem of diagnostic error. N Engl J Med. 2019;381:1939–1946.

[5] Rosai J. Rosai and Ackerman's Surgical Pathology. 11th ed. Philadelphia: Elsevier; 2018.

[6] Kumar V, Abbas AK, Aster JC. Robbins and Cotran Pathologic Basis of Disease. 10th ed. Philadelphia: Elsevier; 2020.

[7] Weedon D. Weedon's Skin Pathology. 5th ed. Edinburgh: Churchill Livingstone; 2020.

[8] Nakhleh RE. Patient safety and error reduction in surgical pathology. Arch Pathol Lab Med. 2008;132:181–185.

[9] Raab SS, Grzybicki DM. Quality in cancer diagnosis. CA Cancer J Clin. 2010;60:139–165.

[10] Faderl SH, Mills SE. Diagnostic uncertainty and the limits of morphologic interpretation. Hum Pathol. 2015;46:1501–1507.

[11] Richards S, Aziz N, Bale S, et al. Standards and guidelines for the interpretation of sequence variants. Genet Med. 2015;17:405–424.

[12] Epstein JI, Netto GJ. Biopsy Interpretation of the Prostate. 6th ed. Philadelphia: Wolters Kluwer; 2021.

[13] Cibas ES, Ducatman BS. Cytology: Diagnostic Principles and Clinical Correlates. 5th ed. Philadelphia: Elsevier; 2020.

[14] Lester SC. Reporting pathology results: clarity, accuracy, and responsibility. Am J Surg Pathol. 2014;38:1145–1152.

[15] Nakhleh RE, Fitzgibbons PL. Reexamination of errors in pathology and laboratory medicine. Arch Pathol Lab Med. 2019;143:1385–1390.

[16] Bussolati G, Leonardo E. Morphologic misdiagnosis in pathology: limits of morphology and the role of molecular testing. Virchows Arch. 2020;476:139–150.

[17] Helmreich RL. On error management: lessons from aviation. BMJ. 2000;320:781–785.

[18] Steiner DF, Chen PH, Mermel CH. Closing the translation gap: AI applications in pathology. Nat Med. 2020;26:1456–1466.

Deep Science Publishing, 2025
https://doi.org/10.70593/978-93-7185-400-9

DeepScience
Open Access Books

Chapter 17: From Confusion to Clarity: Case Vignettes in Diagnostic Redemption with real-world cases where morphology and molecular insight resolved long-standing dilemmas

Case One

I recall the day it arrived, a slide folded so neatly in its paper envelope: such fictitious simplicity, pink and blue stain on a piece of liver tissue. The patient was a middle aged man with chronically raised liver enzymes. It was an easy clinical question: benign or malignant. Yet the tissue whispered contradiction. The hepatocytes were large and their cytoplasm was clear, although the architecture was almost intact. No classic invasion pattern or high mitotic rate; and only a hint of cellular disarray were present. I leaned into the microscope and felt the warmth of the light on my face. A definitive diagnosis based solely on morphology was impossible. There was an enigma that could not be solved at this point. I then turned to molecular testing. Molecular panels using next-generation sequencing technology generated a report revealing a silent mutation within the TERT promoter as well as a microvariant of TP53. While individually both variants were unclear (or of uncertain significance) collectively, they created a clinical picture that supported the likelihood of very early-stage hepatocellular carcinoma. I carefully recorded the diagnosis including the uncertainty surrounding each of the clues as well as the assurance provided by molecular evidence. This patient will likely require follow-up monitoring and timely interventions to prevent cancer progression and benefit from the combination of the microscope and sequencer.

Case Two

Morphologic findings in a core biopsy from a young woman's palpable yet difficult-to-visualize breast lesion were somewhat ambiguous, as they included irregular ducts and mild crowding with minimal nuclear atypia. I sat back and considered the alternatives (ductal carcinoma in situ vs. a reactive change). Although the architectural arrangement

of the neoplastic tissue urged caution, I placed an order for a molecular assay that ultimately showed an amplification of HER2 and a subtle mutation in TP53 that implied the presence of malignancy. Morphology vacillated between possible carcinoma and possible non-neoplastic change, whereas the molecular results provided a decisive indication of carcinoma. I wrote the final report in a way that indicated the ambiguities present in the histological findings while providing a definitive molecular interpretation, recognizing that my carefully worded report will direct the clinician to the correct diagnosis without misleading them.

Case Three

This particular slide represented a boy who had developed a rapidly expanding neck mass. Fine needle aspiration revealed collections of small round cells, with hyperchromasia, homogeneity of cell size, and a fragmentary background. Could these represent lymphoma, or possibly a poorly-differentiated carcinoma? Immunohistochemistry provided several clues, including the fact that the cells were positive for CD99, which suggested that the tumor was likely an Ewing sarcoma, but some of the cells could not be classified. A molecular diagnostic test for EWSR1-FLI1 gene fusions was then performed and revealed the presence of such a fusion, thus confirming the diagnosis of Ewing sarcoma. I felt a quiet sense of accomplishment, knowing that the patient's treatment plan and prognosis would now be based upon accurate information, rather than speculation, and that his life would now be directed by clarity rather than confusion.

Case Four

A seventy-year-old man had a pulmonary nodule found incidentally during evaluation for unrelated reasons. Upon microscopic examination, the glands were somewhat disorganized, and the spacing and cytoplasm of the glandular structures did not appear to match those typically associated with either adenocarcinoma or squamous cell carcinoma. I felt a level of discomfort due to the ambiguity of the histologic findings. Next-generation sequencing (NGS) was subsequently performed and identified an ALK gene rearrangement, a finding that was not identifiable using histomorphology alone. The histomorphology had raised questions regarding the identity of the tumor; however, NGS provided the answers. I then prepared the final report with precise wording, balancing clinical utility with the recognition of the nuances evident when examining the microscopic features of tissues.

Case Five

A middle-aged woman presented with a renal mass that was suspected to be an oncocytoma based upon radiographic studies. Core biopsy was performed. The histologic features of the cells within the biopsy specimen included ample cytoplasm,

eosinophilia, and a nesting pattern. It was very difficult to differentiate chromophobe carcinoma from oncocytoma using histomorphology. However, mitochondrial staining and molecular cytogenetic studies were subsequently performed and identified a pattern consistent with oncocytoma. With increased confidence, the final report was completed; however, there remained a lingering recollection of the fact that histomorphology had indicated multiple possibilities, and molecular diagnostic testing had allowed for the identification of certainty from ambiguity.

Case Six

A teenage girl presented with an ovarian mass. The histologic appearance was difficult to interpret, with the stroma being cellular and the epithelial components appearing rudimentary. Classic markers did not clearly identify the tissue. Histomorphology had essentially reached its limits of clarity. Molecular panels were therefore used to analyze the tumor for various genetic alterations. These tests demonstrated the presence of a FOXL2 mutation, consistent with adult granulosa cell tumor. In this example, the use of molecular sequencing clarified the pathologist's vision, transforming hesitation into precision.

Case Seven

A patient with a long-standing enlargement of her thyroid gland underwent a biopsy. The histologic pattern of the thyroid tissue was characterized by follicular arrangements that were similar to hyperplastic nodules. Capsular invasion was barely detectable. The molecular panel revealed RAS mutations, thereby shifting the balance of evidence toward follicular carcinoma. Histomorphology provided the narrative for the patient's condition, and molecular diagnostic testing provided the conclusion. The patient's care team will utilize the findings of this report to determine whether surgical intervention is necessary, and if so, the extent of the surgery required to remove the tumor completely. Additionally, the patient will be monitored throughout her lifetime to ensure that no additional tumors develop.

Case Eight

A young man was evaluated for a mediastinal mass, and his pathology results indicated large cells with clear cytoplasm and a fibrous stroma, suggesting that he may have lymphoma. Immunohistochemical studies were inconclusive. Subsequent genetic testing for specific gene fusions related to mediastinal germ cell tumors was performed, and a fusion consistent with this type of tumor was identified. Therefore, morphological studies had identified a range of possible diagnoses, and molecular studies had focused the range of possible diagnoses down to a single, actionable diagnosis. As a result, the young man's treatment can now be optimized to include only the treatments that are most likely to result in a cure.

Case Nine

A seventy-five-year-old woman with a prior history of colorectal cancer presented with a liver lesion. Microscopic examination of the liver lesion identified glandular structures, but some of the cells exhibited atypical features and other cells seemed to be benign. Immunohistochemical studies were partially helpful. Sequencing studies revealed a KRAS mutation and microsatellite instability. The molecular signatures of the liver lesions confirmed that she had metastatic adenocarcinoma. This case served as a reminder that while morphology provides guidance, it is the genome that determines clarity..

Case Ten

Morphologic findings in a core biopsy from a young woman's palpable yet difficult-to-visualize breast lesion were somewhat ambiguous, as they included irregular ducts and mild crowding with minimal nuclear atypia. I sat back and considered the alternatives (ductal carcinoma in situ vs. a reactive change). Although the architectural arrangement of the neoplastic tissue urged caution, I placed an order for a molecular assay that ultimately showed an amplification of HER2 and a subtle mutation in TP53 that implied the presence of malignancy. Morphology vacillated between possible carcinoma and possible non-neoplastic change, whereas the molecular results provided a decisive indication of carcinoma. I wrote the final report in a way that indicated the ambiguities present in the histological findings while providing a definitive molecular interpretation, recognizing that my carefully worded report will direct the clinician to the correct diagnosis without misleading them.

Case Eleven

This particular slide represented a boy who had developed a rapidly expanding neck mass. Fine needle aspiration revealed collections of small round cells, with hyperchromasia, homogeneity of cell size, and a fragmentary background. Could these represent lymphoma, or possibly a poorly-differentiated carcinoma? Immunohistochemistry provided several clues, including the fact that the cells were positive for CD99, which suggested that the tumor was likely an Ewing sarcoma, but some of the cells could not be classified. A molecular diagnostic test for EWSR1-FLI1 gene fusions was then performed and revealed the presence of such a fusion, thus confirming the diagnosis of Ewing sarcoma. I felt a quiet sense of accomplishment, knowing that the patient's treatment plan and prognosis would now be based upon accurate information, rather than speculation, and that his life would now be directed by clarity rather than confusion.

Case Twelve

A seventy-year-old man had a pulmonary nodule found incidentally during evaluation for unrelated reasons. Upon microscopic examination, the glands were somewhat disorganized, and the spacing and cytoplasm of the glandular structures did not appear to match those typically associated with either adenocarcinoma or squamous cell carcinoma. I felt a level of discomfort due to the ambiguity of the histologic findings. Next-generation sequencing (NGS) was subsequently performed and identified an ALK gene rearrangement, a finding that was not identifiable using histomorphology alone. The histomorphology had raised questions regarding the identity of the tumor; however, NGS provided the answers. I then prepared the final report with precise wording, balancing clinical utility with the recognition of the nuances evident when examining the microscopic features of tissues..

Case Thirteen

A middle-aged woman presented with a renal mass that was suspected to be an oncocytoma based upon radiographic studies. Core biopsy was performed. The histologic features of the cells within the biopsy specimen included ample cytoplasm, eosinophilia, and a nesting pattern. It was very difficult to differentiate chromophobe carcinoma from oncocytoma using histomorphology. However, mitochondrial staining and molecular cytogenetic studies were subsequently performed and identified a pattern consistent with oncocytoma. With increased confidence, the final report was completed; however, there remained a lingering recollection of the fact that histomorphology had indicated multiple possibilities, and molecular diagnostic testing had allowed for the identification of certainty from ambiguity.

Case Fourteen

A 70 year old man underwent a digital rectal exam and a prostate nodule was noted. Biopsy of the prostate nodule demonstrated cribriform glands that could represent either benign mimics or adenocarcinoma. Therefore, histological ambiguity was present. IHC utilizing AMACR and p63 stains provided further support that basal cell layers were absent from the cribriform glands. Molecular analysis, therefore, revealed an ERG gene rearrangement, thereby confirming prostate adenocarcinoma. The combination of morphology and molecular data represents an example of how careful consideration can result in accurate and definitive reporting.

Case Fifteen

A young woman underwent ultrasound examination of the neck and a thyroid nodule was identified. FNA of the thyroid nodule demonstrated nuclei that represented those

found in the follicular variant of papillary carcinoma, but were not definitive enough to establish the diagnosis. Molecular testing, however, revealed a BRAF V600E mutation. Therefore, morphology had raised suspicions, and molecular evidence established the presence of malignancy. The combination of morphology and molecular data avoided both overtreatment and undertreatment of her condition. Thus, the combination provided an elegant solution to her diagnostic dilemma, a dialog between her eyes and the sequencer.

Case Sixteen

A young child underwent MRI examination of the head due to symptoms of hydrocephalus. A cerebellar mass was identified. Histology of the cerebellar mass demonstrated densely packed small blue cells. The differential diagnosis of the small blue cells included medulloblastoma and atypical teratoid/rhabdoid tumor. However, IHC was inconclusive, and morphology alone was unable to resolve the differential diagnosis. Molecular studies of the cerebellar mass revealed a deletion of the SMARCB1 gene, thus establishing a diagnosis of atypical teratoid/rhabdoid tumor. Therefore, while morphology had narrowed the differential diagnosis, molecular studies had provided the necessary information to conclusively identify the tumor. In addition, the child's situation required urgency, and molecular studies were able to provide the critical information in a timely manner.

Case Seventeen

A middle-aged man presented with a renal mass. Histology revealed clear cells arranged in nests, suggesting clear cell carcinoma but with unusual stromal features. Immunohistochemistry was supportive but did not explain the stromal anomaly. Molecular testing identified VHL mutation consistent with conventional clear cell carcinoma, aligning morphology and genotype. The case underscored the necessity of integrating visual assessment with molecular evidence for confident diagnosis.

Case Eighteen

The middle-aged male patient was diagnosed with a renal mass. Histological evaluation indicated the presence of clear cell carcinoma based on morphology; however, the tumor also exhibited unusual stromal characteristics. Although immunohistochemical studies supported the presence of clear cell carcinoma, they were unable to clarify the abnormal stromal changes. However, molecular testing confirmed the presence of a VHL gene mutation which is indicative of conventional clear cell carcinoma, therefore correlating both histological findings and genetic alterations. This case clearly illustrates the importance of using morphologic evaluations in conjunction with molecular diagnostics to provide a definitive diagnostic conclusion.

Case Eighteen

A young adult patient presented with a mediastinal mass. The histological evaluation of this mass demonstrated a sheet like arrangement of large epithelial cells characterized by irregular nuclei. Although immunohistochemical studies suggested that the neoplasm was a thymic carcinoma, they were inconclusive. Therefore, molecular studies were conducted to identify mutations within the KIT gene, which are characteristic of thymic carcinomas. The morphology of the tumor suggested that it may be a thymic carcinoma, but the molecular studies enabled accurate classification and thereby informed the development of a precise treatment plan. The study reflected a high degree of confidence when reporting on the final diagnosis as well as acknowledged the potential for ambiguity prior to conducting molecular studies

Case Nineteen

A middle aged female patient presented with an ovarian lesion. The histological evaluation of this lesion revealed papillary structures with atypical nuclei, but without stromal invasion. Based on morphology alone, it was impossible to determine whether the lesion represented a borderline tumor or an early carcinoma. Molecular studies were performed to identify a mutation within the KRAS gene, which has been associated with borderline serous tumors. The results of these molecular studies confirmed that the ovarian lesion was a borderline serous tumor, thus providing the necessary information to ensure proper clinical management. Additionally, the patient benefited from avoiding overtreatment as well as retaining her reproductive option.

Case Twenty

A seventy year old male patient presented with a lung nodule. The histological evaluation of the lung nodule demonstrated adenocarcinoma with unusual solid patterns, thereby raising questions regarding the possibility that the lung nodule may represent either a metastatic tumor or a primary lung tumor. Immunohistochemical studies failed to resolve the question. Molecular analysis of the tumor tissue was then conducted to evaluate the presence of specific mutations within the EGFR gene. Specifically, molecular analysis revealed the presence of a deletion within exon 19 of the EGFR gene, thereby confirming that the lung nodule was a primary lung adenocarcinoma and thereby enabling the patient to receive targeted therapy. Morphologically, the tumor presented many possible explanations for its appearance, whereas molecularly, there was one correct answer.

I lay my head back against the microscope as I conclude my final presentation and close the microscope. A quiet reflection begins to settle over the laboratory as I reflect on the twenty cases and their respective journeys from confusion to clarity, and from ambiguity

to definitiveness. The morphology in each of the twenty vignettes served as the first map, a visual language encoded in architecture, color, and cellular pattern. Through the use of the microscope, I was able to visualize what I would have otherwise seen with the naked eye. However, as significant as the microscope was in allowing me to see what the naked eye could not see, it was never enough on its own. Each cell, each tissue fragment contained both possibilities and pitfalls, and each time molecular insight was required to serve as the compass to guide the journey through the uncertain fog of doubt..

Morphology teaches us to slow down, to observe the details and nuances of a specimen. It teaches us patience and respect for both the specimen and the gravity of the decision-making process involved in interpreting the specimen. Molecular diagnostics teaches us precision and probability along with the terminology of genetics, helping to clarify when a specimen appears unclear because it is obscured by a lack of visibility.

Each modality, taken alone, is incomplete. However, they can be used together to create a complete picture. These two modalities of pathology serve as opposing forces that provide a "time" element to the diagnostic decision-making process.

This is also an important lesson for humans, particularly as it relates to the role of the pathologist. As the pathologist, the physician has reached the intersection of principal and outcome. Every un-clear film frame represents a moral dilemma. There is no weakness in stating that there is ambiguity - it is actually an expression of loyalty to the truth. Combining the illumination provided by molecular evidence with the respect that should be given to morphology is an education in humility and control over oneself. Each report written is a story, a delicate balance of confidence and caution, evidence and interpretation, science and conscience.

The pattern demonstrated in these twenty cases is similar. When morphology is insufficient or unable to determine a diagnosis, molecular information is able to do so. Conversely, when molecular information is abundant, yet inconclusive, morphology can serve as the framework for the molecular findings. While each of the twenty cases clearly illustrate that failure is not something that should be feared but rather viewed as a terrain that can be navigated ethically, they also demonstrate that diagnostic salvation is not found in perfection, but in the dynamic interaction between the observation of the specimen, the reflection of that observation, and the analytical accuracy of the findings.

Ultimately, what these vignettes present to us is a philosophy of practice. While the microscope and the sequencer are tools of discovery, it is the pathologist who is the tool of synthesis. The pathologist interprets the findings, integrates the information, and communicates those findings to the clinician. The process of diagnosing is as much an art as it is a science. The diagnostic process is an ongoing dance of skills and timing - between uncertainty and certainty, empirical knowledge and intuitive leaps. Lastly,

while the cases presented remind us that clarity is not a destination but a journey, that journey should be made with the utmost moral awareness and intellectual humility.

The twenty patients whose stories were included in this chapter trusted their narratives to the language of pathology. We must honor that trust through diligent observation, thoughtful application of molecular principles, and human communication. The movement from ignorance to knowledge is not merely a line of information that we travel to reach the correct explanation, but it is an ethical and cognitive journey where the pathologist is both the witness and the guide.

As I set down my pen, the message is simple and enduring. Morphology and molecular insight are complementary, doubt and clarity are reciprocal, and the honest pathologist will walk between them. Through the twenty journeys of the microscope and the genome, we gain new perspectives, not only on our world but also on how we may understand it. The redemptive nature of diagnosis is in the union of observation and interpretation, caution and courage, and science and humanism. It is in this space that pathology realizes its potential to transform pieces of tissue into knowledge, wisdom, and hope.